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CHAPTER I 
 
OVERVIEW 
 
Prostate cancer is the most diagnosed non-skin cancer among American men.  Its 
high prevalence and the lack of an ultimate cure for late-stage disease makes the disease a 
significant public health concern. Research in the Abdulkadir Laboratory has long 
focused on the molecular genetics of prostate cancer with the goal of gaining a deeper 
understanding of this complex disease to improve the health of the thousands affected by 
prostate cancer each year.  As in other cancer types, prostate cancer development occurs 
with the accumulation of common genetic lesions or changes in gene expression that lead 
to transformation of cells.  These changes include gain of expression or function of 
oncogenes and loss of expression of tumor suppressor genes.  My dissertation work 
focuses on a tumor suppressor gene whose expression is lost during prostate cancer 
progression, NKX3.1. Serving as a useful mouse model of the very earliest changes which 
lead to prostate cancer, Nkx3.1-deficient mice display early, pre-cancerous lesions. 
Our studies attempt to elucidate the mechanisms by which NKX3.1 loss is related 
to cancer development.  One such proposed link is the increase in oxidative stress in 
Nkx3.1-deficient mouse prostates.  Many studies, including clinical trials and mouse 
models of cancer, have suggested that increased oxidative stress promotes prostate 
tumorigenesis. As shown in Chapter III, I tested the hypothesis that Nkx3.1 loss-mediated 
reactive oxygen species (ROS) promote prostate tumorigenesis by quenching ROS in the 
Nkx3.1-deficient prostate.  Surprisingly, I found that antioxidant supplementation 
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increased rather than decreased proliferation in the Nkx3.1-deficient prostate.  These 
results resemble the findings of the recent Selenium and Vitamin E Cancer Prevention 
Trial (SELECT) which showed that the antioxidant vitamin E increased the risk of 
prostate cancer development in disease-free men.  To determine if antioxidant 
supplementation has a similar effect in the human prostate in the setting of NKX3.1 loss, 
I tested the influence of polymorphisms in NKX3.1 on prostate cancer risk in the four 
randomization arms of the SELECT trial.  Our findings in Chapter IV highlight the 
importance of gaining a more thorough understanding of oxidative stress in the 
development of prostate cancer.    
As a transcription factor, another way that NKX3.1 may influence tumorigenesis 
is through regulation of its direct target genes.  Chapter V of my dissertation focuses on 
the role of one of these target genes, peroxiredoxin 6 (PRDX6).  PRDX6 is also a direct 
target gene of the important oncogene MYC.  PRDX6 is a dual function enzyme with 
peroxidase and phospholipase A2 function.  In a mouse model with focal high MYC 
expression, areas of MYC expression are tightly correlated with loss of Prdx6 expression.  
In order to investigate the role Prdx6 plays in prostate tumor progression, I rescued Prdx6 
expression in mouse prostate cancer cell line Myc-CaP, showing that Prdx6 promotes in 
vitro and in vivo proliferation and anchorage-independent growth.  I show that although 
high MYC levels are associated with decreased Prdx6 expression in early prostate cancer 
lesions of the mouse prostate, Prdx6 promotes tumor progression in advanced prostate 
cancer cells.   Thus, the antioxidant protein PRDX6 may have diverse functions 
throughout tumor progression, highlighting the complexity of the role of antioxidants in 
prostate cancer.  Further studies will be needed to elucidate the role of PRDX6 in human 
3 
prostate tumorigenesis and to determine the mechanism of MYC-associated decrease in 
PRDX6 expression.        
My dissertation makes significant contributions to the understanding of 
antioxidant chemoprevention in prostate cancer and the role of the NKX3.1 and MYC 
target gene PRDX6 in prostate tumorigenesis.   
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CHAPTER II 
 
INTRODUCTION 
 
Prostate anatomy and physiology 
The prostate is an exocrine gland surrounding the urethra and the bladder neck in 
men (Figure 1). The function of the prostate is to produce a slightly alkaline secretion that 
makes up about one-sixth the volume of seminal fluid of humans (1) .  These secretions 
contain metal ions, proteases, and highly charged organic molecules and are believed to 
promote the survival and motility of sperm in the female reproductive tract (1).  The 
human prostate is made up of several major regions, including the central, transition, and 
peripheral zones (Figure 1). These zones have a differing propensity for cancer 
development.  
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Figure 1.  Human prostate anatomy and zones 
The human prostate is located inferior to the bladder surrounding the urethra and ejaculatory ducts.  
Pictured are a sagittal view (left) and a coronal view (right) of the prostate including five prostate zones.  
The location of the bladder, ejaculatory duct, and urethra are also noted. Figure is adapted from (2). 
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The substructure of the prostate consists of exocrine gland tubules filled with 
prostatic secretions. The lumen of a prostate tubule is lined with the androgen-dependent, 
secretory luminal epithelial cells and basal epithelial cells (Figure 2). In the normal 
human prostate, basal epithelial cells reside beneath luminal epithelial cells in a 
continuous layer, with contacts to the surrounding basement membrane. The tubules are 
surrounded by a layer of smooth muscle cells in the stroma, which help to propel the 
prostatic secretions into the urethra during ejaculation.  Also contained in the epithelial 
cell layer are rare neuroendocrine cells, which produce peptide hormones. 
 
 
 
Figure 2.  Normal human prostate histology  
General cartoon of prostate histology including luminal, basal, neuroendocrine cells, smooth muscle 
cells, and surrounding basal lamina.  The lumen of the normal prostate gland is usually filled with 
prostatic secretions.  
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Prostate cancer incidence and mortality 
Prostate cancer is the second leading cause of cancer-related death among 
American men.  As the most common non-skin cancer in men, an estimated 238,590 
prostate cancer diagnoses will be made in 2013 (3). Fortunately, the majority of these 
cases will remain indolent and not progress to metastatic disease. However, in those cases 
that do progress, the disease is ultimately incurable. An estimated 29,720 men will die of 
prostate cancer in the U.S. in 2013 (3). There are over 2.5 million men in the U.S. with a 
history of prostate cancer who are alive, making prostate cancer a major public health 
concern (3).  One out of every six American men will be diagnosed with prostate cancer 
at some point during their lifetime and one out of every 36 men will die from the disease.    
 
Prostate cancer risk factors 
At present, the etiology of prostate cancer is not completely understood.  Those 
factors with proven links to the disease include age, race, family history/genetics, and 
obesity/diet.  
Age  
The risk of prostate cancer in those over age 65 is almost 14 times higher than 
those under 65 (4).  In 2010 (the most recent year assessed) the prostate cancer rate per 
100,000 individuals was 10.2 for men 20-49 years old, 310.4 for men 50-64 years old, 
858.8 for men 65-74 years old, and 619.6 for men 75 years or older (3).  Some propose 
that the correlation of advanced age with prostate tumorigenesis may be due to increased 
levels of oxidative stress as the body ages (5–7). This elevated oxidative stress during 
aging may be due to decreased antioxidant capacity of cells with age or due to chronic 
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inflammatory processes. The prostate is an organ with an especially high presence of age-
associated inflammation, with the majority of men having subclinical inflammation of 
some degree in the prostate gland, and clinically evident prostatitis presenting in 
approximately 16% of the U.S. male population (8, 9).  Ultimately, the mechanistic link 
between age and prostate cancer development is not clear, and possible mechanisms 
relating elevated oxidative stress and inflammation to prostate cancer development are 
currently under intense current investigation.    
Race 
Race strongly influences the chance a man will develop and die from prostate 
cancer in the U.S. Age-adjusted prostate cancer incidence rates per 100,000 U.S. males 
tabulated by SEER showed a rate of 144.9 for whites, 228.5 for blacks, 81.8 for 
Asian/Pacific Islanders, 77.8 for American Indian/Alaskan Natives, and 125.8 for 
Hispanics (3). Mortality rates also greatly vary with age-adjusted prostate cancer 
mortality rates per 100,000 U.S. males of 21.2 for whites, 50.9 for blacks, 10.1 
Asian/Pacific Islanders, 20.7 for American Indian/Alaskan Natives, and 19.2 for 
Hispanics. Alarmingly, African-American men have the highest rates of prostate cancer 
incidence in the world (10).  The reasons for the discrepancies in incidence and mortality 
rates have been widely discussed, including genetic factors, environmental factors, and 
socio-economic factors, but no final consensus has been reached (10).   
Family history/genetics 
A positive family history, i.e. having at least one first degree relative with prostate 
cancer, increases risk 2.4-fold (11). Historically, genetics behind this link had not been 
well described and consistent susceptibility loci had not been identified for a wide 
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population (12, 13). This may have been due to the fact that several incompletely 
penetrant prostate cancer susceptibility loci contribute to the prostate cancer phenotype 
and these combinations of loci are heterogeneous throughout diverse populations (13).  
Single nucleotide polymorphisms and prostate cancer 
However, recent findings from genome wide association studies (GWAS) have 
identified several single nucleotide polymorphisms (SNPs) which may significantly 
contribute to increased risk of prostate cancer.  SNPs are DNA bases at specific loci that 
vary among individuals of a species.  SNPs may confer alterations to gene function (if 
present regions of DNA which code for protein) or expression (if present in regulatory 
regions of DNA). SNPs can affect tendency to manifest a specific phenotype, i.e. prostate 
cancer development.  Recent studies have found several SNPs on chromosome 8q24, 
housing the oncogene MYC, which may account for a large portion of hereditary prostate 
cancer (14, 15).  SNPs in other genes found to be linked to increased prostate cancer risk 
in GWAS studies include β-microseminoprotein (MSMB), NKX3.1, and G-protein 
coupled receptor family C group 6 member A (GPRC6A) (16). 
Obesity/diet 
Another set of risk factors that have been described in prostate tumorigenesis are 
obesity and dietary factors.  Obesity is thought to alter hormone levels (such as 
testosterone and leptin), which may contribute to prostate tumor development (17). 
Obesity has been clearly shown to increase risk of recurrence and mortality from prostate 
cancer (18, 19). However, only a weak, non-significant correlation has been observed 
between body mass index (BMI) and prostate cancer incidence (20, 21). Intake of animal 
fat, red meat, and dairy fat have been shown to increase the risk of total or advanced 
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prostate cancer, while fish and seafood intake are negatively correlated with prostate 
cancer risk (17). The reasons for the association may include altered circulating levels of 
hormones due to increased fat mass (22), and the presence of mutagenic compounds 
formed during the cooking of meat such as heterocyclic amines and polycyclic aromatic 
hydrocarbons (23).  The fact that the well-established prostate cancer risk factors are 
either non-modifiable or modifiable only with difficulty makes prostate cancer a truly 
challenging disease to prevent.     
Cigarette smoking  
There is no consistent effect of cigarette smoking on prostate cancer risk (24).  
Some studies have shown as much as a 30% increased risk in prostate cancer with 
cigarette smoking (25). Another study has shown different results, indicating duration of 
cigarette use and cumulative amount of cigarette use are not related to increased risk (26).  
There is a consensus, however, that current and former smokers have an increased risk of 
mortality due to prostate cancer (24). The most definitive prospective study to show this 
was the Health Professionals Follow-Up Study (27).  This study found that current 
smokers had an increased risk of prostate cancer-specific mortality compared to never 
smokers (HR, 1.61; 95% confidence interval [CI], 1.11-2.32) and also had an increased 
risk of biochemical recurrence (27).  Interestingly, those who had quit smoking for more 
than 10 years or had quit less than 10 years prior but had smoked less time overall did not 
have a significant increase in prostate cancer-specific death, indicating that current use of 
cigarettes has the most meaningful effect on prostate cancer-associated death (27). The 
link between current cigarette use and prostate cancer progression and death is not 
understood.   
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Prostate cancer diagnosis 
 
Screening  
Prostate cancer is diagnosed by several techniques.  The first screening technique 
which has been used historically is the digital rectal exam (DRE).  The American 
Urological Association (AUA) recommends that men over the age of 40 with a life 
expectancy of more than 10 years have a yearly DRE to examine if the prostate has 
nodules, hardening, gross asymmetry, or gland fixation. The second screening technique 
is serum prostate specific antigen (PSA) screening, which detects the PSA protein, a 
protein expressed and secreted only from prostate epithelial cells.  PSA is present at 
higher levels in the blood when the prostate is growing abnormally.  The test was made 
widely available in the late 1980s and early 1990s and has greatly increased the 
proportion of prostate tumors that are caught at a very early, treatable stage. The AUA 
also suggests that PSA screening be performed yearly on men over 40.    
While PSA screening does increase the number of early stage tumors detected, it 
also increases the number of tumors found that would have remained indolent for the life 
of the individual, not invading or metastasizing, until the death of the man by other 
causes. Therefore, PSA screening can result in overtreatment.  Side effects of prostate 
cancer treatment can include urinary incontinency, sexual impotency, bowel dysfunction, 
and loss of fertility which may have been avoided if a tumor was destined to remain 
indolent and did not require treatment. Thus, in 2012 the U.S. Preventive Services Task 
Force reported that the PSA screening in prostate cancer diagnosis of relatively healthy 
men was not recommended (28).  Nevertheless, DRE and PSA remain as the major 
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screening modalities to detect prostate cancer at as early a stage as possible.  The inability 
to reliably determine the clinical outcome of a tumor at diagnosis, and the necessity for 
treatment, is a major challenge in prostate cancer.  
Biopsy  
Upon a positive DRE or a repeated PSA above 4.0 ng/L, a prostate biopsy is 
performed to assess stage and grade of the tumor (29). Generally, 8-12 evenly spaced 
cores of prostate tissue are taken to survey the presence of cancer in the gland.  Prostate 
cancer is commonly multifocal, with an average presence of five independent loci at 
diagnosis (30). A “Gleason Pattern” is given by a pathologist to represent the histological 
appearance and differentiation of the prostate (31). The scores range from 1 to 5, with 5 
being the least differentiated and most aggressive cancer tissue.  The “Gleason Score” is 
given by providing the sum of the most prevalent pathology type, with the next most 
prevalent type (e.g. 4 + 3 = 7) (31).   
 
Prostate cancer treatment 
 
Low-risk prostate cancer treatment - prostatectomy and radiation 
Using the Gleason Score, DRE findings, and sometimes information from an 
imaging modality such as transrectal ultrasound (TRUS), doctors estimate the grade of 
the tumor and discuss treatment options for the patient following guidelines accepted by 
clinical practice (32).  There are no definitive rules for treatment and much is decided as 
a discussion between patient and doctor comparing the mortality risk with the side effect 
risk, taking into consideration the patient’s life expectancy and current health status. 
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Patients with low risk tumors, i.e. with a Gleason score of less than six, a low tumor 
stage, and a PSA ≤ 10 ug/L, may opt for “active surveillance.”  Active surveillance 
consists of no immediate treatment, but instead monitoring status by PSA and DRE every 
6 to 12 months followed by a biopsy if changes are observed in either test (29).   
Patients with a low-risk tumor may also opt for radical prostatectomy, removal of 
the entire prostate gland.  This can be curative, but comes with possibility of side effects 
such as incontinency and impotency. However, recent minimally invasive nerve-sparing 
laparoscopic and robotic-assisted surgery has decreased side effect occurrence (33).  
Another primary treatment option for low risk disease, with similar results as 
prostatectomy, is brachytherapy (34). This is performed by putting radioactive seeds into 
the prostate and irradiating the tissue to ablate the functional prostate gland. The vast 
majority of low-risk prostate cancer patients are cured by radical prostatectomy or 
brachytherapy, with 10-year biochemical free recurrence of about 80-90% each (34), 
(35).   
Definitive grading of the prostate histology is possible after radical prostatectomy 
due to having access to the entire gland.  This allows for the determination of whether 
additional therapy would be beneficial to the patient.  If the tumor was found to have 
spread beyond the prostate gland, invading nearby tissue or regional lymph nodes, 
androgen deprivation therapy is often begun immediately after surgery (29).  In addition, 
external beam radiation may be started 3-6 months post-surgery if the tumor was 
determined to be invasive from positive surgical margins (29).   
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Androgen-deprivation therapy  
PSA testing is used to monitor for recurrence after surgery or radiotherapy. A rise 
in the PSA of 0.2 ng/L after surgery or 2 ng/L after radiation is considered biochemical 
recurrence.  If androgen-deprivation therapy (ADT) was not already started immediately 
post-surgery due to tumor invasion outside the prostate, it will be started upon 
biochemical recurrence. ADT involves decreasing the action of androgens in the body by 
either inhibiting their circulating levels or their ability to carry out their normal biological 
effects (36).  ADT causes inhibition of tumor growth and PSA to fall in almost all cases. 
However, in most cases there is recurrence of tumor growth, with an average survival of 
5 years after PSA rise following initial ADT in patients with no evidence of metastatic 
disease (37).  A prostate tumor which is no longer inhibited by lack of androgens is 
termed castrate-resistant prostate cancer (CRPC) and has often metastasized to distant 
sites.  The most common site for prostate cancer metastasis is bone, followed distantly by 
liver and lung (37).     
CRPC treatments 
Treatment for CRPC is not curative but can only prolong survival for a short 
period of time.  The overall survival time for men with CRPC is 2-3 years (38).  In the 
last decade, docetaxel chemotherapy with prednisone has been the standard treatment for 
CRPC (32).  Docetaxel prolongs survival for an average of 3 months (39).  Many studies 
are investigating additional therapies for CRPC. In 2012, a new anti-androgen 
enzalutamide was approved for treatment of CRPC.  Enzalutamide (also called 
MDV3100) is an androgen receptor antagonist which binds AR more strongly than 
previous antiandrogens and prevents translocation of AR to the nucleus (40). 
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Enzalutamide increased survival in CRPC patients after chemotherapy almost 5 months 
over placebo (41).  A recently FDA-approved immunotherapy called Sipuleucil-T 
activates the body’s own immune system against prostate cancer cells (42).  Other 
treatments that have shown a survival benefit in Phase III clinical trials include novel 
taxanes, other androgen signaling inhibitors, and bone-directed agents (43).  
Unfortunately, all of these agents prolong survival for only 4 months or less.   
 
Challenges in prostate cancer 
 
There are several major challenges in the prostate cancer field. First, the challenge 
of distinguishing tumors which will remain indolent from those that will quickly progress 
to metastatic disease is a major clinical problem.  While at least 70% of those diagnosed 
with prostate cancer will not progress to metastatic disease, the current grading and 
staging of tumors is not completely accurate in identifying high-risk patients.  Many 
patients are over treated, while some may have benefited from more aggressive therapy.  
Secondly, effective therapies for each stage of the disease are needed to increase survival 
and ultimately to completely prevent progression to end stage disease.  Ultimately, a 
prevention method is greatly desired, to decrease the widespread prevalence of the 
disease and avoid the high treatment-related morbidity and health care costs associated 
with prostate cancer.  However, to determine an efficacious prevention method, a more 
thorough understanding of prostate tumor progression is needed.   
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Prostate cancer etiology 
 
Prostate cancers are primarily adenocarcinomas, or cancers of the prostate 
glandular epithelial cells. Despite the prevalence of the disease, the mechanisms behind 
prostate carcinogenesis are not completely understood. The two major mechanisms 
behind prostate tumorigenesis that are highly investigated include androgen-driven 
mechanisms and oxidative stress-driven mechanisms.   
Androgen-driven mechanisms 
The prostate gland is an organ whose development and function is largely 
dependent on circulating androgens. The androgen receptor (AR) is a transcription factor 
that is expressed in the epithelial and stromal compartments of the prostate.  In normal 
physiology, activation of the androgen receptor via hormone binding causes it to 
translocate to the nucleus to mediate its effects on gene transcription. The global set of 
androgen receptor target genes has been identified via ChIP-seq technology (44, 45) and 
include genes involved in prostate growth and differentiation.  Androgen treatment in 
vitro promotes cell proliferation, differentiation, and survival (46, 47).    
The vast majority of prostate tumors are androgen-dependent at diagnosis and 
when androgens are depleted, tumors strongly regress, supporting androgen mediation of  
prostate cancer (36).  The regression usually lasts for 1-3 years (48), but inevitably, 
almost all tumors recur, with an average survival of 9-13 months post-recurrence (49). 
This suggests that the normal androgen signaling, mediated by circulating androgens 
binding normally to AR, has become aberrant and is fueling cancer growth. This can 
occur through mutations to the AR gene that allow the protein to respond to other ligands 
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or become ligand-independent (50). Therefore, while androgens drive prostate tumor 
growth, tumors often attain mutations which allow them to proliferate in the absence of 
androgens.  Other factors must be identified to find an effective treatment of hormone-
refractory tumors.   
Oxidative stress-driven mechanisms  
Elevated oxidative stress is present in many cancer types, and prostate cancer is 
no exception (5, 51, 52). Oxidative stress, damage which occurs in cells due to an excess 
of ROS, can result from an overproduction of ROS or an incomplete quenching of ROS.  
ROS, class of free radicals, are highly reactive chemicals containing oxygen with at least 
one unpaired electron in their outer shell. Some level of ROS are required for normal 
cellular functions, but an imbalance of ROS levels often lead to substantial cellular 
pathology.   
Sources of ROS  
ROS can be generated through several mechanisms in the cell.  ROS are 
generated as normal byproducts of cellular respiration (53).  In some cases, poor 
functioning of the electron transport chain allows further elevated levels of oxidative 
radicals to be formed (53).  Several pro-oxidant enzymes, such as NADPH oxidase 
enzymes (NOX) in the cell membrane, produce ROS in response to cellular signals (54). 
In addition, inflammatory cells release ROS upon activation during an immune response 
causing oxidative stress in the tissue (55).  
ROS types  
 There are many different types of ROS, each with diverse physiological functions 
and abilities to react with substrates causing damage to cellular components.  Superoxide 
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(O2·-), hydrogen peroxide (H2O2), and the hydroxyl radical (HO·) are the most common 
ROS in cells (56). Superoxide is formed as a byproduct of cellular respiration and by 
NADPH oxidase enzymes and is converted by cellular antioxidants to H2O2 (53, 54). 
These common ROS react with other compounds in the cell to form other reactive species 
such as lipid peroxides, which can also damage cellular components by oxidation. Other 
ROS include the hypochlorite ion (OCl-) and singlet oxygen (1O2).     
Cellular antioxidants  
 ROS are quenched by antioxidant molecules and enzymes in the cell.  The most 
abundant and important antioxidant molecule in cells is glutathione (GSH).  Glutathione 
is a tri-peptide (L-gamma-glutamyl -L-cysteinyl-glycine) which is oxidized itself to 
quench ROS and is then converted to its reduced from by antioxidant enzymes known as 
glutathione peroxidases (Gpx) (57).  Other non-enzymatic antioxidants include essential 
nutrients such as alpha-tocopherol (α-T), gamma tocopherol (γ-T), and vitamin C.  The 
unique chemical properties of antioxidant molecules dictate the specific types of reactive 
species they quench.  Selenium, another important antioxidant compound, exerts its 
antioxidant effect by acting as a required component in a set selenium-containing proteins 
(selenoproteins) which act as cellular antioxidant enzymes. Table 1 lists several 
antioxidant molecules used as supplements in humans that have been studied in prostate 
tumorigenesis, highlighting the ROS they preferentially quench and other mechanisms of 
antioxidant action.  
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Table 1. Antioxidant supplements and their functions 
 
 
 
Antioxidant Solubility ROS preferentially quenched Other antioxidant functions Citations 
N-acetyl cysteine  water soluble hydroxyl radical, nitrogen dioxide,  carbonate radical   
increases intracellular glutathione 
(GSH) levels by providing cysteine (58, 59)  
Selenium water soluble N/A required for synthesis of vital antioxidant selenoproteins (60) 
Vitamin C 
(ascorbic acid) water soluble 
aqueous peroxyl radicals; regenerates oxidized α-
T to assist in quenching of lipid peroxides increase antioxidant protein expression (61–64)  
Alpha-
tocopherol lipid soluble lipid peroxyl radicals 
induction of antioxidant enzymes via 
the Nrf2 transcription factor 
(65, 66) 
 
Gamma-
tocopherol lipid soluble 
lipid peroxyl radicals; quenches reactive nitrogen 
species better than α-T 
with α-T, induces the Nrf2 transcription 
factor and antioxidant enzymes  (65, 67, 68) 
Beta-carotene lipid soluble lipid peroxyl radicals vitamin A precursor (69, 70)  
Lycopene lipid soluble lipid peroxyl radicals induction of antioxidant enzymes via the Nrf2 transcription factor (69, 70) 
Soy 
isoflavanones lipid soluble lipid peroxyl radicals 
induction of antioxidant enzymes via 
the Nrf2 transcription factor (71, 72)  
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Mammalian cells contain a wide variety of antioxidant enzymes, including 
superoxide dismutase, catalase, selenoproteins such as glutathione peroxidases, and 
thioreductases.  Proper levels of cellular antioxidant molecules and enzymes are required 
to prevent damage to cells by ROS that are generated normally during cellular 
metabolism and those induced by exogenous sources.  Antioxidant enzymes are normally 
upregulated upon oxidative stress to rid the cells of the damaging ROS.  If antioxidant 
molecules and proteins cannot quench ROS adequately, high levels of ROS can cause 
significant damage to cellular components and greatly alter normal cell homeostasis.  
ROS effects  
Classically, oxidative stress has been known to cause oxidative damage to DNA, 
lipids, and proteins.  DNA oxidation can lead to mutations which can either decrease cell 
viability or cause cellular transformation (73).  Lipid and protein oxidation can 
significantly alter the function of proteins, leading to substantial pathology (74).  
However, recent research has shown that the effect oxidative stress has on cells 
can vary greatly depending on the level of ROS, the type of ROS, and the type of cell 
(normal or cancerous).  For example, low levels of ROS are necessary for intracellular 
signaling processes and can promote proliferation in many circumstances (75–77).  
However, high levels of ROS often lead to cell cycle arrest, senescence, or cell death 
(78–82).  In addition, a certain level of ROS in a normal cell might cause the cell to die, 
but the same level in a cancer cell may allow the cell to live and even promote 
proliferation (Figure 3). Due to the various effects ROS can have, the precise role that 
they play in the development of tumors is not completely understood. 
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Figure 3. Differential effects of ROS depending on level and cell type  
ROS can have very different effects on a cell depending on several factors. In addition to the actual type of 
reactive species, the amount of a certain reactive species and the cell type with which it is interacting play a 
major role in determining the effect. The image depicts how a higher level of ROS may cause cell death 
while lower levels may promote cell signaling.  In addition, a certain level of ROS (indicated by the dashed 
blue line) may cause cell death in a normal cell, but may promote proliferative cell signaling in a cancer 
cell.   
 
 
Oxidative stress has been implicated in the etiology of prostate cancer in several 
studies. Studies in human prostate cancer cell lines have suggested that ROS promote 
tumorigenicity (51, 83–86).  However, it has not been conclusively shown that ROS 
initiate prostate cancer, promote later stages of the disease, or are merely a side effect of 
the process.  Studies such as these and along with pre-clinical studies (described below) 
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have prompted clinicians to determine the efficacy of antioxidant chemoprevention in 
human prostate cancer.  
 
Prostate cancer chemoprevention 
 
Because of the high prevalence of prostate cancer world-wide, the high treatment-
related morbidity, and the ultimate lack of cures for advanced disease, prostate cancer is a 
key target for cancer prevention measures. Studies have investigated the ability of dietary 
factors to prevent disease, suggesting several foods that decrease prostate cancer risk 
such as fish/seafood (87), cruciferous vegetables (88), and tomato products (89). While 
some moderate links to modifiable lifestyle factors have been described, the desire for an 
easily usable supplement has spurred many years of research dedicated to identifying 
chemical compounds which can prevent prostate cancer.  The two major classes of 
chemoprevention agents target the two major factors in prostate cancer epidemiology, 
androgens and oxidative stress. Chemopreventative agents have been studied in pre-
clinical and clinical studies of prostate cancer development, and while they have shown a 
temporary promise for efficacy, ultimately have proven ineffective.   
Pre-clinical prostate chemoprevention studies 
Models  
Chemoprevention has primarily been tested in genetically engineered and 
carcinogen-driven mouse models of prostate cancer. The most commonly used transgenic 
mouse model employed in these studies is the transgenic adenocarcinoma of mouse 
prostate (TRAMP) model, which is driven by prostate-specific expression of large and 
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small T antigens, inactivating the p53 and pRb tumor suppressor pathways (90).  These 
mice develop neuroendrocrine prostate cancer by 10 weeks of age and distant metastasis 
by as early as 12 weeks of age (90, 91). TRAMP mice provide a reliable source of tumors 
and metastases for use in chemoprevention trials. However, the model progresses very 
quickly, unlike most human prostate cancers, and employs changes in protein function 
(loss of p53 and pRb) which are not generally observed early in human prostate 
tumorigenesis (92, 93). In addition, TRAMP mice display neuroendocrine tumors, tumors 
which express markers of neuroendocrine cell differentiation, while the vast majority of 
human prostate cancers are adenocarcinomas.  Therefore, TRAMP is not the best model 
to use for prostate cancer prevention, as it may instead better reflect treatment of 
neuroendocrine prostate tumors. Other mouse models which have been used for 
chemoprevention studies include LADY mice (a somewhat slower progressing, large-T 
antigen driven model) (94) and PTEN-deficient mice (model with lack of the prostate 
tumor suppressor gene PTEN) (95).  Arguably, the best models for chemoprevention 
would be those which exhibit the earliest changes in the initiation of prostate cancer and 
have a slow progression over the lifespan of the animal, as is seen in human prostate 
cancer. Many other models of early-stage tumorigenesis in mouse prostate have been 
developed, but few, if any, have been used in chemoprevention studies (96).   
The most common rat model used is the Dunning rat model (97), in which a 
spontaneously arising rat prostate tumor was used to generate cell lines that are injected 
orthotopically to study inhibition of disease progression.  Induced models of rat prostate 
cancer used include hormone and carcinogen-induced models (reviewed in (98)). 
Spontaneous prostate cancer can also be studied in canines, but the inefficiency of studies 
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with this species have prevented any significant progress in chemoprevention research 
(96).   
Androgen-directed prevention measures  
Androgen inhibition slows growth or causes apoptosis of currently existing 
prostate tumor cells in cell line models and transgenic mouse models.  The ability to test 
the efficacy of androgen directed chemoprevention in transgenic mouse models of 
prostate cancer is difficult as the prostate-specific promoters used to drive transgene 
expression are androgen-responsive. For example, the anti-androgen flutamide was able 
to inhibit tumorigenesis in the TRAMP model (99); however, this was associated with a 
decrease in T-antigen expression from the probasin promoter, which could have mediated 
the observed effect. A similar effect was seen with the 5-α reductase inhibitor dutasteride 
in TRAMP mice (100). Despite the lack of good models for testing androgen-directed 
prevention measures in the pre-clinical testing, the centrality of androgens in prostate 
growth and proliferation makes androgen inhibition a good target for chemoprevention.  
Oxidative stress-directed prevention measures  
Numerous studies have been performed in mouse models of prostate cancer to 
analyze the efficacy of various antioxidant compounds for prostate cancer prevention 
(101), (102).  Many compounds have been shown to slow tumor development in the 
TRAMP mouse including N-acetylcysteine (103), compounds from spinach leaves, green 
tea, cruciferous vegetables (103–105), and tomatoes (106, 107), tocopherols and 
tocotrienols (68, 108), and selenium-containing compounds (109). A combination of 
vitamin E (as α-tocopherol succinate), selenium, and lycopene in the diet were shown to 
strikingly inhibit cancer development in the LADY mouse (110), but the omission of 
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lycopene prohibited this effect (111) indicating it was the crucial component.  Two 
compounds with purported antioxidant properties, curcumin and resveratrol, inhibited 
tumor development in the Pten-deficient mouse prostate (112).  Selenium and vitamin E 
failed to prevent prostate cancer development in carcinogen and androgen driven model 
of rat prostate cancer, and vitamin E even showed a marginally significant increase in 
prostate cancer formation (113).  While some studies showed “chemoprevention” of 
prostate cancer, the weakness of most of these studies is that a rapid progression to 
advanced cancer is seen in these models, due to inactivation of potent tumor suppressor 
genes.  Therefore, they are not ideal models for chemoprevention.  Some, but not all of 
these compounds have been tested in human studies, with mostly negative results, 
questioning the accuracy of commonly used pre-clinical rodent models of prostate cancer 
for chemoprevention.   
Clinical prostate cancer chemoprevention studies  
Androgen-directed prevention measures 
Because androgens are crucial in the development of prostate cancer, and removal 
of them by physical or chemical means inhibits prostate tumor growth, inhibition of 
androgen levels in the normal prostate has been investigated as a chemopreventative 
measure. The major target for this measure has been the enzyme 5-alpha-reductase, the 
rate limiting enzyme responsible for the conversion of testosterone to the more 
biologically potent dihydrotestosterone (DHT). Two drugs, finasteride and dutasteride, 
have been used in human trials to inhibit 5-alpha-reductase (114, 115).  
The Prostate Cancer Prevention Trial (PCPT), one of the largest randomized 
controlled clinical chemoprevention studies performed in U.S. history, began in 1993 
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(116).  The PCPT investigated the ability of the 5-alpha-reducatse inhibitor finasteride (5 
mg per day), to prevent prostate cancer development in a healthy male population.  
Finasteride had received FDA approval for use in BPH in 1992, where it effectively 
decreased prostate volume and improved urinary symptoms (117, 118).  As finasteride 
decreases PSA levels, participants received a prostate biopsy, regardless of clinical signs, 
at study completion (year 7). The final results of PCPT published in 2003 showed an 
almost 25% reduction in total prostate cancer risk with finasteride treatment (119).  
Results of the trial were not completely well received, however, due to the fact that they 
observed an increased risk of advanced cancer (Gleason 7-10) in the finasteride-
supplemented group (119).  Subsequent analysis by the investigators suggested that this 
finding may be explained by an increased chance of detecting advanced cancer due to a 
similar number biopsies taken from the significantly smaller prostate volume in the 
finasteride group (114).  Tumor extent was lower and detected earlier in the finasteride 
group (114).   
A subsequent trial, Reduction by Dutasteride of Prostate Cancer Events 
(REDUCE), was performed with a more potent 5-alpha-reducatse inhibitor and on men at 
an increased risk of prostate cancer due to slightly elevated PSA.  The results of 
REDUCE showed a similar reduction in overall risk as PCPT and an increased risk of 
advanced disease in years 3 and 4 of the study (115).  The unexpected increase in 
advanced tumor development with 5-alpha-reductase inhibitors has spurred much 
controversy (120, 121) with scientists and clinicians questioning the study design and the 
implications for clinical practice.  This problem has prevented these agents from 
receiving FDA approval for prostate cancer chemoprevention (122).   
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Oxidative stress-directed prevention measures  
Positive results from antioxidant chemoprevention in mouse models of prostate 
cancer and antioxidant effects on human prostate cancer cells suggested that oxidative 
stress may be a causative mechanism for human prostate cancer. Several epidemiological 
studies and clinical trials supported this idea.  In a U.S. male population, high plasma 
levels of γ-tocopherol were significantly associated with a decreased risk of prostate 
cancer, and higher selenium levels had a trend toward a decreased risk of prostate cancer 
(123).  Higher plasma levels of lycopene were associated with a decreased risk of 
prostate cancer (124, 125).  Intake of cruciferous vegetables moderately decreases risk 
(88, 126), and components of green tea seem to decrease risk of prostate cancer (127, 
128).   
Two intervention studies assessing antioxidant chemoprevention for other cancer 
types suggested that supplementation with the antioxidants vitamin E and selenium may 
substantially decrease prostate cancer risk.  The first of these studies, the Nutritional 
Prevention of Cancer (NPC) trial, assessed the ability of selenium to prevent recurrent 
nonmelanoma skin cancer in the Eastern U.S (129).  While the authors did not observe a 
decrease in skin cancer recurrence as hypothesized, in secondary analysis of the results, a 
decrease in incidence of prostate cancer (63% decrease), lung cancer, colorectal cancer, 
total cancer incidence, and total cancer-associated mortality was noted (130).  The second 
study, the Alpha-tocopherol Beta-Carotene Cancer Prevention Study (ATBC), tested the 
ability of α-tocopherol and beta-carotene to decrease the incidence of lung cancers and 
other cancers (131).   α-T did not decrease the risk of lung cancer, and beta-carotene 
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increased the risk of lung cancer by 16% (132).  Secondary analyses showed that α-
tocopherol supplementation decreased prostate cancer risk by 34% (133).  
However, the evidence for an overall role of antioxidant compounds in preventing 
prostate cancer development was not completely clear.  For example, while increased 
plasma levels of γ-T were associated with a lower risk of prostate cancer, high α-T levels 
alone were not (123).  Significant decreases in risk with higher α-T and selenium levels 
were only seen with high γ-T levels (123).  In another important investigation, 
supplementation with the important antioxidant beta-carotene did not decrease prostate 
cancer risk (134).   
Nevertheless, using the results from NPC and ATBC as rationale, and in order to 
determine the efficacy of vitamin E and selenium for prostate cancer chemoprevention, 
the Selenium and Vitamin E Cancer Prevention Trial (SELECT) was launched in 2001. 
SELECT was the largest randomized controlled prostate cancer chemoprevention trial to 
date (135, 136). It tested the ability of α-tocopherol (400 IU/day) and selenium (200 μg/d 
from L-selenomethionine) to prevent prostate cancer in over 32,000 men in the U.S., 
Canada, and Puerto Rico with no history of prostate cancer, low PSA, and negative DRE.   
SELECT began recruitment in August 2001 and continued through June 2004.  
35,533 men were recruited from 427 sites and randomized into four intervention groups: 
vitamin E, selenium, vitamin E + selenium, or placebo (137). Unlike the PCPT, prostate 
cancer diagnoses in SELECT were made by community standard of care. There was 
widespread hope for the confirmation of an effective chemopreventative measure for 
prostate cancer. Unfortunately, however, when an interim analysis was performed on data 
gathered until August 1, 2008, discontinuation of study supplement was recommended 
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since there was convincing evidence that neither trial supplement reduced the risk of 
prostate cancer (137). An initial publication of study results in January 2009, reported no 
statistically significant change of prostate cancer risk in any of the intervention groups 
(137). However, a non-statistically significant increase in prostate cancer was seen in the 
vitamin E arm (p = 0.06) in the analysis.  
A second analysis of results published in 2011 including, 54,464 additional 
person-years of follow-up, again showed that there were no significant decreases in 
prostate cancer risk in any randomization arm (138). Alarmingly, there was a 17% 
increased risk of prostate cancer in the vitamin E arm (hazard ratio [HR], 1.17; 99% CI, 
1.004-1.36, p = 0.008). Interestingly, the vitamin E + selenium arm did not show a 
significantly elevated risk, suggesting that selenium is somehow protective in the setting 
of vitamin E supplementation (138).  
These disappointing results have led to controversy over the failure of vitamin E 
and selenium to prevent prostate cancer (139).  Some have critiqued the form and dosage 
of selenium used as major reasons for the failure of the trial (140, 141).  Other authors 
note that the form of vitamin E used in the trial, α-T, decreases the levels of γ-tocopherol 
in the body (142).  γ-T is the form which has stronger epidemiological evidence for 
association with decreased prostate cancer risk; and thus, decreasing γ-T levels could be 
to blame for an increased risk.  Others have suggested that while vitamin E and selenium 
may prevent cancer in a subpopulation, they are not protective in the general population 
(143).  
Due to the large amount of money and effort spent on the SELECT trial, and the 
anticipation for finding a simple, broadly applicable prevention measure, current research 
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is focused on determining the mechanisms by which vitamin E may increase prostate 
cancer risk and on identifying subgroups of participants who may have been at 
significantly increased or decreased risk. Determining these factors will deepen 
understanding of prostate tumorigenesis, influence future attempts at prostate cancer 
chemoprevention, and direct current recommendations for prostate cancer prevention and 
treatment.   
 
NKX3.1 in prostate tumorigenesis 
 
Molecular genetics of prostate cancer  
While much remains unknown about prostate cancer initiation, the steps of tumor 
progression have been studied in more detail.  A widely accepted general progression of 
gene expression changes occurring during the progression towards malignant and 
metastatic disease has been described (144) (Figure 4).  First, the proliferation of the 
prostate epithelial cells increases and the gland becomes hyperplastic.  This hyperplasia 
can continue uncontrolled and eventually lead to the cells becoming dysplastic, altering 
their normal size and shape.  Such changes result in the appearance of prostatic 
intraepithelial neoplasia (PIN) lesions, an accepted precursor to prostate cancer.  These 
PIN lesions can progress with additional changes to become localized adenocarcinoma.  
With additional alterations, the adenocarcinoma can become locally invasive and then 
metastasize to distant sites.  
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Figure 4. Model of prostate cancer progression and associated genetic alterations  
Cartoon depicting the initiation and progression of human prostate tumorigenesis with the common genetic 
lesions or gene expression changes that occur during each step of progression.  Adapted from Abate-Shen 
and Shen (144). 
 
Each of these steps in prostate tumorigenesis is accompanied by changes in gene 
expression, either through loss or gain or DNA encoding genes, or through modulation of 
gene expression at the RNA or protein level. One of the earliest gene expression changes 
in prostate cancer, thought to occur prior to PIN development, is loss of expression of the 
tumor suppressor gene NKX3.1 (145).   
While these lesions can and do occur in the manner described above, the disease 
is heterogeneous. Different patients can have widely different gene expression changes 
(146, 147). This makes finding a widespread treatment for recurrent prostate cancer 
difficult.   
NKX3.1 homeobox transcription factor 
Nkx3.1 was first described in mice by Charles Bieberich and colleagues in 1996  
as a member of the NK family of homeobox genes (148).  Homeobox proteins were 
classically described in body segment determination in Drosophila development and 
contain a consensus homeodomain which binds DNA and directs gene transcription 
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(149).  While the homeodomain is similar among homeobox proteins, additional 
specificity to binding sites is conferred by interaction with other transcription factors 
(149).  Thus, Nkx3.1 is a homeobox transcription factor which regulates gene 
transcription of a distinct set of target genes.   
 NKX3.1 expression and Nkx3.1-null phenotype 
NKX3.1 expression is almost completely confined to the prostate epithelial cells 
and its expression is highly androgen-dependent, as castration greatly diminishes Nkx3.1 
expression in mice (148).  Shortly after its description in mice, the human NKX3.1 gene 
was isolated and shown to be at a gene locus which is commonly deleted in prostate 
cancer (150).  This discovery prompted investigators to hypothesize that NKX3.1 plays an 
important role in maintaining the differentiation state of the prostate epithelium, 
preventing cancer development as a tumor suppressor.   
Subsequent studies in Nkx3.1-deficient mice have shown that Nkx3.1 is crucial 
for the proper development and maintenance of the prostate gland (151, 152). Nkx3.1-
deficient prostates display increased epithelial proliferation, leading to hyperplasia, with 
the epithelial cells growing into the lumen of the glands (151, 152). Additional studies 
showed that indeed, Nkx3.1 expression is completely lost in 5% of benign prostatic 
hyperplasias, 20% of high-grade prostatic intraepithelial neoplasias, 34% of hormone-
refractory prostate cancers, and 78% of metastases (153), suggesting that Nkx3.1 acts as a 
tumor suppressor gene in the prostate.  
NKX3.1 functions 
In order to determine the functional role played by Nkx3.1 in the prostate, 
microarray studies were performed in Nkx3.1+/+ and Nkx3.1-/- mouse prostate (154), 
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(155).  Gene expression profiles can be analyzed on the level of groups of genes using 
Gene Set Enrichment Analysis (GSEA), highlighting the major gene sets regulated by a 
gene of interest (156, 157). GSEA analysis of the Nkx3.1+/+ and Nkx3.1-/- mouse prostate 
microarrays showed many significantly changed gene sets, including gene sets involved 
in oxidative stress and cell cycle regulation (158).   
Oxidative stress regulation 
Nkx3.1-/- mice have elevated prostatic oxidative stress, as shown by increased 
ROS levels in prostate tissue (159).  In addition, they show an increased presence of 
oxidative damage to DNA and protein (155, 159).  Loss of Nkx3.1 in the prostate 
epithelium may induce ROS in an indirect or direct manner.  ROS may be elevated in 
Nkx3.1-null epithelium partially due to the elevated level of proliferation, indicating 
elevated metabolic activity in cells, which can lead to increased oxidative stress (160). 
However, Nkx3.1 also appears to have a direct role in regulation of oxidative stress 
through direct regulation of anti- and pro-oxidant target genes. Chromatin 
immunoprecipitation with massively parallel DNA sequencing (ChIP-seq) analysis 
coupled with analysis of gene expression changes in Nkx3.1-/- mice showed that the 
antioxidant genes glutathione peroxidase 2 (Gpx2) and peroxiredoxin 6 (Prdx6), and the 
pro-oxidant gene quiescin Q6 sulfhydryl oxidase 1 (Qsox1) are direct target genes of 
Nkx3.1 (158).  Expression of the antioxidants Gpx2 and Prdx6 is decreased, while 
expression of the pro-oxidant Qsox1 is increased in Nkx3.1-/- mice suggesting an 
environment which promotes increased oxidative stress. It has been proposed that this 
increased oxidative stress is a mechanism through which Nkx3.1-loss promotes 
tumorigenesis (155, 161, 162).      
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Cell cycle regulation  
The Nkx3.1-/- mouse displays prostatic hyperplasia and increased levels of 
proliferation markers Ki67 and PCNA relative to the Nkx3.1+/+ mouse (151, 163). 
NKX3.1 expression has also been shown to decrease proliferation of human prostate cell 
lines (164–168). Studies by Magee et al. showed that Nkx3.1-deficiency extended the 
proliferative phase of prostate regeneration after castration and testosterone replacement 
in mice (154).  These studies suggest that Nkx3.1 plays a role inhibiting progression of 
the cell cycle.   
Response to DNA damage  
NKX3.1 has also recently been shown to play a role in repairing DNA damage, 
thus promoting cell survival after genetic insult. NKX3.1 localizes to sites of DNA 
damage, recruiting and activating ataxia telangiectasia, mutated protein (ATM), a protein 
essential for the DNA repair process (169).  NKX3.1 was also shown to bind the DNA 
unwinding enzyme topoisomerase I, enhancing its DNA cleavage activity and promoting 
survival in the presence of DNA damage (170, 171).   
NKX3.1 target gene regulation  
For many years, the direct target genes of Nkx3.1 were not known.  Initial 
microarray studies performed in wild type and Nkx3.1-deficient mice identified genes 
dysregulated upon Nkx3.1-loss (154, 155, 158).  Significant gene networks dysregulated 
upon Nkx3.1 loss were those involved in aminoacyl-tRNA synthesis, oxidative stress 
control, and cell cycle control (158).  Recent ChIP-seq experiments performed by the 
Abdulkadir laboratory and others have identified the genome-wide set of genes bound by 
Nkx3.1 (158, 172).  Integration of these data with gene expression profiling data yielded 
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a set of 282 “direct” Nkx3.1 target genes, genes either activated (153 genes) or repressed 
(129 genes) by Nkx3.1 binding (158). The major groups of genes in the Nkx3.1 direct 
target genes were the aminoacyl-tRNA synthesis pathway and MAPK signaling (158). 
This suggests that Nkx3.1 plays a role in regulation of protein biosynthesis and signaling 
related to cell cycle progression.   
Nkx3.1 and Myc co-regulate a set of target genes 
Changes in gene expression, classically increases in oncogenes and decreases in 
tumor suppressor genes, accompany and drive carcinogenesis.  However, in most cancer 
systems, the ability of tumor suppressors and oncogenes to regulate expression of the 
same genes has not been described.  In a recent study published by the Abdulkadir 
laboratory, 65 target genes were found to be directly regulated by Nkx3.1 and Myc via 
GeneGO analysis of ChIP-seq data for both transcription factors (158).  The shared direct 
target genes were enriched in pathways involved in tumorigenesis, and many were 
regulated in the mouse prostate (158).   
Peroxiredoxin 6 (PRDX6) 
One of the direct targets co-regulated by Nkx3.1 and Myc is the dual-function 
enzyme peroxiredoxin 6 (PRDX6).  PRDX6 is a member of the peroxiredoxin 
superfamily, which is a group of cysteine-dependent peroxidases (173), which reduce 
hydrogen peroxide and other peroxides, functioning as antioxidant enzymes. PRDX6 is 
of interest to prostate tumorigenesis as it may regulate prostatic oxidative stress.  PRDX6 
is unique among the 6 member family in that it also has a second catalytic function, 
phospholipase A2 (PLA2) activity (174).  This is also interesting as some of the main 
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products of PLA2 activity are prostaglandins, a class of compounds that have been 
suggested to play an important role in prostate tumorigenesis (175–177).   
PRDX6 is expressed widely, but has only been extensively studied in the lung 
where it functions to protect against oxidative stress (178–180) and to promote proper 
lung surfactant metabolism (181, 182). The role of PRDX6 in cancer has not been widely 
investigated.  In general it has been shown to be upregulated in cancer cell lines and 
tumor tissue relative to normal cells and tissue (183–186) and to increase proliferation, 
migration, and tumorigenicity in cancer cell lines (187–189).  It is not known how 
PRDX6 may function in the normal or transformed prostate; therefore, significant 
investigation is needed to determine the role of PRDX6 and other NKX3.1-MYC co-
regulated genes in prostate tumorigenesis.  
 
Summary and Rationale of Studies 
One of the most important challenges in prostate cancer today is determining 
efficacious prevention measures for the disease. Recent studies have shown that success 
in this endeavor will require having a more thorough knowledge of the molecular 
mechanisms behind prostate cancer. After large scale clinical trials, it is still not 
conclusively known if antioxidant chemoprevention will prevent development of the 
disease. In fact, data from the SELECT trial suggest that in some cases these compounds 
may even promote prostate cancer (138).   
To begin to address these challenges, I have conducted studies in mouse models 
of prostate tumorigenesis and in human clinical samples.  To help determine if oxidative 
stress is a causative mechanism early in prostate tumorigenesis, and if antioxidant 
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chemoprevention may prevent disease, I tested antioxidant chemoprevention in mice 
which develop an early prostate cancer precursor lesion. I measured aspects of 
tumorigenesis to determine if ROS play a role in this very early stage of disease.   
Next, to attempt to explain some of the mechanisms of early prostate 
tumorigenesis in humans, and to determine if there are certain populations who perform 
better or worse with antioxidant chemoprevention, I used samples from the SELECT trial 
to genotype genetic variants.  I set out to investigate if variants in the tumor suppressor 
gene NKX3.1 modified prostate cancer risk associated with antioxidant supplementation.  
During this analysis, I serendipitously found that a SNP in the Bcl-2 family member gene 
BNIP3L also modified risk with antioxidant supplementation in SELECT.  Findings from 
this study will help further our understanding of the molecules and processes involved in 
early prostate tumorigenesis.  
Lastly, while the transcription factor NKX3.1 is known to play a role in prostate 
tumorigenesis, all of its mechanisms of action are not understood.  Due to its possible 
role in regulation of oxidative stress in the prostate, I decided to investigate one of the 
direct target genes of NKX3.1, the antioxidant gene PRDX6.  My studies began to 
analyze the effect that PRDX6 regulation may have in the initiation and progression of 
prostate cancer.   
Through my use of preclinical and clinical samples, I have completed a study of 
antioxidant chemoprevention and NKX3.1 target gene regulation in early prostate 
tumorigenesis.  
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CHAPTER III 
 
ANTIOXIDANT SUPPLEMENTATION PROMOTES PROSTATE EPITHELIAL 
CELL PROLIFERATION IN Nkx3.1 MUTANT MICE 
 
Introduction 
 
Due to the high prevalence and significant treatment-related morbidity associated 
with human prostate cancer, there is a strong interest in preventive approaches.  In order 
to accomplish this, a more thorough understanding of the relationship between oxidative 
stress and the steps of prostate tumor progression is needed.  In recent years, extensive 
research has been devoted to the relationship between oxidative stress and the etiology of 
prostate cancer (5, 7, 52, 101).  In addition, the prostate gland has been associated with 
chronic inflammation (8), a condition linked to elevated oxidative stress.  Many studies 
have proposed a positive correlation between elevated oxidative stress and prostate 
cancer progression and have argued the value of antioxidants in preventing prostate 
cancer (reviewed in (102)).  However, it is notable that the majority, if not all, of these 
studies have employed models of late stage, aggressive disease, focusing on later steps in 
carcinogenesis rather than prevention of prostate cancer initiation (68, 103, 104, 83, 110, 
112, 190).  
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) was initiated in 
2001 to conduct a large, randomized controlled clinical trial on the efficacy of the 
antioxidants selenium and vitamin E in the prevention of prostate cancer (135).  Results 
39 
from two previously published clinical trials (130, 191) suggested that these two 
antioxidants could prevent prostate cancer development.  However, initial results 
published in 2009 (137) showed that neither selenium, vitamin E, nor their combination 
significantly prevented prostate cancer in the study population.  Follow-up results 
published in late 2011 (138) showed that vitamin E supplementation increased rather than 
decreased the risk of development of prostate cancer.  This troubling finding highlights 
the importance of understanding the role of ROS in prostate tumorigenesis.  In fact, one 
of the lead authors of the SELECT trial has suggested that any success in future 
chemoprevention may reside in the identification of specific risk factors in individuals 
that will help determine the effect any agent may have on their tumor development (192).  
NKX3.1 is a homeodomain transcription factor whose loss of expression 
correlates with human prostate cancer progression (150, 153, 193). NKX3.1 expression is 
lost early in tumorigenesis, suggesting that it is an early step in the progression to 
malignant disease.  While several studies have investigated the role Nkx3.1 loss plays in 
prostate cancer (145, 154, 167, 169, 170, 172, 194–198), much remains unknown.  
Nkx3.1-/- mice are a model of the early stages of prostate tumorigenesis, exhibiting 
hyperplasia and dysplasia at 8 weeks of age and progressing to prostatic intraepithelial 
neoplasia (PIN), a precursor lesion to prostate cancer, later in life  (151, 152, 199).  With 
additional genetic lesions, such as the loss of one allele of the Pten tumor suppressor 
gene, these mice develop prostate cancer (151, 152, 200).  Ouyang et al. showed that 
prostates of Nkx3.1-/- mice show dysregulation of several antioxidant and pro-oxidant 
control enzymes, accompanied by elevated oxidative stress (155).  They and others have 
suggested that increased oxidative stress may be an important way in which Nkx3.1 loss 
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promotes prostate tumor initiation (161), .  However, the ability of oxidative stress to 
mediate the hyperplasia of the Nkx3.1-/- mouse prostate has not been examined.   
In this study, I tested the ability of antioxidant supplementation to prevent the 
prostate pathology of Nkx3.1-/- mice.  Interestingly, Ifound that antioxidant 
supplementation did not inhibit, but instead promoted, the hyperplastic phenotype of the 
Nkx3.1-/- prostate. NAC supplementation of Nkx3.1-/- prostate also induced expression of 
a pro-proliferative gene signature, as demonstrated by Genome Set Enrichment Analysis 
(GSEA).  This suggests that ROS restrain the proliferative potential of the prostate 
epithelium in the setting of Nkx3.1-loss.  Our studies give new insight into the failure of 
antioxidants to prevent prostate cancer in healthy men.   
 
Methods 
 
Animals  
 
Nkx3.1-/- mice have been described (152).  Mice were maintained at Vanderbilt 
University Medical Center in compliance with national and institutional animal welfare 
standards.  For NAC supplementation, Nkx3.1+/+ and Nkx3.1-/- pups were weaned at 3 
weeks of age and littermates were divided between NAC treatment cages or vehicle 
cages.  Mice received vehicle or 5mM NAC (Sigma) in drinking water ad lib beginning 
at weaning for 13 weeks.  The pH of NAC solution was adjusted to that of regular 
drinking water.  Analysis of water intake and weight data after the conclusion of the 
experiment showed that the NAC dosage achieved was 158.5 mg/kg/day in Nkx3.1+/+ 
mice and 140.7 mg/kg/day in Nkx3.1-/- mice.  At the end of 13 weeks of supplementation, 
the mice were euthanized following BrdU intraperitoneal injection (50mg/kg) for prostate 
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histological analysis.  Animal protocol M/08/047 was approved by Vanderbilt's 
Institutional Animal Care and Use Committee.  
Quantitative reverse transcription-PCR (qRT-PCR) 
Total RNA was extracted from snap-frozen mouse anterior prostate tissue 
according to the Trizol® manufacturer’s protocol.  RNA was treated with RQ1 Rnase-
free DNAse (Promega) according to manufacturer’s protocol and incubated at 37°C for 
20 minutes, followed by purification using the RNA Clean Up protocol from the RNeasy 
Mini Kit (Qiagen). 1 µg RNA was subjected to reverse transcription using M-MLV 
Reverse Transcriptase (Invitrogen).  Quantitative real time PCR was performed using 
SYBR® Green and the Applied Biosystems 7300 Real Time PCR system with gene-
specific primers designed using Applied Biosystems Primer Express® software. The 
following primers were used: 18s forward (5’-CGCCGCTAGAGGTGAAATTCT-3’), 
18s reverse (5’-CGAACCTCCGACTTTCGTTCT-3’), Gpx2 forward (5’-
TGACCCGTTCTCCCTCATG-3’), Gpx2 reverse (5’-GCGCACGGGACTCCATAT-3’), 
Prdx6 forward (5’-TCTGGCAAAAAATACCTCCGTTA-3’), Prdx6 reverse (5’-
GCCCCAATTTCCGCAAAG-3’), Qsox1 forward (5’-GGCTGGGAGGGTGACAGTT-
3’), and Qsox1 reverse (5’-std 18 GCCCCTACCACCAAGCAA-3’). The expression of 
each mRNA was normalized to 18s rRNA expression.  
ChIP-qPCR of Nkx3.1 binding sites in LNCaP cells 
Chromatin immunoprecipitation (ChIP) was performed using the ChIP Assay kit 
(Millipore) as described by the manufacturer with the following modifications.  LNCaP 
cells (ATCC) were grown in RPMI medium supplemented with 10% fetal bovine serum 
(FBS) and 1 nM dihydrotestosterone (DHT) for 48 hours.  Cells were fixed in 1% 
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formaldehyde at 37oC for 10 minutes to crosslink protein-DNA complexes.  Next, cells 
were thoroughly washed with ice-cold PBS, pelleted, and resuspended in SDS lysis 
buffer [1% SDS, 10 mM EDTA, 50 mM Tris at pH 8.1].  Chromatin was sheared to a size 
of ~300-500 base pairs and diluted 1:10 with ChIP dilution buffer.  An aliquot of the 
diluted sample (1%) was saved as input.  Samples were precleared and precipitated 
overnight at 4oC with anti-NKX3.1 (Santa Cruz Biotechnology) or normal goat IgG 
(Santa Cruz Biotechnology) antibodies.  Antibody complexes were collected with Protein 
A Agarose/Salmon Sperm DNA (Millipore) for 2 h and washed extensively per 
manufacturer’s instructions.  Samples were reverse cross-linked at 65oC overnight with 
0.3 M NaCl and 30 µg of RNase A (Qiagen).  Input and bound DNA were purified with a 
PCR Purification kit (Qiagen) and analyzed by qPCR (Applied Biosystems 7300) using 
SYBR Green.  The following primers were used for qPCR:  QSOX1 forward (5’-
CCTTCATTGCTATTCACTGGCTAA-3’), QSOX1 reverse (5’-
TCCCCAACTGCAATGCAAA-3’), PRDX6 forward (5’- 
GGTGGCCGAAAGACTTTTTG-3’), PRDX6 reverse (5’- 
TGGCTCTTCCTAAAGCTGTTATCA-3’), GPX2 forward (5’- 
GAATCAGTCTAGCAAAGGATCAAACA-3’), and GPX2 reverse (5’-
GCATAGAGGGTGTAGTTACTGAGAACA-3’).  Immunoprecipitated DNA was 
normalized to 1% input.  Results are presented as mean ± SD. 
Dihydroethidium staining  
DHE staining was performed on anterior prostate tissue frozen in Tissue Tek® 
OCT embedding medium. 10 μm sections were cut and stained with 10 μM 
dihydroethidium (Molecular Probes) for 30 minutes in a 5% CO2 incubator and 
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visualized on a Zeiss fluroescent microscope.  Fluorescence intensity of each image was 
scanned and scored using Bio Rad GS-700 Imaging Densitometer and BioRad Quantity 
One ® software. 
Histology and immunohistochemistry 
Tissue was fixed overnight in 10% formalin solution and washed in 70% ethanol.  
Tissue processing and hematoxalin and eosin (H&E) staining was performed by the 
Vanderbilt Translational Pathology Shared Resource.  For immunohistochemistry, 
paraffin embedded sections were deparaffinized, rehydrated, and steam/pressure antigen 
retrieval was performed.  The following antibodies were used: anti-BrdU (mouse, 1:200, 
Santa Cruz Biotechnology), anti-phospho histone H3 (rabbit, 1:500, Millipore), anti-
cleaved caspase-3 (rabbit, 1:200, Cell Signaling), anti-smooth muscle actin (mouse, 
1:2000, Sigma), anti-p63 (PIN cocktail, Biocare Medical), anti-AR (rabbit, 1:600 Santa 
Cruz Biotechnology), anti-p16 (rabbit, 1:1000, Santa Cruz Biotechnology), anti-8-
Hydroxydeoxyguanosine (8-OHdG) (mouse, 1:1000, QED Bioscience), anti-p27 (mouse,  
1:2000, BD Transduction Laboratories), and anti-p21 (mouse, 1:50, Santa Cruz 
Biotechnology).  Horseradish peroxidase (HRP) conjugated secondary antibodies 
(BioRad) were used to detect primary antibodies and 3, 3’-diaminobenzidine (Sigma) or 
Nova Red (Vector Laboratories) were used as the chromogenic substrates.  Counterstain 
was performed with hematoxylin.    
Immunohistochemistry quantification 
Three independent fields of anterior prostate using a box objective at 60x were 
observed for 8-OHdG immunohistochemical staining in one year old Nkx3.1+/+ and 
Nkx3.1-/- mice and for BrdU, pHH3, and/or activated caspase 3 staining in the Nkx3.1 +/+ 
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and Nkx3.1-/- vehicle and NAC-supplemented mice.  Number of total cells and cells 
staining positive for each of the markers were recorded and data was reported as percent 
cells positive for the marker.  In all cases, at least 500 total cells were counted per mouse. 
Statistical Analysis 
Statistical analysis for immunohistochemistry, qRT-PCR, and fluorescence 
intensity image data was performed using two tailed Student’s t-Test, with two samples 
of unequal variance.  All results are presented as mean ± Standard Deviation.   P values ≤ 
0.05 are considered significant.   
Microarray and Genome Set Enrichment Analysis (GSEA) 
Total prostate RNA from four vehicle and four NAC-supplemented Nkx3.1-/- mice 
was extracted from snap-frozen mouse anterior prostate tissue according to the Trizol® 
manufacturer’s protocol. RNA was treated with RQ1 Rnase-free DNAse (Promega) 
according to manufacturer’s protocol, followed by purification using the RNA Clean Up 
protocol from the RNeasy Mini Kit (Qiagen).  RNA was processed and microarray 
analysis was performed by the Vanderbilt Genome Sciences Resource Core.  Briefly, 
RNA was quantified using the Qubit RNA assay and RNA quality was assessed with the 
Agilent Bioanalyzer.  cDNA was generated using the Ambion® WT Expression Kit.  
After fragmentation, the cDNA was labeled and hybridized to Affymetrix Mouse Gene 
1.0 ST arrays.  Arrays were scanned with Affymetrix Gene Chip Scanner [version 3.2.2].  
CEL files were imported to R [version 2.15.1] for quality control and pre-processing. 
Arrays for three vehicle and four NAC-supplemented mice passed quality control. Using 
the Affy package [version 1.34.0] (201), raw intensity scores for probes were normalized 
by quantiles, background corrected with RMA (202), and summarized by median polish 
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using PM-only probes. The C2 (curated) gene sets of MSigDB [version 3.0] were queried 
using GSEA [version 2.07] (156) to test for differences between vehicle and NAC-
supplemented prostates. Relationships between functional terms were visualized in 
Cytoscape [version 2.8.3] (203) with the Enrichment Map package [version 1.2] (204). 
All microarray and GSEA analysis was performed on a node running Debian Linux 
[version 6.0.5]. 
 
Results 
 
Nkx3.1 directly regulates antioxidant and pro-oxidant genes in the prostate  
  Previous gene expression analyses have revealed mis-expression of 
antioxidant and pro-oxidant genes in the Nkx3.1 null mouse prostate, including 
Glutathione peroxidase (Gpx2), Peroxiredoxin 6 (Prdx6), and quiescin Q6 sulfhydryl 
oxidase 1 (Qsox1 or Qscn6) (154, 155, 158). I performed qRT-PCR analysis on anterior 
prostates to confirm these gene expression changes. Expression of the antioxidant genes 
Gpx2 and Prdx6 was decreased in 10-11-week-old and 16-17-week-old Nkx3.1-/- mice, 
while expression of the pro-oxidant gene Qsox1 was elevated in these mice (Figure 5A).  
Examination of chromatin immunoprecipitation coupled to massively parallel sequencing 
(ChIP-seq) analysis for Nkx3.1 in mouse prostate (158) and the human prostate cancer 
cell line LNCaP (PDA, ML and SAA, manuscript in preparation) performed by our 
laboratory revealed binding sites for Nkx3.1 in both human and mouse tissue at all three 
genes (Figure 5B, 5C). Binding in LNCaP was confirmed via ChiP-qPCR (Figure 5D)  
Therefore, Gpx2, Prdx6 and Qsox1 are direct target genes of the Nkx3.1 transcription 
factor.  
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Figure 5. Nkx3.1-/- mouse prostate shows dysregulation of oxidative stress genes and increased 
oxidative stress levels  
(A) Quantitative reverse transcriptase-PCR analysis of RNA from 10-11-week and 16-17-week-old 
Nkx3.1+/+ and Nkx3.1-/- mouse anterior prostate for the expression of Gpx2, Prdx6, and Qsox1. Expression 
levels are relative to 18s rRNA. (10-11 weeks: n = 4 Nkx3.1+/+, n = 2 Nkx3.1-/-; 16-17 weeks: n = 3 
Nkx3.1+/+, n = 5 Nkx3.1-/-) (B) ChIP-seq screen shots from Integrative Genomics Viewer (IGV) displays 
direct binding of Nkx3.1 to the gene loci of Gpx2, Prdx6 and Qsox1 in mouse prostate, (C) and to GPX2, 
PRDX6 and QSOX1 in the human prostate cancer cell line LNCaP. (D) ChIP-qPCR analysis for Nkx3.1 
binding sites in GPX2, PRDX6, and QSOX1. Results are presented for each binding site primer set with 
anti-NKX3.1 antibody and IgG control.  Immunoprecipitated DNA was normalized to 1% input. (E) 
Percent positive stained anterior prostate epithelial cells from immunohistochemical staining for 8-OHdG 
in one-year-old Nkx3.1+/+ and Nkx3.1-/- anterior prostate. (n = 5 in each group) Student’s t-Test * = p ≤0.05.    
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Nkx3.1-/- mouse prostate displays increased oxidative stress 
The most common oxidative DNA base lesion, 8-OHdG, is commonly used as a 
marker of persistent oxidative stress (205).  Immunohistochemical staining of one-year-
old mouse anterior prostate showed significantly increased staining in Nkx3.1-/- mice 
(Figure 5E). These results confirm earlier findings of increased oxidative DNA damage 
in the prostates of independently generated Nkx3.1-/- mice (155) 
NAC supplementation of Nkx3.1-/- mice does not inhibit hyperplastic prostate 
phenotype 
 To determine if increased oxidative stress plays a causative role in the hyperplasia 
and dysplasia observed in the Nkx3.1-/- mouse prostate, I supplemented Nkx3.1-/- mice 
with 5mM NAC in their drinking water from 3 weeks of age until mice were sacrificed at 
16 weeks of age (Figure 6A). The 5mM NAC concentration was chosen to achieve a 
dosage of approximately 125 mg/kg/day for 13 weeks, a dosage and treatment duration 
shown to inhibit plasma ROS, decrease oxidative DNA and protein lesions in the 
prostate,  and decrease the incidence of prostate anterior lobe hyperplasia in the 
Transgenic Adenocarcinoma Mouse Prostate (TRAMP) model (103, 190).  Examination 
of water intake and weight data revealed that the achieved dosage for the Nkx3.1-/- mice 
was approximately 140 mg/kg/day. The 13 week NAC supplementation decreased ROS 
levels in the anterior prostate as shown by decreased staining for superoxide using the 
fluorescent dye dihydroethidium (DHE) (Figure 6B, 6C).  
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Figure 6. Antioxidant supplementation of Nkx3.1-/- mice decreases prostatic ROS  
(A) Nkx3.1-/- mice were supplemented with 5mM N-acetylcysteine (NAC) ad lib in their drinking water 
postweaning for 13 weeks. Mice were sacrificed for analysis at the end of supplementation (16 weeks of 
age). (B) Dihydroethidium (DHE) staining of frozen anterior prostate from Nkx3.1-/- vehicle or NAC-
supplemented mice. (C) Quantification of DHE staining density. (n = 3 in each group)  Student’s t-Test * = 
p ≤0.05.    
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 Histological analysis of Nkx3.1-/-anterior prostate, the prostatic lobe which 
displays the severest Nkx3.1-/- phenotype, showed that the NAC supplementation did not 
reverse the Nkx3.1-/- phenotype.  Observation of 23 control and 24 NAC-supplemented 
Nkx3.1-/- prostates revealed that the NAC-supplemented prostates did not have less 
hyperplasia or dysplasia than the control prostates (Figure 7A).  Immunohistochemical 
staining for smooth muscle actin was unchanged between supplemented and control 
mice, suggesting the prostate epithelial cells did not alter gland structure or invade the 
stromal compartment (Figure 7B).  Immunostaining for p63 (basal cell marker) and 
androgen receptor (AR) remained unchanged with supplementation, showing no major 
histological alterations of the prostate epithelium after NAC supplementation (Figure 
7B). 
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Figure 7.  NAC supplementation does not alter prostate histology in Nkx3.1-/- mice  
(A) Hematoxalin and eosin stained sections of Nkx3.1-/- anterior prostate do not display significant 
histological changes with NAC supplementation. (B) Immunohistochemical staining of anterior prostate for 
smooth muscle actin (SMA), p63, and androgen receptor (AR) do not have significant changes in staining 
pattern.  Scale bar = 0.1mm.   
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NAC supplementation of Nkx3.1-/- mouse prostate promotes increased proliferation  
 To assess cell proliferation in the prostate after NAC supplementation, mice were 
injected with BrdU three hours prior to sacrifice to label cells undergoing DNA synthesis, 
indicating the proportion of cells progressing though the cell cycle. Surprisingly, the 
percentage of anterior prostate epithelial cells staining positive for BrdU was increased 
by 60% in the NAC-supplemented Nkx3.1-/- mice (p = 0.02, n = 10 in each group, Figures 
8A, 8B).  Staining for the mitotic cell marker pHH3 was also increased by 30% in the 
NAC-supplemented animals (p = 0.05, n = 15 vehicle, n = 16 NAC, Figures 8C, 8D).  
However, activated caspase-3 staining revealed that apoptosis was unchanged with NAC 
supplementation (p = 0.59, n = 10 in each group, Figures 8E, 8F).  The observed increase 
in proliferation without a concurrent decrease in apoptosis suggests NAC 
supplementation increases prostate epithelial cell numbers in the Nkx3.1-/- prostate.    
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Figure 8.  NAC supplementation promotes epithelial proliferation in the Nkx3.1-/- prostate 
(A), (C), (E) Representative images from immunohistochemical staining of Nkx3.1-/- vehicle and NAC-
supplemented anterior prostate with antibodies specific to BrdU (A), pHH3 (C), and activated caspase-3 
(E). (B), (D), (F) Quantification of immunohistochemical stains. p values for a Student’s t-Test are shown.  
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NAC supplementation of Nkx3.1+/+ mouse prostate does not affect proliferation  
 To determine if NAC supplementation affects prostate epithelial cell proliferation 
in the absence of Nkx3.1-loss and elevated oxidative stress, I supplemented Nkx3.1+/+ 
mice with NAC in the same manner as was used for the Nkx3.1-/- mice.  The dosage 
achieved in the Nkx3.1+/+ mice was comparable to the Nkx3.1-/- mice at approximately 
160 mg/kg/day.  The NAC supplementation did not alter overall prostate histology in the 
Nkx3.1+/+ mice (Figure 9A).  BrdU and pHH3 immunohistochemical analyses showed 
that NAC supplementation did not alter the proliferation index of the Nkx3.1+/+ anterior 
prostate (Figure 9B, 9C).  
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Figure 9.  NAC supplementation does not alter epithelial proliferation in the Nkx3.1+/+ prostate  
(A) H&E sections of Nkx3.1+/+ vehicle and NAC-supplemented anterior prostate show no change in 
histology. Scale bar = 0.1mm. (B) Quantification of BrdU immunohistochemical staining in Nkx3.1+/+ 
vehicle and NAC-supplemented anterior prostate. (C) Quantification of pHH3 immunohistochemical 
staining in Nkx3.1+/+ vehicle and NAC-supplemented anterior prostate.  p value for a Student’s t-Test is 
shown.   
 
NAC supplementation of the Nkx3.1-/- mouse prostate promotes expression of a pro- 
proliferative gene signature 
ROS have been shown to induce senescence and quiescence in human and mouse 
models of disease (206).  Because quenching of prostatic ROS with NAC increased 
epithelial cell proliferation, I hypothesized that oxidative stress in the Nkx3.1-null 
prostate induces cell cycle arrest. I performed immunohistochemical staining for well-
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defined markers of senescence (p16, p21) and quiescence (p27) in Nkx3.1-/- vehicle and 
NAC-supplemented prostates. Expression of these markers remains unchanged with NAC 
supplementation (Figure 10).  
 
 
Figure 10.  NAC supplementation of the Nkx3.1-/- prostate does not alter expression of well-
established senescence and quiescence markers 
Immunohistochemical staining of Nkx3.1-/- vehicle and NAC-supplemented anterior prostate for p16, p27, 
and p21.  p16 inset: positive control for p16 staining from PbCre4; Ptenf/f prostate (207).  p21 inset: 
positive control for p21 staining from PbCre4; Ptenf/f; p53f/+ prostate(208).  Scale bar = 0.1mm.    
 
In order to analyze global gene expression changes associated with NAC 
supplementation of the Nkx3.1-/- prostate, we performed Affymetrix microarray analysis 
on total RNA extracted from three Nkx3.1-/- vehicle and four Nkx3.1-/- NAC-
supplemented anterior prostates. Genome Set Enrichment Analysis (GSEA) (156, 157) is 
used to determine if the expression of a priori defined gene sets, relating to biological 
pathways or experimental conditions, is significantly altered in the experimental tissue of 
interest.  GSEA allows for detection of modest gene expression changes of many genes in 
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one pathway that as a group may have a functional biological effect.  The GSEA 
Molcular Signatures Database (MSigDB) collections consist of sets of human genes.  We 
compared our mouse gene expression data to the human gene sets using the human genes 
orthologous to the mouse genes.  Using the C2 (curated) gene sets collection, we 
identified many gene sets that were significantly enriched or depleted in NAC-
supplemented  Nkx3.1-/- prostates, including several that are associated with proliferation 
control and quiescence (Appendix A and Appendix B). 
To obtain a broader picture of the relationships between the significantly altered 
gene sets in NAC-supplemented Nkx3.1-/- prostates, we performed Enrichment Map 
analysis (204). This is a method for GSEA interpretation and visualization which 
constructs networks from gene sets (nodes) containing overlapping genes. Analysis of 
identified networks using Enrichment Map can yield important information about the 
broad biological processes altered in a treatment group.  Enrichment Map results for all 
networks containing ≥5 nodes are presented in Figure 11A. The first network I term 
“proliferation control” and consists of 7 nodes. One of these upregulated “proliferation 
control” gene sets 
(GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN) is a gene set 
consisting of transcripts that are downregulated during quiescence of hemopoetic stem 
cells (HSCs) and another is a set upregulated in dividing leukemia stem cells compared to 
quiescent HSCs (GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP) 
(Figure 7B, (209)). Another upregulated “proliferation control” gene set is 
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER, consisting of genes 
controlling cell division and proliferation and associated with an increased severity and 
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early relapse in cervical cancer (Figure 11B, (210)). Enrichment of this network in the 
NAC-supplemented prostate serves as further quantitative evidence of increased 
proliferation in Nkx3.1-/- prostate upon NAC supplementation. Another network 
upregulated in the NAC-supplemented Nkx3.1-/- prostates contains gene sets comprised in 
a large part by chemokine/growth factor genes such as 
REACTOME_G_ALPHA_I_SIGNALLING_EVENTS (Figure 11A, 11B).  A network 
consisting of sets involved in immune regulation was depleted in NAC-supplemented 
Nkx3.1-/- prostates (Figure 11A).    
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Figure 11.  NAC supplementation promotes proliferation of a pro-proliferative gene expression 
signature in Nkx3.1-/- prostate 
(A) Enrichment Map (204) analysis for Genome Set Enrichment Analysis (GSEA) C2 (curated) gene set 
data obtained from vehicle and NAC-supplemented Nkx3.1-/- anterior prostate. Map displays the related 
gene networks containing ≥5 gene sets with a false discovery rate (FDR) q value <0.25.  Node size 
corresponds to gene set size. Hue designates which manner in which the gene sets are altered (red = 
enriched in NAC-supplementation, blue = depleted in NAC-supplementation). Color intensity represents 
significance by enrichment p value. Line thickness connecting the gene set nodes represents the degree of 
gene overlap between the two sets. (B) GSEA Enrichment plots (156, 157) for selected gene sets from the 
“proliferation control” network and the “chemokines/growth factors” network.  Nominal p value (statistical 
significance of the enrichment) and the FDR are presented.  
 
 
 
 
59 
The ‘leading edge’ is the subset of genes within a specific MSigDB gene set 
which drives the observed association in GSEA.  Analysis of the leading edge genes may 
help to determine which changes in gene expression are responsible for a given 
phenotype.  Leading edge genes from the “proliferation control” network (Table 2) 
include many classic pro-proliferative genes such Ccna2 (CCNA2 in human), Cdc6, Tk1, 
and Gmnn.  Leading edge genes in the “chemokines/growth factors” network (Table 3) 
include many involved in pathways that have proven links to prostate cancer, including 
chemokines/chemokine receptors (Ccl2, Cxcl5, Cxcr1, Cxcr2) (211),(212), the endothelin 
axis (Ednrb, Ednra) (213), and neuropeptides (Npy, Npy1r, Npy5r, Pyy) (214).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
Table 2.  Leading edge genes from a sample of “proliferation control” gene sets with significant 
enrichment  
 
 
 
 
 
 
 
 
 
 
 
Gene set name  Leading edge genes 
GRAHAM_NORMAL_QUIESCENT_ 
VS_NORMAL_DIVIDING_DN 
CD36, TK1, CPA3, RACGAP1, DLGAP5, CDC6, 
PRC1, COTL1, DTL, BUB1, MCM10, CDC20, 
CCNB2, RRM2, MCM6, MELK, NDC80, CCNA2, 
CENPM, GMNN, RAD51AP1 
GRAHAM_CML_DIVIDING_ 
VS_NORMAL_QUIESCENT_UP 
CD36, TUBB6, CCL2, SERPINB2, XIST, PF4, TK1, 
CPA3, HGF, RACGAP1, FAM38B, DLGAP5, 
CDC6, MPO, PRC1, COTL1, BUB1, MCM10, 
CDC20, CCNB2, PBK, RRM2, PPBP, UBE2S, 
CDC7, TPX2, CLEC11A, NEK2, MICAL2, MELK, 
NDC80, ASPM, KPNA2, HMMR, CCNA2, CENPM, 
GMNN, RAD51AP1, BRCA1, ECT2, PMP22, 
AURKA, CSTA, ESPL1, ACOT7, ELOVL6 
ROSTY_CERVICAL_CANCER_ 
PROLIFERATION CLUSTER  
TK1, SHCBP1, NETO2, RACGAP1, DLGAP5, HN1, 
PLK1, CDC6, MKI67, PRC1, CDCA3, DTL, BUB1, 
ASF1B, E2F1, MCM10, CDC20, CCNB2, PBK, 
RRM2, CDCA8, UBE2S, DBF4, TPX2, NEK2, 
MELK, NDC80, ASPM, KPNA2, CELSR3, HMMR, 
CCNA2, CENPM, GMNN, RAD51AP1, BRCA1, 
ECT2, AURKA, ESPL1, HMGA1, AURKB, 
NCAPH, TACC3, TTK, E2F8, LRP8, LMNB1 
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Table 3. Leading edge genes from a sample of “chemokines/growth factors” gene sets with significant 
enrichment 
 
 
 
 
 
REACTOME_GPCR_ 
LIGAND_BINDING 
EDNRB, CXCR2, CCL7, CCL2, CXCL13, 
FFAR1, PF4, NPY, NPY1R, OPN4, C3, HTR5A, 
ADORA2B, GRM3, HEBP1, PROK2, CCL3, 
S1PR3, CCL11, NPS, C5AR1, CNR1, AVPR1B, 
VIP, SSTR1, FPR1, ANXA1, CALCRL, 
OPRM1, P2RY13, WNT2B, PDYN, UTS2, F2, 
TSHR, UTS2R, S1PR2, CCL4, GNG3, TAC1, 
CXCL11, APLN, GNB3, HRH3, DARC, 
HTR1A, AVPR1A, ADORA1, ADORA3, 
DRD5, TAS1R2, TACR3, FSHB, NPY5R, 
CCR3, CCL22, PPBP, RHO, HTR1D, HTR4, 
HCRT, BDKRB2, C3AR1, MC4R, ADM2, 
APLNR, CXCR3, TAS1R1, SSTR2, WNT6, 
OPRL1, GRM5, PROKR2, ADRA1D, LPAR4, 
OPRK1, FZD4, CHRM5, NPSR1, TAAR1, 
GPBAR1, MC2R, FFAR2, WNT4, WNT8A, 
HTR6, CCL17, CXCR5, SCT, ADCYAP1, 
ADRB3, LPAR1, TSHB, SSTR3, SSTR4, 
OPRD1, GHRHR, TRH, HRH4, PYY, CCL25, 
CCR10, OPN5, GALR2, QRFPR, HCRTR2, 
ADRA2C, CXCR1, GPR17, AGT, PPYR1, 
FZD10, CALCB, KISS1R, CASR, CCR7, 
EDNRA, HTR1B, CRHR2, MTNR1B, P2RY2, 
BDKRB1, HRH1, PRLH, CCR1, TRHR, OXT, 
P2RY4, GIPR, CXCL5 
 
REACTOME_G_ALPHA_ 
I_SIGNALLING_EVENTS 
CXCR2, CXCL13, PF4, NPY, NPY1R, C3, 
HTR5A, HEBP1, ADCY2, S1PR3, C5AR1, 
CNR1, ADCY4, SSTR1, FPR1, ANXA1, 
OPRM1, P2RY13, PDYN, S1PR2, GNG3, 
CXCL11, APLN, GNB3, HRH3, HTR1A, 
ADORA1, ADORA3, ADCY10, NPY5R, CCR3, 
PPBP, RHO, HTR1D, BDKRB2, C3AR1, 
APLNR, CXCR3, SSTR2, OPRL1, OPRK1, 
CXCR5, LPAR1, SSTR3, SSTR4, OPRD1, 
HRH4, PYY, CCL25, CCR10, OPN5, GALR2, 
ADRA2C, CXCR1, GPR17, AGT, PPYR1, 
CASR, CCR7, HTR1B, MTNR1B, BDKRB1, 
ADCY8, CCR1, GNAT1, P2RY4, CXCL5 
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Discussion 
 
 Our study has provided novel evidence of prostate tumor promotion by 
antioxidant supplementation.  Using Nkx3.1-null mice, I have modeled antioxidant 
chemoprevention in the early stages of prostate tumorigenesis and shown an increase in 
prostate epithelial proliferation upon NAC supplementation.  These results suggest that 
ROS can be anti-tumorigenic in the early stages of prostate cancer and that antioxidant 
chemoprevention may be ineffective or harmful in many circumstances.   
 In this report I have confirmed that Nkx3.1-/- mice display increased prostatic 
oxidative stress.  The hyperproliferative state of the Nkx3.1-/- prostate may promote 
increased oxidative stress through one of many indirect mechanisms.  However, I have 
shown that the oxidative stress regulatory genes Gpx2, Prdx6, and Qsox1 are 
dysregulated in the mutant mice and are shown to be direct targets of the Nkx3.1 
transcription factor in both the mouse and human prostate.  Therefore, I propose that loss 
of Nkx3.1 expression may directly affect oxidative stress maintenance through 
dysregulation of these target genes.   
 To determine if elevated oxidative stress is a causative mechanism for the 
hyperplasia observed in the Nkx3.1-/- prostate, I supplemented Nkx3.1-/- mice with the 
antioxidant NAC.  NAC is a precursor for the most prevalent antioxidant molecule in 
cells, glutathione (GSH).  NAC has been safely used for many years in mice and humans 
and has been shown in previous studies to increase GSH concentration, decrease 
oxidative stress, and have beneficial clinical effects (58, 215).  While NAC 
supplementation did decrease ROS levels in the Nkx3.1-/- prostate, it did not alter the 
63 
hyperplastic phenotype.  Upon immunohistochemical staining with BrdU and pHH3, I 
observed that NAC supplementation promoted proliferation in the Nkx3.1-/- prostate.  
Surprisingly, rather than inhibit the hyperplastic phenotype, NAC supplementation 
promotes hyperplasia in the Nkx3.1-/- prostate.  In the Nkx3.1+/+ prostate, NAC 
supplementation did not increase proliferation, suggesting that the mechanism by which 
NAC increases proliferation in the Nkx3.1-/- prostate is related to elevated oxidative 
stress.   
 I propose that in the setting of Nkx3.1-loss, ROS are preventing further increases 
in proliferation of the prostate epithelium or inducing cell cycle arrest, a phenomenon 
which has been observed in other systems (reviewed in (216)). I hypothesized that 
elevated ROS in the Nkx3.1-/- prostate is activating an anti-proliferative pathway or 
inhibiting a pro-proliferative pathway, reducing the proliferative potential of the prostate 
epithelial cells.  By decreasing these ROS by antioxidant supplementation, the epithelial 
cells are free to proliferate at a higher level. To first test this hypothesis, I performed 
immunohistochemical analysis of well-established senescence and quiescence markers.  
This did not reveal any changes with NAC supplementation of the Nkx3.1-/- prostate. To 
further investigate the possible mechanism behind the increased proliferation upon NAC 
supplementation, we performed global gene expression analysis on vehicle and NAC-
supplemented Nkx3.1-/- prostate. Analysis of the gene expression data with GSEA and 
Enrichment Map revealed a significant enrichment in expression of gene sets involved in 
proliferation control and chemokine/growth factor function and depletion of an immune 
modulation cluster in NAC-supplemented prostates. Some of the gene expression 
changes may be a result of elevated proliferation, whereas others may be the factors 
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directly modulated by antioxidant supplementation and causing the change in 
proliferation. Pro-proliferative gene sets enriched in Nkx3.1-/- prostate upon NAC 
supplementation included gene sets such as 
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN, which is a set of 
genes which are downregulated in normal quiescent cells as compared to normal dividing 
cells.  These genes were upregulated in NAC-supplemented prostates, indicating that a 
pro-cell division phenotype was present. Genes in these pro-proliferative gene sets 
included many from classic pro-proliferative gene families such as cyclin genes, cell 
division cycle (cdc) genes, and aurora kinase genes. In addition other genes in these sets 
classically implicated in proliferation and cell cycle progression include thymidine kinase 
1 (TK1), polo-like kinase 1 (PLK1), and E2F1.  
NAC-enriched chemokine/growth factors gene sets included genes involved in 
pathways that been implicated in prostate tumorigenesis, including 
chemokines/chemokine receptors (Ccl2, Cxcl5, Cxcr1, Cxcr2) the endothelin axis 
(Ednrb, Ednra) and neuropeptides (Npy, Npy1r, Npy5r, Pyy). Upregulation of genes in 
these pathways could play a role in the increased proliferation with NAC 
supplementation. While direct ROS-mediated inhibition of chemokines has not described, 
this is a possible mechanism by which NAC quenching of ROS could allow for increased 
pathology of the prostate.   
The third major cluster of gene sets which was altered in the NAC-supplemented 
prostates was an immune modulation cluster. This cluster of gene sets was depleted in the 
NAC-supplemented group. One of the most common genes present in these gene sets is 
STAT1, a transcription factor that is known to inhibit proliferation, induce cell cycle 
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arrest, and induce apoptosis in cancer cells (217).  STAT1 is generally considered to 
promote anti-cancer immune responses (218). Therefore, depletion of STAT1 and related 
genes could help promote increased cell division upon NAC supplementation. 
 In addition to gene expression changes at the RNA level, ROS may modulate 
activity of proteins to affect proliferation, as has been thoroughly described in the 
literature (216).  For example, the important cell cycle regulator CDK1 has been shown 
to be inhibited by oxidative stress by changing its phosphorylation status (219), causing 
cell cycle arrest and apoptosis. Protein phosphatases are a class of molecules that have 
been shown to be modulated by oxidative stress (220). Many protein phosphatases have 
been shown to be inhibited by oxidative stress, allowing for phosphorylation and 
activation of proteins involved in pro-proliferative signaling such as MAPK and Akt 
(221). However, elegant studies have also shown in non-transformed cells that oxidative 
stress can activate protein phosphatase 2A, which dephosphorylates pRb, prohibiting cell 
cycle progression (222, 223). Thus, antioxidants could inhibit these changes, allowing for 
greater proliferation.   
 Based upon our findings, I propose a potential model for Nkx3.1-loss associated 
ROS and NAC supplementation in prostate tumor initiation (Figure 12). Loss of Nkx3.1 
expression in the prostate causes dysregulation of antioxidant and pro-oxidant direct 
target genes, resulting in elevated ROS in the hyperplastic Nkx3.1-/- prostate. These ROS 
may actually limit proliferation in the Nkx3.1-/- prostate by inhibiting expression of pro-
proliferative genes. ROS have been shown to induce cell cycle arrest or decrease 
proliferation in several models of non-cancerous and cancerous cells (78–80, 224) and, in 
some of these cases, antioxidant supplementation has been explicitly shown to reverse 
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these ROS-induced effects. Thus, NAC may be increasing proliferation of the Nkx3.1-
null prostate by decreasing ROS-mediated inhibition of pro-proliferative genes. An 
alternative hypothesis would be that NAC works through a ROS-independent mechanism 
to ellicit its effect.  NAC has been shown to modulate gene expression, cellular signaling 
pathways, intracellular trafficking, secretion, immune function, and mitochondrial 
function (59).    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Potential model for Nkx3.1-loss associated ROS and NAC supplementation in prostate 
tumor initiation.  
 
 
Results from this study emphasize the need for a deeper understanding of the role 
ROS play in prostate tumor progression.  The effect of ROS on cells is not always pro-
tumorigenic.  The level of ROS present in a tissue can influence the effect seen, with high 
levels of ROS promoting senescence or cell death, but lower levels promoting DNA 
mutations or activating pro-proliferative signaling.  The cell type with which ROS 
interacts also determines its effect.  In a normal cell, a certain level of ROS may kill the 
cell or cause a cell to undergo cell cycle arrest, while in a cancer cell the same level of 
ROS may promote proliferation and invasion.   
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Despite the ability of antioxidants to inhibit cancer in several mouse models, I 
have shown that the antioxidant NAC promotes proliferation in the Nkx3.1-/- prostate.  I 
propose that the Nkx3.1-/- mouse is a good model for antioxidant chemoprevention, 
exhibiting early lesions similar to those of cancer-naïve men in whom clinicians desire to 
prevent malignant disease.  Indeed, antioxidants may function to inhibit tumor 
progression at later stages, effectively treating cancer in some settings. However, at early 
stages, ROS may actually slow or prevent tumor progression from occurring (225, 226). 
In addition, different antioxidant compounds may affect the prostate in unique ways.  
Alternatively, ROS may have different effects on prostate tumor progression based on the 
genetic lesions or gene expression changes present.   
The recent alarming results from the SELECT trial, in which “antioxidant 
chemoprevention” increased prostate cancer risk, can be informed by our study.  While 
the proliferation upon NAC supplementation is not increased to an extremely large 
degree, it is nevertheless a significant increase and could become more pronounced with 
long term supplementation.  NAC was not the specific antioxidant used in the SELECT 
trial; however, the results can yield important information due to the fact that NAC 
should decrease the overall oxidative state and possibly reflect possible results seen by 
other antioxidants.  In fact, a recently published study using selenium and vitamin E in a 
rat model of prostate tumorigenesis showed a similar finding, that vitamin E 
supplementation showed a marginally significant increase in prostate tumor formation 
(113).   
In the setting of certain genetic lesions or expression changes, such as Nkx3.1-
loss, depleting ROS may actually allow cells to escape a ROS-mediated inhibition of 
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proliferation, increasing the chance of transformation of the prostate epithelium.  The 
increased prostate cancer risk in the SELECT study population may indeed be driven by a 
subset of participants with an inherited polymorphism in Nkx3.1 (rs11781886) that is 
associated with increased prostate cancer risk (227).  Depletion of ROS by vitamin E may 
have modified the risk from the levels normally associated with the polymorphism, 
producing the surprising detrimental effect with vitamin E chemoprevention.  Oxidative 
stress and antioxidant levels have been shown in previous studies to modify cancer risk 
associated with inherited polymorphisms (228–232). Studies are ongoing using the 
SELECT biorepository to determine if antioxidant supplementation increased the prostate 
cancer risk associated with the functional NKX3.1 variant (rs11781886) (233).  
Our report provides valuable insight into the inconsistent results among 
preclinical and clinical studies on the efficacy of prostate cancer antioxidant 
chemoprevention (102).  I suggest that investigation of prostate cancer chemoprevention 
specifically in physiologically relevant models, with analysis of the complexities of 
specific gene expression changes, is critically needed if clinically applicable results are 
desired.  Caution should be taken when using antioxidants for prostate cancer prevention, 
because the effect which they have, beneficial or harmful, may lie in the makeup of the 
prostate gland of each unique individual.   
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CHAPTER IV 
 
GENETIC VARIANTS AND PROSTATE CANCER RISK  
IN THE SELECT TRIAL  
 
Introduction  
 
Secondary results from two previous clinical trials (the Nutritional Prevention of 
Cancer Trial [NPCT] (191), and the Alpha-Tocopherol Beta-Carotene Cancer Prevention 
Study [ATBC] (130)) indicated that selenium or vitamin E supplementation was able to 
reduce prostate cancer incidence. Therefore, to test the ability of these agents to 
effectively prevent prostate cancer development, the multi-center Selenium and Vitamin 
E Cancer Prevention Trial (SELECT) was initiated in 2001 (135, 136).  
SELECT had over 32,000 prostate cancer naïve participants in the United States, 
Puerto Rico, and Canada. Upon initiation of the study, there was great hope and 
confidence in the field that a new prevention strategy for prostate cancer prevention 
would emerge that could decrease disease burden in a widespread population. 
Unfortunately, neither selenium nor vitamin E alone or in combination was able to 
prevent prostate cancer development, and vitamin E supplementation actually increased 
the risk of prostate cancer (138). 
Recent studies from our laboratory have identified the prostate cancer tumor 
suppressor NKX3.1 as possible genetic risk factor for prostate cancer development upon 
antioxidant supplementation. I reported that supplementation with the antioxidant N-
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acetyl-cysteine promotes prostate epithelial cell proliferation in the Nkx3.1-/- mouse, a 
mouse model of the earliest stages of transformation of the prostate gland (159).  These 
mice are deficient in the homeobox transcription factor Nkx3.1, and at advanced age 
display a hyperplastic/dysplastic prostate phonotype similar to the prostate cancer 
precursor lesion seen in humans, prostatic intraepithelial neoplasia (PIN) (151, 152, 199).  
NKX3.1 expression is significantly decreased during human prostate tumorigenesis (150, 
153, 193), suggesting that NKX3.1 acts as a tumor suppressor in the prostate. Nkx3.1-null 
mice exhibit dysregulation of oxidative stress control genes and display increased 
oxidative stress (155, 159) which has been proposed as a mechanism of tumor promotion 
upon NKX3.1 loss.  However, antioxidant supplementation of these mice increased rather 
than decreased prostate epithelial proliferation in the Nkx3.1-null mice (159). These 
results are reminiscent of the SELECT trial, where vitamin E supplementation in cancer 
naïve individuals increased prostate cancer risk in a moderate, but significant manner 
(138). Therefore, I propose that loss of NKX3.1 expression may play an important role in 
elevated prostate cancer risk upon antioxidant supplementation.    
In order to test this hypothesis in a human population, I set out to investigate if 
individuals with altered NKX3.1 expression or activity due to two prostate cancer-related 
genetic polymorphisms (rs11781886 and rs2228013) have an increased cancer risk upon 
antioxidant supplementation in the SELECT trial. Using the SWOG-defined case-cohort 
from the SELECT trial, we genotyped rs2228013 and rs11781886 to investigate the 
interaction of NKX3.1 genotype and prostate cancer risk in all intervention arms of the 
study.  I hypothesized that individuals with low NKX3.1 expression or activity 
(possessing risk alleles for rs11781886 or rs2228013) and supplemented with the 
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antioxidants vitamin E or selenium, would have an elevated prostate cancer risk 
compared to those with the polymorphisms in the placebo group.  Our results show that 
prostate cancer risk associated with rs11781886 genotype is significantly increased by 
supplementation with selenium and vitamin E.  These findings suggest that 
supplementation with antioxidants can alter risk associated with established genetic risk 
factors for prostate cancer and highlight specific populations with especially elevated 
risk.        
In our investigation of genetic variants that may modify the increased prostate 
cancer risk with antioxidant supplementation in SELECT, I made the chance finding that 
the polymorphism rs11781866 on 8p21 in the region of the Bcl-2 and adenovirus E1B 19 
kDa interacting protein 3 like (BNIP3L) gene modified risk with vitamin E 
supplementation. BNIP3L is a member of the BH3-only type of Bcl-2 family members 
and has been implicated in cancer as having both pro-survival and pro-apoptotic 
functions. Our results on rs11781866 are the first data showing a genetic polymorphism 
not previously described in prostate tumorigenesis that modifies the risk of prostate 
cancer in the vitamin E arm of SELECT.  These findings shed important light on the 
mechanisms of prostate tumor initiation and may help explain the reasons behind the 
increased risk of prostate cancer upon vitamin E supplementation.  
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Methods 
 
Study Populations  
 
 
Nashville Men’s Health Study (NMHS)  
 
Study samples were composed of 790 men over 40 years of age who were 
scheduled for a diagnostic prostate biopsy from 2002-2008 at Vanderbilt University 
Medical Center, the Tennessee Valley Veteran’s Administration Hospital, or Urology 
Associates, in Nashville, TN. Patient data, such as Gleason scores, clinical outcome, and 
PSA levels, were recorded as described (234).  
SELECT  
Study samples were composed of the SELECT trial case-cohort study defined by 
the Southwestern Oncology Group (SWOG). A subcohort representative of SELECT 
participants was created a priori as the comparison group for biomarker studies using the 
following approach. Men randomized into the study were stratified into 9 age/race 
cohorts: <55 (African American only), and 55-59, 60-64, 65-69, ≥70 years for both 
African Americans and others.  Beginning in 2005 and annually until 2009, men with 
new diagnoses of prostate cancer had matching men randomly selected for the subcohort 
from the set of men with blood samples available within the same age-race stratum.   A 
ratio of 1:3 was used for African Americans and 1:1.5 for others.  Cases used in this 
analysis are as of July 31, 2009.  The SELECT trial study population characteristics have 
been described (137, 138).  The subjects from the SWOG defined case-cohort genotyped 
for this analysis included 1,866 cases and 3,135 non-cases for a total of 5,001 samples.  
Study case-cohort characteristics are presented in Table 6.   
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SNP selection and genotyping  
 
Nashville Men’s Health Study  
SNP analysis was performed using the ABI Taqman Allelic Discrimination Assay 
for rs11781886. Single SNP allelic discrimination was carried out using the ABI 7900HT 
machine.  The genotyping was performed at the DNA Resources Core at the Vanderbilt 
Center for Human Genetics Research.  
SELECT  
SNP Analysis was performed using the ABI Prism Taqman Allelic Discrimination 
Assays for rs11781866, rs11781886, and rs2228013. Single SNP allelic discrimination 
was carried out using the ABI 7900HT, which allows single-plex SNP interrogation over 
a large volume of samples. The genotyping was performed at the Dana Farber/Harvard 
Cancer Center High Throughput Genotyping Core Facility.     
Genotype statistical analysis for SELECT genotyping 
SNP association with total, low grade (Gleason ≤6), and high grade (Gleason 7-
10) prostate cancer risk was assessed over all four intervention arms of SELECT.  Hazard 
ratios and associated p-values were calculated using a Cox proportional hazards model. 
Cases outside the subcohort enter the proportional hazards model just prior to diagnosis 
and remain in until diagnosis.  Noncases in the subcohort enter the model at 
randomization and continue until they are censored.  Cases in the subcohort appear in the 
model twice: once treated as noncases in the subcohort (entering at randomization, 
censored just prior to diagnosis), and once treated as cases outside the subcohort (235). 
We chose the weighting method of Prentice because it produced less biased estimates in a 
simulation study (236).     
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Because the sampling scheme used in creating the subcohort was stratified, all 
analyses were stratified based on the nine age/race groups.  The different strata were 
weighted based on their subcohort selection probability. 
Noncases were censored as of the earlier of July 31, 2009 or the date they were 
last known to be alive/date of death. 
While genotype at rs2228013 was not correlated with baseline PSA level category 
(p = 0.3090 and p = 0.7852), rs11781886 genotype was significantly correlated with 
elevated baseline PSA category (p < 0.0001).  However, the difference in PSA between 
genotypes was too small to have relevance for prostate cancer detection and was 
consistent among intervention arms (Table 4). Therefore, multivariate analysis for 
prostate cancer risk associated with all SNPs does not include baseline PSA level.   
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Table 4. Mean baseline PSA levels with genotype at rs11781886 in SELECT case-control cohort  
 
 Genotype Intervention arm 
 Placebo      Vitamin E Selenium    Vitamin E + Selenium  
rs11781886 Mean 
PSA 
(ng/mL) 
SD N Mean 
PSA 
(ng/mL) 
SD N Mean 
PSA 
(ng/mL) 
SD N Mean 
PSA 
(ng/mL) 
SD N 
TT 1.68 1.06 607 1.67 1.08 718 1.69 1.04 704 1.66 1.04 653 
CT  1.73 1.08 496 1.78 1.05 478 1.86 1.10 445 1.74 1.01 481 
CC 1.78 1.04 93 1.92 1.10 105 1.88 1.08 78 1.79 1.05 68 
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Target SNPs rs11781886 and rs11781866 were modeled in a joint effects model 
relative to the TT genotype in the placebo arm.  Individual hazard ratios were calculated 
for each of the three possible genotypes and four intervention arms.  An additional 
analysis was done to test for linear trend, where the genotypes were modeled 0, 1, and 2 
for TT, CT, and CC respectively. Also, a joint effects model and linear trend analysis 
were performed using a 2 level model for these SNPs, with TT compared to CT and CC 
genotypes combined for rs11781886 and TT and CT genotypes combined compared to 
CC for rs11781866.  
The target SNP rs2228013 was modeled in a joint effects model relative to the 
GG genotype in the placebo arm.  Individual hazard ratios were calculated for the GG 
compared to AG and AA genotypes combined, due to the small number of samples with 
the AA genotype, and the four intervention arms.  An additional analysis was done to test 
for linear trend, where the genotypes were modeled 0 and 1 for GG and AG/AA 
respectively.   
Additional baseline covariates included in the models were family history of 
prostate cancer (yes or no), smoking status (nonsmoker, current smoker, former smoker), 
and body-mass index (linear). 
All statistical analyses were performed using SAS version 9.2 software (SAS 
Institute, Cary, NC, USA). All statistical tests are two-sided, and P <0.05 was considered 
statistically significant. Genotype effects for rs11781886 and rs11781866 were calculated 
using a 3 level model (TT, CT, CC), unless otherwise noted. Genotype effects for 
rs2228013 were calculated using a 2 level model (GG, AG/AA).  
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Microarray analysis of SELECT trial supplement clinical study  
The microarray experiment by Tsavachidou and colleagues (237) was 
downloaded from Array Express (http://www.ebi.ac.uk/arrayexpress/experiments/E-
MEXP-1327/).  Affymetrix HG-U133A Arrays and matching patient data were analyzed 
for quality control in Bioconductor using packages affy (version 1.38.1), affyPLM 
(version 1.36.0), affyIO (version 1.28.0), and simpleaffy (version 2.36.0) in R version 
3.0.0. Four of the 85 arrays did not pass quality control (DI02, DI04, DI45 and DI81). 
The remaining 81 arrays were normalized by quantiles, background corrected by RMA, 
and probesets were summarized by median polish. A Welch T-test was used to assess 
expression differences between individual genes.  
Transcription Factor Motif Analysis  
The sequence containing the rs11781866 SNP was extracted from Ensembl 
human genome version 71 and analyzed for vertebrate transcription factor binding sites at 
Jaspar (found at: 
http://jaspar.genereg.net/cgibin/jaspar_db.pl?rm=browse&db=core&tax_group=vertebrat
es).  The score threshold was set at 80% [a measure of degeneracy] and the top 
transcription factors were recorded. 
 
Results 
 
Nashville Men’s Health Study (NMHS) pilot genotyping study  
To determine the ability to successfully genotype rs11781886, 790 DNA samples 
from the Nashville Men’s Health Study were genotyped. The minor allele frequencies in 
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the white and black individuals for rs11781886 do differ from the MAF in the worldwide 
population of 0.301 (238, 239) (Chi-Squared goodness of fit test p = 0.001565 and p = 
0.028643 for white and black respectively) (Table 5). I then compared the observed 
MAFs for whites and blacks in the NMHS cohort to the subpopulations most similar to 
the race of the subgroups (CEU - Utah Residents (CEPH) with Northern and Western 
European ancestry- with a MAF of 0.265 for whites, and ASW - Americans of African 
Ancestry in SW USA - with a MAF of 0.311 for blacks) (238, 239). The MAFs observed 
were not significantly different to race-specific MAFs (Chi-Squared goodness of fit test p 
= 0.811 for whites and p = 0.061 for blacks). It should be noted, however, that the MAFs 
calculated from general populations while the NMHS consists of men who are at a higher 
risk for prostate cancer diagnosis as they were selected due to the fact they were 
scheduled for a diagnostic biopsy of the prostate. Therefore, results from the NMHS 
genotyping may not be representative of the overall population.  For this reason, I also 
did not observe an increase in prostate cancer diagnosis related to rs11781886 (227) 
(Table 5).   
 
Table 5. Nashville Men’s Health study rs11781866 genotyping results 
 Overall  White Black 
Total genotypes (N) 790 698 92 
Minor allele frequency 0.275 0.262 0.375 
Proportion of cancer outcome with CC genotype 0.368 0.395 0.286 
Proportion of cancer outcome with TT genotype 0.369 0.373 0.324 
 
 
 
 
79 
SELECT biorepository for case-control cohort genotyping analysis  
To determine if NKX3.1 levels/activity could modulate prostate cancer risk upon 
antioxidant supplementation, we genotyped a cohort of SELECT participants for the 
rs1781886 and rs2228013 variants in a cohort of SELECT participants (n = 5,001). SNP 
rs11781886 is found in the 5’ untranslated region (UTR) of NKX3.1 and leads to lower 
NKX3.1 expression (227). Located in the second exon of NKX3.1, rs2228013 alters 
NKX3.1 phosphorylation and activity (240).  The Southwestern Oncology Group 
(SWOG)-defined case-cohort characteristics are described in Table 6.  In general, the 
case-cohort participants reflected the characteristics of the overall SELECT population. 
One exception to this is race distribution, as SWOG over selected from the proportion of 
African American cases and controls to increase the power to detect significant findings 
in this important group.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Location of NKX3.1 SNPs genotyped in this study.  Modified from (227), this image depicts 
the genetic location of SNP rs11781886 in the 5’ UTR of the NKX3.1 gene (227), and rs2228013 in the 2nd 
exon of the NKX3.1 gene (240).  
 
 
80 
Table 6. Baseline characteristics of SELECT case-control cohort (n = 5,001) 
   Noncases Cases High-Grade 
Cases 
Low-Grade 
Cases 
    N = 3,135 N = 1,866 N = 540 N = 1,081 
Characteristic N (%) N (%) N (%) N (%) 
Age, y     
  <55 126 (4.0%) 42 (2.3%) 11 (2.0%) 22 (2.0%) 
  55-59 832 (26.5%) 503 (27.0%) 123 (22.8%) 311 (28.8%) 
  60-64 926 (29.5%) 565 (30.3%) 150 (27.8%) 339 (31.4%) 
  65-69 724 (23.1%) 437 (23.4%) 138 (25.6%) 242 (22.4%) 
  ≥70 527 (16.8%) 319 (17.1%) 118 (21.9%) 167 (15.4%) 
        
Race     
  White (non-Hispanic) 2,175 (69.4%) 1,521 (81.5%) 439 (81.3%) 899 (83.2%) 
  African American 756 (24.1%) 253 (13.6%) 79 (14.6%) 130 (12.0%) 
  Other 204 (6.5%) 92 (4.9%) 22 (4.1%) 52 (4.8%) 
        
Body mass index (kg/m 2)     
  <25 606 (19.3%) 357 (19.1%) 98 (18.1%) 207 (19.1%) 
  25-<30 1,466 (46.8%) 950 (50.9%) 244 (45.2%) 583 (53.9%) 
  ≥30 1,052 (33.6%) 556 (29.8%) 197 (36.5%) 289 (26.7%) 
  Unknown 11 (0.4%) 3 (0.2%) 1 (0.2%) 2 (0.2%) 
        
Smoking Status     
  Never 1,292 (41.2%) 894 (47.9%) 263 (48.7%) 516 (47.7%) 
  Former 1,553 (49.5%) 868 (46.5%) 246 (45.6%) 500 (46.3%) 
  Current 267 (8.5%) 99 (5.3%) 28 (5.2%) 63 (5.8%) 
  Unknown 23 (0.7%) 5 (0.3%) 3 (0.6%) 2 (0.2%) 
        
Baseline PSA     
  0.00-0.99 1,391 (44.4%) 134 (7.2%) 33 (6.1%) 73 (6.8%) 
  1.00-1.99 1,070 (34.1%) 486 (26.0%) 140 (25.9%) 269 (24.9%) 
  2.00-2.99 444 (14.2%) 627 (33.6%) 196 (36.3%) 360 (33.3%) 
  ≥3 230 (7.3%) 618 (33.1%) 171 (31.7%) 378 (35.0%) 
  Unknown 0 (0.0%) 1 (0.1%) 0 (0.0%) 1 (0.1%) 
        
History of Diabetes     
  No 2,737 (87.3%) 1,733 (92.9%) 491 (90.9%) 1,018 (94.2%) 
  Yes 398 (12.7%) 133 (7.1%) 49 (9.1%) 63 (5.8%) 
        
First-degree relative with          
prostate cancer 
    
  None 2,626 (83.8%) 1,284 (68.8%) 384 (71.1%) 733 (67.8%) 
  ≥1 507 (16.2%) 582 (31.2%) 156 (28.9%) 348 (32.2%) 
  Unknown 2 (0.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
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Table 6, continued  
 Noncases Cases High-Grade 
Cases 
Low-Grade 
Cases 
 N = 3,135 N = 1,866 N = 540 N = 1,081 
 Characteristic N (%) N (%) N (%) N (%) 
 
SELECT intervention assignment 
    
  Vitamin E + Selenium 772 (24.6%) 448 (24.0%) 138 (25.6%) 257 (23.8%) 
  Vitamin E alone 800 (25.5%) 518 (27.8%) 148 (27.4%) 291 (26.9%) 
  Selenium alone 782 (24.9%) 465 (24.9%) 138 (25.6%) 265 (24.5%) 
  Placebo 781 (24.9%) 435 (23.3%) 116 (21.5%) 268 (24.8%) 
        
     
SNP: RS11781886     
TT 1,717 (54.8%) 984 (52.7%) 273 (50.6%) 579 (53.6%) 
CT 1,184 (37.8%) 737 (39.5%) 227 (42.0%) 411 (38.0%) 
CC 211 (6.7%) 136 (7.3%) 37 (6.9%) 86 (8.0%) 
Unknown 23 (0.7%) 9 (0.5%) 3 (0.6%) 5 (0.5%) 
       
SNP: RS2228013     
GG 2,864 (91.4%) 1,693 (90.7%) 488 (90.4%) 978 (90.5%) 
AG 233 (7.4%) 150 (8.0%) 45 (8.3%) 90 (8.3%) 
AA 5 (0.2%) 2 (0.1%) 0 (0.0%) 2 (0.2%) 
Unknown 33 (1.1%) 21 (1.1%) 7 (1.3%) 11 (1.0%) 
        
SNP: RS11781866     
TT 1,424 (45.4%) 842 (45.1%) 238 (44.1%) 488 (45.1%) 
CT 1,374 (43.8%) 809 (43.4%) 246 (45.6%) 463 (42.8%) 
CC 318 (10.1%) 201 (10.8%) 52 (9.6%) 120 (11.1%) 
Unknown 19 (0.6%) 14 (0.8%) 4 (0.7%) 10 (0.9%) 
 
The increased total prostate cancer risk for the vitamin E arm in the case-cohort 
(HR 1.178, 95% CI 0.987-1.405, p = 0.0688) (Table 8) was similar to that of the entire 
SELECT study (HR 1.17, 95% CI 1.004-1.36, p = 0.008) (138).  The increase in risk with 
vitamin E supplementation did not reach statistical significance for low grade prostate 
cancer (HR 1.070, 95% CI 0.867-1.319, p = 0.5294) (Table 9) or high grade prostate 
cancer (HR 1.250, 95% CI 0.942-1.658, p = 0.1224) (Table 10) in the case-cohort.  
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Effect of NKX3.1 polymorphisms rs11781886 and rs2228013 on prostate cancer risk 
in SELECT 
 
The minor allele frequency in the case-cohort for rs11781886 was 0.2631, which 
is similar to the frequency in a worldwide population of 0.301 (238, 239). The observed 
minor allele frequency of 0.0386 for rs2228013 was similar to the published frequency of 
0.022 (238, 239).   
rs11781886 
Genotype at rs11781886 was not associated with a significant change in overall, 
low or high grade prostate cancer risk in the case-cohort as a whole, including all 
intervention arms (Table 7).  I analyzed the interaction of risk associated with 
rs11781886 with intervention arm to determine if antioxidant supplementation modifies 
prostate cancer risk associated with genotype.  None of the intervention arms 
significantly altered the overall trend in total, low grade, or high grade prostate cancer 
risk associated with rs11781886 (Tables 8-10).   
 
Table 7. Effect of polymorphisms rs11781886 and rs2228013 total, low grade, and high grade 
prostate cancer risk in all participants of SELECT case-control cohort  
 
Polymorphism Hazard 
Ratio 
95% HR Confidence 
Limits 
p value 
Total    
rs11781886 1.072 0.967-1.188 0.1852 
rs2228013 0.953 0.759-1.196 0.6773 
Low grade     
rs11781886 1.076 0.951-1.218 0.2463 
rs2228013 1.008 0.771-1.318 0.9529 
High grade     
rs11781886 1.099 0.939-1.286 0.2390 
rs2228013 0.933 0.654-1.329 0.6994 
83 
Table 8. Effect of genotype at rs11781886 and rs2228013 on total prostate cancer risk in each intervention arm of the SELECT case-control cohort  
 
Genotype Intervention arm 
 Placebo 
N = 1220     
Vitamin E 
N = 1318 
Selenium    
N = 1247 
Vitamin E + Selenium   
N = 1216 
rs11781886 HR 95% CI p value HR 95% CI p value HR 95% 
CI 
P value HR 95% CI P value 
All genotypes 1.000      ref Ref 1.178 0.987-
1.405 
0.0688 1.091 0.913-
1.304 
0.3367 1.021 0.853-
1.222 
0.8171 
             
TT 1.000      ref Ref 1.142 0.891-
1.463 
0.2951 1.074 0.836-
1.379 
0.5753 1.218 0.947-
1.567 
0.1238 
CT  1.175 0.895-
1.542 
0.2448 1.500 1.124-
1.971 
0.0036 1.218 0.918-
1.617 
0.1710 0.966 0.733-
1.272 
0.8048 
CC 1.144 0.690-
1.898 
0.6015 1.233 0.744-
2.042 
0.4162 1.676 1.011-
2.777 
0.0450 0.987 0.541-
1.803 
0.9671 
p trend 0.2897   0.8548   0.6457   0.0634   
     
rs2228013     
All genotypes             
             
GG 1.000      ref Ref 1.165 0.968-
1.403 
0.1066 1.064 0.882-
1.283 
0.5191 1.037  0.859-
1.252 
0.7074 
AG or AA 0.912  0.574-
1.447 
0.6952 1.137 0.742-
1.740 
0.5557 1.365 0.876-
2.128 
0.1685 0.740  0.456-
1.203 
0.2247 
p trend 0.6952   0.8330   0.2934   0.4722   
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Table 9.  Effect of genotype at rs11781866 and rs2228013 on low grade prostate cancer risk in each arm of the SELECT case-control cohort 
 
 
Genotype Intervention arm 
 Placebo Vitamin E Selenium Vitamin E + Selenium   
Low grade cases             
 HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value 
All genotypes 1.00 ref Ref 1.070 0.867-
1.319 
0.5294 1.004 0.812-
1.241 
0.9728 0.932 0.752-
1.154 
0.5166 
rs11781886             
TT 1.000    ref Ref 1.159 0.864-
1.554 
0.3251 1.018 0.754-
1.375 
0.9054 1.182 0.874-
1.599 
0.2764 
CT  1.261 0.917-
1.734 
0.1537 1.267 0.910-
1.765 
0.1608 1.172 0.836-
1.643 
0.3560 0.915 0.658-
1.273 
0.5977 
CC 1.160 0.649-
2.074 
0.6156 1.341 0.742-
2.424 
0.3312 1.811 1.016-
3.228 
0.0441 1.010 0.487-
2.095 
0.9795 
p trend 0.2212   0.7016   0.6488   0.0802   
     
rs2228013     
All genotypes             
GG 1.000    ref Ref 1.079 0.865-
1.346 
0.4997 0.987 0.789-
1.235 
0.9082 0.956 0.764-
1.197 
0.6968 
AG or AA 0.974 0.568-
1.670 
0.9232 1.036 0.621-
1.728 
0.8915 1.386 0.833-
2.308 
0.2091 0.761 0.431-
1.343 
0.3461 
p trend 0.9232   0.9705   0.3317   0.6115   
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Table 10.  Effect of genotype at rs11781866 and rs2228013 on high grade prostate cancer risk in each arm of the SELECT case-control cohort 
 
Genotype Intervention arm 
 Placebo      Vitamin E Selenium    Vitamin E + Selenium   
High grade cases             
 HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value 
All genotypes 1.00 ref ref  1.250 0.942-
1.658 
0.1224 1.201 0.902-
1.598 
0.2099 1.212 0.911-
1.612 
0.1868 
rs11781886             
TT 1.000    ref Ref 1.015 0.672-
1.533 
0.9447 1.059 0.710-
1.579 
0.7796 1.297 0.871-
1.931 
0.2002 
CT  1.027 0.656-
1.609 
0.9058 1.753 1.146-
2.680 
0.0096 1.308 0.839-
2.039 
0.2355 1.078 0.692-
1.678 
0.7401 
CC 1.164 0.519-
2.611 
0.7123 1.131 0.515-
2.484 
0.7600 1.325 0.559-
3.140 
0.5224 1.079 0.435-
2.676 
0.8695 
p trend 0.7586   0.3596   0.6433   0.4247   
     
rs2228013     
GG 1.000  ref Ref 1.209 0.896-
1.630 
0.2138 1.173 0.869-
1.584 
0.2969 1.197  0.887-
1.616 
0.2407 
AG or AA 0.909 0.444-
1.862 
0.7938 1.223  0.635-
2.354 
0.5472 1.240 0.593-
2.589 
0.5677 0.928  0.448-
1.922 
0.8413 
p trend 0.7938   0.8278   0.7724   0.7592   
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However, allelic variation at rs11781886 in the different intervention arms was 
associated with significantly altered prostate cancer risk compared to the homozygous 
major allele genotype (TT) in the placebo group (Tables 8-10).  The CT genotype at 
rs11781886 in the vitamin E arm was strongly associated with an increased risk of total 
(HR 1.500, 95% CI 1.124-1.971, p = 0.0036) and high grade (HR 1.753, 95% CI 1.146-
2.680, p = 0.0096) prostate cancer (Table 8 and Table 10).  There is a significant 45% 
increased overall prostate cancer risk (HR 1.450, 95% CI 1.117-1.882, p = 0.0052) and a 
significant 64% increase in high grade prostate cancer risk (HR 1.638, 95% CI 1.089-
2.463, p = 0.0178) associated with having at least one C allele (genotype CT or CC) at 
rs11781886 with vitamin E supplementation (Table 8 and Table 10).   
The CC genotype at rs11781886 in the selenium arm was associated with an 
increased risk of total (HR 1.676, 95% CI 1.011-2.777, p = 0.045) and low grade (HR 
1.811, 95% CI 1.016-3.228, p = 0.0441) prostate cancer risk relative to the TT genotype 
in the placebo group (Table 8, Table 9).  There is a marginally significant increased 
overall prostate cancer risk associated with having at least one C allele at rs11781886 
with selenium supplementation (HR 1.277, 95% CI 0.976-1.669, p = 0.0744) (Table 8).  
Presence of the C allele in the vitamin E + selenium arm, however, was not associated 
with an increased risk (HR 0.968, 95% CI 0.742-1.264, p = 0.8134) (Table 8).  
rs2228013 
Contrary to a previously published report (240), rs2228013 was not associated 
with an increased risk of high grade prostate cancer (Table 7), nor was it associated with 
an increased overall risk of total prostate cancer in the study-wide population. 
Randomization arm did not significantly modify prostate cancer risk with rs2228013 
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genotype (Table 8).  There were no significant associations with any genotype at 
rs2228013 in any randomization arm with prostate cancer risk for total prostate cancer 
(Table 8) or for low (Table 9) or high grade cancers (Table 10).  
Effect of BNIP3L polymorphism rs11781866 on prostate cancer risk in SELECT 
The rs11781866 minor allele frequency (MAF) in the case-cohort was 0.324, 
which is similar to  the published frequency in a worldwide dataset of 0.284 (238, 239). 
The dbSNP MAF ranges from 0.184 in a population of Mexican ancestry in California to 
0.350 in a population of Northern and Western European ancestry in Utah (241).   
rs11781866 modulates prostate cancer risk in the vitamin E arm of SELECT 
I first analyzed the effect of genotype at rs11781866 on overall prostate cancer 
risk in all case-cohort subjects  Genotype at rs11781866 did not effect overall risk in the 
case-control cohort as a whole (HR 0.994, 95% CI 0.904-1.093, p = 0.9045) (Table 11). 
Risk of high grade and low grade disease was also not altered by rs11781866 in the total 
case-cohort population (Table 11).   
 
Table 11. Effect of polymorphism rs11781866 on total, low grade, and high grade prostate cancer 
risk in all participants of SELECT case-control cohort  
 
 Hazard Ratio 95% HR Confidence Limits p value 
Total  0.994 0.904-1.093 0.9045 
Low grade 0.984 0.877-1.104 0.7823 
High grade 1.009 0.874-1.164 0.9060 
 
 
However, when subjects were examined by intervention arm, I observed a 
significant interaction between rs11781866 genotype on total prostate cancer risk (p = 
0.0372) only in the vitamin E arm (Table 12).  When the risks for genotype with vitamin 
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E supplementation were compared to placebo with TT genotype, I observed 26% higher 
risk with the presence of at least one T allele in the vitamin E arm (HR 1.262, 95% CI 
1.046-1.521, p = 0.0149), but no increased risk for those homozygous for the minor allele 
C in the vitamin E arm.  Interestingly, individuals with the TT genotype in the vitamin E 
arm had a substantially higher risk (+42%) than those in the placebo group (HR 1.423, 
95% CI 1.092-1.855, p = 0.0089) (Table 12). This risk decreased with each addition of a 
C allele to the genotype (Table 12).  Notably, this significant genotype-specific 
modification of risk was not observed in the other intervention arms. The risk of high 
grade disease was not modulated by rs11781866 genotype in the vitamin E arm or in any 
other arm of the trial; instead, the risk modulation was specific to low-grade cases (Table 
13).   
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Table 12. Effect of genotype at rs11781866 on total prostate cancer risk in each intervention arm of the SELECT case-control cohort  
 
 
 
Genotype Intervention arm 
 Placebo 
N = 1220          
Vitamin E 
N = 1318 
Selenium   
N = 1247  
Vitamin E + Selenium 
N = 1216   
 HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value 
All 
genotypes 
1.000       ref ref 1.178 0.987-
1.405 
0.0688 1.091 0.913-
1.304 
0.3367 1.021 0.853-
1.222 
0.8171 
             
TT 1.000       ref ref 1.423 1.092-
1.855 
0.0089 1.259 0.962-
1.648 
0.0929 1.127 0.861-
1.475 
0.3839 
CT  1.125 0.858-
1.476 
0.3947 1.256 0.958-
1.646 
0.0995 1.171 0.893-
1.536 
0.2537 1.164 0.883-
1.533 
0.2807 
CC 1.47    0.930-
2.324 
0.0989 1.115 0.736-
1.689 
0.6062 1.216 0.801-
1.846 
0.3576 1.104 0.717-
1.701 
0.6531 
p trend 0.1069   0.0372   0.1504   0.2472   
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Table 13.  Effect of genotype at rs11781866 on low and high grade prostate cancer risk in each arm of the SELECT case-control cohort 
 
 
Genotype Intervention arm 
 Placebo      Vitamin E Selenium    Vitamin E + Selenium   
Low 
grade 
cases 
            
 HR 95% CI p value HR 95% CI p value HR 95% CI p value HR 95% CI p value 
All 
genotypes 
1.00 Ref ref 1.070 0.867-1.319 0.5294 1.004 0.812-1.241 0.9728 0.932 0.752-1.154 0.5166 
             
TT 1.000    Ref ref 1.450 1.059-1.985 0.0206 1.263 0.915-1.743 0.1549 1.058 0.766-1.462 0.7308 
CT  1.226 0.891-1.687 0.2111 1.115 0.803-1.549 0.5145 1.079 0.778-1.496 0.6496 1.088 0.781-1.517 0.6177 
CC 1.624 0.957-2.753 0.0721 0.996 0.575-1.620 0.8953 1.141 0.690-1.886 0.6074 1.167 0.699-1.947 0.5543 
p trend 0.0559   0.0063   0.0583   0.2629   
     
High 
grade 
cases 
            
 HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value 
All 
genotypes 
1.00 Ref ref  1.250 0.942-1.658 0.1224 1.201 0.902-1.598 0.2099 1.212 0.911-1.612 0.1868 
             
TT 1.000    Ref ref 1.303 0.847-2.005 0.2281 1.256 0.815-1.936 0.3011 1.282 0.835-1.969 0.2562 
CT  1.081 0.691-1.693 0.7326 1.420 0.924-2.181 0.1097 1.395 0.908-2.144 0.1287 1.461 0.949-2.251 0.0852 
CC 1.085 0.496-2.371 0.8386 1.328 0.717-2.462 0.3672 1.105 0.547-2.233 0.7814 0.993 0.490-2.012 0.9845 
p trend 0.7405   0.9101   0.7804   0.6828   
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rs11781866 may regulate BH3-only family member gene BNIP3L  
 
To begin to investigate a possible mechanism behind the modification of prostate 
risk in the vitamin E group with rs11781866 genotype, I examined the gene locus around 
the SNP.  rs11781866 is found at position 26,298,209 on chromosome 8p21, in a large 
intron of BNIP3L (Figure 14A).  Other genes in this region include PPP2R2A, PNMA2, 
and DPYSL2.  To investigate change in expression of genes around rs11781866 with 
SELECT trial supplements, we analyzed a randomized, placebo-controlled phase IIA 
study of prostate cancer patients before prostatectomy that was conducted using the 
identical supplements and dosage as used in SELECT (237).  Participants scheduled for a 
prostatectomy indicated for prostate cancer treatment were randomized to take 200 μg of 
L-selenomethionine (selenium), 400 IU of all-rac-alpha-tocopheryl acetate (vitamin E), a 
combination of 200 μg of L-selenomethionine and 400 IU of vitamin E, or placebo for 3-
6 weeks prior to prostatectomy. Using laser-capture microdissection, tumor tissue, 
normal epithelial tissue, and normal stromal tissue were isolated and RNA was extracted 
for microarray analysis (237).  Analysis of these data showed that BNIP3L was 
overexpressed in vitamin E-supplemented tumor tissue relative to placebo-supplemented 
tumor tissue (Figure 14B).  Expression of other genes in the region of rs11781866 was 
not affected by randomization arm (Figure 14B).  This suggests Bcl-2 family member 
protein BNIP3L may play a role in the increased prostate cancer risk upon vitamin E 
supplementation in SELECT.   
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Figure 14.  rs11781866 locus and nearby gene regulation with SELECT trial supplements 
A. Genome view of the rs11781866 locus on chromosome 8p21. Image modified from NBI sequence 
viewer.  Gene positions and symbols in their actual genomic positions are shown at the top of the figure in 
green. A schematic cartoon (not drawn to scale) of the BNIP3L gene with the position of rs11781866 is 
shown below in as an enlarged image.  B. Relative expression of genes in prostate tissue from Tsavachidou 
et al. (237) supplemented with SELECT trial supplements (200 μg of L-selenomethionine (Selenium), 400 
IU of all-rac-alpha-tocopheryl acetate (Vitamin E), a combination of 200 μg of L-selenomethionine and 
400 IU of vitamin E (Combo), or placebo for 3-6 weeks prior to prostatectomy in laser-capture 
microdissected tumor cells and adjacent normal epithelium and stromal cells.  C. Diagram of the sequence 
around rs11781866 including the putative FOXC1 binding site. 
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To explore the mechanism by which BNIP3L may be regulated by rs11781866 
genotype, we determined the consensus transcription factor binding motifs at the 
rs11781866 locus.  Table 14 lists the transcription factor motifs present with the major 
allele (T) and minor allele (C) at rs11781866.  Notably, with the major allele, two 
FOXC1 binding motifs are present, while the minor allele genotype eliminates both of 
these putative binding site motifs (Table 14 and Figure 14C).  Interestingly, FOXC1 
expression was also elevated by 400 IU of all-rac-alpha-tocopheryl acetate (vitamin E) in 
the Phase IIA clinical trial in normal stroma and tumor cells (Figure 14B).   
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Table 14. Transcription factor consensus motifs at rs11781866  
rs11781866 Major allele 
GCAGGAAAAGCTGtACTGGAGAGAGGT 
         
Model ID TF name Score 
Relative 
score Start End Strand 
predicted motif 
sequence predicted site sequence 
MA0032.1 FOXC1 4.238 0.81912061 8 15 1 GTA AAGCTGtA 
MA0032.1 FOXC1 5.653 0.89827216 14 21 -1 GTA CTCCAGTa 
MA0158.1 HOXA5 4.334 0.80557451 11 18 1 CNNNAAT CTGtACTG 
MA0113.1 NR3C1 8.522 0.80019789 1 18 -1 ANNNNGTNC CAGTaCAGCTTTTCCTGC 
         
rs11781866 Minor allele 
GCAGGAAAAGCTGcACTGGAGAGAGGT 
         
Model ID TF name Score 
Relative 
score Start End Strand 
predicted motif 
sequence predicted site sequence 
MA0122.1 Nkx3-2 5.659 0.80999296 12 20 1 NTAAGT(G/A)NN TGcACTGGA 
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Discussion 
 
SELECT was initiated as a large phase III clinical trial to test the efficacy of the 
antioxidants α-T and selenium to prevent prostate cancer development in a widespread 
population. What was believed to be strong rationale for the study was provided by data 
from NPCT (191), which showed a 49% decreased prostate cancer risk with selenium 
supplementation, and ATBC, which showed a 34% decreased prostate cancer risk with 
vitamin E supplementation (130).  However, these were secondary results from trials 
designed to study prevention of other cancer types.   
Men enrolled in the study had no evidence of previous prostate cancer and had 
low serum PSA (≤ 4 ng/mL) and a digital rectal exam not suspicious for prostate cancer. 
The primary clinical endpoint was incident prostate cancer cases as diagnosed by the 
standard of care at each study site. At the start of the trial, the authors predicted a 25% 
decrease in prostate cancer risk from supplementation with either vitamin E or selenium 
in the SELECT trial. 
SELECT began enrollment in August 22, 2001 and continued blinded to the trial 
results until October 23, 2008. Surprisingly, when the 7 year planned interim results of 
the trial were compiled in late 2008, neither selenium nor vitamin E alone or in 
combination decreased the risk of prostate cancer (137). Study coordinators ended the 
supplementation after this analysis, as the study supplements had shown no beneficial 
effects. Follow-up continued and another analysis in late 2011 showed that participants in 
the vitamin E-alone arm had a 17% increased risk of prostate cancer (138). The 
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observation that vitamin E, a widely-used, “natural” agent, increases prostate cancer risk 
in a cancer-naïve population has caused significant controversy in the field (242, 243). 
 The unexpected increase in prostate cancer risk with high dose (400 IU/day) 
vitamin E, an important molecule and nutrient in humans, is a significant public health 
concern.  In recent times, a significant body of research has been dedicated to explaining 
the role of oxidative stress in prostate tumorigenesis (5, 7, 9, 52, 101).  Numerous studies 
propose that reactive oxygen species promote cancer development through induction of 
DNA damage or promotion of pro-proliferative signaling, showing that antioxidants 
prevent prostate cancer progression (reviewed in (102)). However, most preclinical 
studies have been performed in models of advanced disease, and therefore, are not ideal 
models for prostate cancer prevention.  Thus, while decreasing oxidative stress with 
antioxidants may inhibit progression to advanced prostate cancer, additional studies must 
be performed to determine their efficacy in prostate tumor prevention. At later stages in 
cancer progression, ROS may promote proliferation and tumor progression by DNA 
mutations and signaling mechanisms.  However, at early stages, elevated ROS may 
inhibit cancer progression, as has been seen in other recent studies (225, 226).  Further, 
recent clinical studies have called into question the prostate cancer antioxidant 
chemoprevention hypothesis  (134, 137, 138, 244, 245). Thus, it is not surprising that 
antioxidant supplementation may not always be efficacious in preventing prostate cancer, 
as was observed in SELECT.    
There are many possible reasons for the failure of SELECT to show the ability of 
selenium or vitamin E to prevent prostate cancer development. Some propose that the 
formulations or doses of the study supplements were incorrect (140, 142, 246, 247).  
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Others suggest that the previous beneficial effects were only efficacious in a certain 
population (e.g. low plasma selenium status in NPC or smokers in ATBC) (243, 248). 
These concerns are warranted and have been widely debated. 
Selenium and prostate cancer prevention  
SELECT showed that selenium as a daily dose of 200 μg L-selenomethione was 
not able to prevent prostate cancer (137, 138).  Many have argued that the form of 
selenium used in SELECT may have been incorrect; however, two recently published 
studies dispute this argument. A recently published study using selenized yeast (the same 
type that was used in the NPC trial (130)) did not show a protective effect in men at high 
risk for prostate cancer (245).  A recent investigation comparing selenized yeast to 
selenomethionine in aged canines (the only other species besides humans known to 
consistently develop sporadic prostate cancer with age) showed no differences in the 
levels of prostatic selenium, DHT, or testosterone and did not have alterations in DNA 
damage, proliferation or apoptosis in the prostate gland (249).   
Thus, instead of reconciling the null effect of selenomethionine in SELECT due 
to its difference in selenium form from NPC, I believe it is most likely that only those 
with low baseline selenium levels will derive benefit from selenium supplementation, as 
was seen in NPC. The average baseline plasma selenium level in SELECT was about 136 
μg/L (137). The NPC trial was conducted with participants from low selenium areas in 
the Eastern U.S. and only showed a preventative effect of selenium supplementation in 
the two lowest quartiles of baseline selenium, at or below 123.2 μg/L (130).  In those in 
the highest quartile of baseline selenium, there was no protective effect (130).  
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Indeed, as many others have suggested, I propose there may be a “U-shaped 
curve” for the benefit of nutritional components: low or high a concentrations of these 
compounds both have the possibility to be detrimental to human health (250) (Figure 15). 
Identification of plasma antioxidant levels may be required for efficacious cancer 
prevention and for avoiding detrimental effects such as those seen in SELECT and other 
studies (251, 252).      
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. A “U-shaped” curve may describe the relationship of many essential nutrients with cancer 
risk reduction. This image redrawn from Walters et al. (250) shows the relative cancer risk associated 
different concentrations of essential nutrients in the body. Lower than optimal concentrations of a certain 
nutrient can increase cancer risk and therefore, individuals specifically deficient in this nutient may benefit 
from supplementation.  However, higher than optimal concentrations of the same nutrient may also 
increase cancer risk. Individuals with optimal or already elevated concentrations of the nutrient, would 
therefore have an increased cancer risk with supplementation.   
 
 
 
 
 
 
 
  99
Vitamin E and prostate cancer prevention  
SELECT and other studies have also shown that α-T did not prevent and, in some 
cases, promoted prostate cancer development (123, 138, 253).  Indeed, it has been argued 
that the vitamin E form used was incorrect, that the dosage was too high, or that vitamin 
E may only be efficacious in a defined subpopulation (113, 139, 141–143).   
α-T and γ-T differ only in the presence of one methyl group on the chromanol 
ring of the common tocopherol structure (254). The additional methyl group in α-
tocopherol may influence its ability to quench certain radical species. For example, γ-
tocopherol has a greater ability than α-tocopherol to trap reactive nitrogen species and has 
been proposed to have greater anti-inflammatory properties than α-tocopherol (67, 255). 
These differences in the two forms of vitamin E could have important biological effects.   
SELECT investigators chose 400 IU α-T primarily because of the striking 
decrease in prostate cancer incidence in the large ATBC trial seen with this form of 
vitamin E (191).  This supplementation decreased plasma γ-T levels by 50%.  Some pre-
clinical and clinical studies suggest that γ-T may be a more potent chemopreventative 
agent than α-tocopherol. The NIH-AARP Diet and Health Study, a large prospective 
questionnaire study about supplemental and dietary α- and γ-T intake, showed no 
protective effect of α-T supplementation, but did show that dietary γ-tocopherol intake 
was associated with a decreased risk of prostate cancer (253).  Another large prospective 
study showed that prostate cancer cases were associated with a lower γ-T level, but not a 
significantly lower α-T level (256). Therefore, the inability of α-T supplementation to 
prevent prostate cancer in SELECT and other studies may be due to the fact that the 
important γ-T levels are severely decreased.   
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The high dosage (400 IU) of α-T used in SELECT, more than 13 times the daily 
recommended value of 30 IU, may have played a role in the promotion of prostate 
cancer. Not only does high dose α-T decrease plasma γ-T (the possible effects of which 
are discussed above), but high dosages of vitamins and minerals may also have 
detrimental effects in other ways. Supra-nutritional dosages of other vitamins and 
minerals have been linked to increased mortality and cancer risk in several recent studies 
(251, 252, 257).  While the mechanism of increased prostate cancer risk in SELECT by 
high dose α-T remains unknown, my studies and the studies of many other investigators 
(233) will attempt to help explain this concerning finding.  
NKX3.1 SNPs and prostate cancer risk in SELECT  
In the wake of the debate over the SELECT results, Dr. Eric Klein, a lead 
researcher of SELECT, has suggested that identification of efficacious 
chemopreventative agents may rely upon finding unique risk factors in individual patients 
(192). Towards this goal, the specimens from the SELECT biorepository (consisting of 
plasma, serum, WBC-derived DNA, and toenails) have been made available to the 
scientific community to investigate the possible reasons for the inability of selenium to 
prevent prostate cancer and the promotion of prostate cancer by the vitamin E in the 
study-wide population.      
In order to help determine the mechanism between increased prostate cancer risk 
in SELECT with antioxidant supplementation and to identify subpopulations with 
modified risk levels, I investigated the relationship between risk associated with two 
functional variants in the prostate tumor suppressor gene NKX3.1 and SELECT 
intervention arm using the SELECT biorepository.  Our analysis was prompted by our 
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observation that Nkx3.1-deficient mice showed increased rather than decreased 
proliferation with antioxidant supplementation (159).  Nkx3.1-/- mice exhibit 
dysregulation of anti- and pro-oxidant genes and increased ROS (159). Inhibition of ROS 
caused a pro-tumorigenic phenotype, perhaps due to lifting a ROS-mediated inhibition of 
proliferation in these early lesions. Therefore, I hypothesized that the significantly 
increased risk of prostate cancer with vitamin E supplementation in SELECT, and the 
lack of prostate cancer prevention with selenium or the combination of selenium and 
viatmin E, was partially driven by individuals deficient in NKX3.1 expression. 
I found that antioxidant supplementation did affect the prostate cancer risk 
associated with allelic variation at rs11781886.  In both the vitamin E and selenium arms, 
presence of the minor allele at rs11781886 was associated with an increased risk of 
prostate cancer (Tables 8-10). The strong increase in prostate cancer risk even with only 
one minor allele with vitamin E supplementation may be explained by the fact that 
NKX3.1 has been shown to be haploinsufficient in many settings (152, 154, 258).  
Vitamin E supplementation more strongly increased high grade risk while selenium more 
strongly increased low grade prostate cancer risk (Tables 8-10).  Thus, the increased risk 
of prostate cancer with antioxidant supplementation in SELECT may be partially due to a 
significant increase in risk upon antioxidant supplementation in those with low NKX3.1 
expression.  At present, the biological mechanism behind this increased risk is unknown; 
however, antioxidant supplementation witn NAC in Nkx3.1-deficient mice promoted 
increased expression of gene sets involved in positive regulation of cell proliferation and 
chemokine/growth factor signaling (159).  Interestingly, however, combination vitamin E 
and selenium supplementation did not significantly modulate risk (Tables 8-10).   
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These data are not the first example of a genetic polymorphism affecting the 
prostate cancer risk associated with antioxidant capacity. Mikhak et al. showed that the 
polymorphism which causes a Ala16Val substitution in the manganese superoxide 
dismutase (SOD2) gene affects high grade prostate cancer risk in the presence of low 
plasma lycopene status (228), with the Ala/Ala genotype having higher risk than the 
Ala/Val or Val/Val genotype.  One hypothesis to explain this is that the Ala/Ala variant, 
which has higher SOD2 activity, leads to more hydrogen peroxide from the superoxide 
reduced by SOD2. This elevated hydrogen peroxide, if it cannot be quenched by 
sufficient levels of plasma antioxidants such as lycopene, can go to cause oxidative 
damage, leading to increased advanced prostate cancer risk (259).  In another a series of 
independent studies analyzing prostate cancer risk with plasma tocopherol, selenium, and 
lycopene levels, SNPs in SOD1 and SOD2 were analyzed (230, 232, 260).  While there 
was not an increased risk of total or aggressive prostate cancer with the SOD1 and SOD2 
SNPs, SNP genotype modified the risk of prostate cancer associated with plasma 
antioxidant levels. Also, the effect of polymorphisms in DNA repair enzymes hOGG1 
and XRCC1 on prostate cancer risk is modified by plasma levels of carotenoids and α-T 
(231).  Description of these and other variants that modify risk associated with 
antioxidant status may help to highlight molecular pathways involved in the mechanisms 
behind the unexpected increased prostate cancer risk with vitamin E supplementation in 
SELECT.    
Unlike Gelmann et al.(240), I found no elevation in high-grade prostate cancer 
risk due to rs2228013 in the SELECT case-cohort, nor did rs2228013 affect total or low 
grade risk in the case-cohort overall or in any intervention arm.  rs2228013 has been 
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shown to modulate NKX3.1 function in vitro (240); however, unlike rs11781886 (227), 
in vivo and human tissue studies to analyze the SNP’s effect on NKX3.1 expression or 
activity in the human prostate have not been reported. Therefore, the effect of rs2228013 
may not be merely a decrease in NKX3.1 function as would be seen with rs11781886 due 
to overall decreased expression of NKX3.1.  Instead, genotype at rs228013 may cause 
different, more complex alteration of NKX3.1 function which has alternate physiological 
effects, resulting in differential influence of antioxidant supplementation.   In addition, 
the case-cohort has a relatively small number of high grade cases, due to the fact that the 
participants were pre-screened for prostate cancer at the initiation of the study.  
Therefore, the population may not be the best representative of high grade cases in the 
general US population. 
Our studies have identified a genetic risk factor (rs11781886) for prostate cancer 
which is modulated by supplementation with the antioxidants selenium and α-T.  Indeed, 
presence of the minor allele at rs11781886 may have partially contributed to the 
increased risk of prostate cancer upon vitamin E supplementation, and the lack of prostate 
cancer prevention with selenium supplementation.  These results suggest that an 
individual’s prostate cancer risk associated with antioxidant supplementation is 
dependent upon genotype at rs11781886. Future studies in mouse models of prostate 
cancer and in human clinical samples will be required to determine the molecular events 
associated with NKX3.1 polymorphisms and prostate cancer development in the presence 
of antioxidant supplementation.  
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Putative BNIP3L SNP rs11781866 and prostate cancer risk in SELECT  
Our work has suggested a possible novel role for BNIP3L in prostate 
tumorigenesis in the setting of vitamin E supplementation.  BNIP3L is a member of the 
BH3-only class of the Bcl-2 gene family on chromosome 8p21 (261).  Bcl-2 proteins are 
master controllers of apoptosis and share one or many of the four conserved BH domains 
(BH1, BH2, BH3, and BH4). The BH domains allow for interactions between the family 
members, some of which are pro-apoptotic and others of which are anti-apoptotic (261). 
The BH3-only class contains only the BH3 domain, and expression of these proteins 
tightly regulated by cellular stress. They antagonize the interaction of the anti-apoptotic 
family members with the pro-apoptotic family members, allowing for the pro-apoptotic 
members to promote apoptosis through permeabilization of the mitochondrial membrane 
(261).  BH3-only proteins serve as master regulators of the cellular response to acute 
stressors.  
BNIP3L shows ~65% sequence homology with BNIP3, with the areas of greatest 
similarity in its BH3 domain and transmembrane domain (262–264). BNIP3L localizes 
primarily to the mitochondria and its RNA is expressed ubiquitously in most human 
tissues(263, 264).  Its transmembrane domain is required for promotion of apoptosis 
(264).   
Multiple reports support the role of BNIP3L as a tumor suppressor.  BNIP3L has 
been shown to promote apoptosis in cells, especially in hypoxic conditions (264–266).  
BNIP3 and BNIP3L are upregulated by hypoxia, mediated by HIF-1α (265, 267). 
Interestingly, BNIP3L has been shown to be a direct target of p53 in hypoxia, promoting 
apoptosis (265), and therefore may be a key dysregulation of gene expression in cancer 
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upon p53 loss. Further support for a tumor suppressor role for BNIP3L comes from a 
report that showed BNIP3L undergoes homozygous deletions in prostate cancer tissue 
(268), and that it is found in a chromosomal region (8p21) which is well-established to 
show loss of heterozygosity in human prostate cancer (150, 269).  
However, other lines of evidence suggest a role for BNIP3L in promoting cell 
survival, perhaps acting as an oncogene.  BNIP3 and BNIP3L have been implicated in 
autophagy (270–272), a process by which cells can break down and recycle organelles 
(273). The process is critical for normal cellular homeostasis and survival in times of 
cellular stress. Autophagy can be triggered due to damage to organelles or stressful 
conditions which require the production of energy from cellular components.   
Autophagy has been shown to play both pro-tumorigenic or anti-tumorgenic roles 
depending on the cellular context (274). Breast, prostate, and ovarian cancers have a high 
chance of deletion of the essential autophagy gene BECLIN1 (BECN1) (275–278), 
BECN1+/- mice develop many types of tumors with age (279), and expression of BECN1 
decreases tumorigenicity in breast cancer cells (280), highlighting the role of autophagy 
in cancer inhibition. Also, BNIP3L has been shown to be deleted in a small portion of 
prostate tumors and deletion is associated with increasing tumor grade (281).  On the 
other hand, autophagy also acts as cellular survival mechanism in times of stress and can 
assist cancer cells undergoing metabolic stress to survive (274).  mTORC1 is a master 
sensor of cellular metabolic flux which inhibits autophagy in times of high nutrient 
conditions. Elevation of ROS, increased hypoxia, stress, and low nutrient conditions 
promote autophagy (274).  
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The precise mechanism by which BNIP3L promotes autophagy is not 
conclusively known; however, several hypotheses have been suggested.  The first idea is 
that BNIP3L causes mitochondrial dysfunction and depolarization, leading to increased 
ROS which induce autophagy(282, 283). The second possibility is that BNIP3L induces 
autophagy by disrupting Bcl-2-Beclin 1 complexes, freeing Beclin-1 from repression by 
Bcl-2 and allowing it to induce autophagy (271).  BNIP3L is a target gene of the 
transcription factor FOXO3, which is inhibited by Akt signaling, and when activated, 
triggers autophagy (284). These and other mechanisms have been proposed (270) and 
will require extensive investigation before a thorough understanding of BNIP3L 
induction of autophagy is reached.    
While support for the role of BNIP3L as a tumor suppressor is abundant in the 
literature, several studies have also suggested that BNIP3L can promote cancer (272, 
273).  Expression of BNIP3L protects breast and prostate cancer cells from hypoxia-
induced cell death (272).  Another very recent study showed that BNIP3L expression was 
associated with high NF-κB expression in glioma (285), which is known to correlate with 
increased tumor grade (286).  There was increased expression of BNIP3L RNA with 
increasing grade (286). Interestingly, higher BNIP3L levels were correlated with different 
phenotypes depending on the stage of the tumor. In astrocytoma tumors, high BNIP3L 
was correlated with significantly lower proliferation, a trend towards higher apoptosis, 
and better tumor free survival. However, high BNIP3L in high grade tumors (grade III 
anaplastic astrocytoma, and grade IV glioblastoma) was correlated with no change in 
proliferation, with lower apoptosis, and no change in tumor free survival (286).  While 
this study was done on a relatively small number of human samples, and more definitive 
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results would be beneficial, this work highlights a possible diversity of effects BNIP3L 
may have depending on the cellular context.   
Another way that BNIP3L could play a pro-tumorigenic role is though 
modification of the tumor microenvironment. Several have suggested that autophagy 
plays an important part in this interplay between tumor and surrounding stroma cells.  In 
what has been termed the “Autophagic Tumor Stroma Model of Cancer Metabolism,” 
oxidative stress in the microenviroment created by tumor cells promotes aerobic 
glycolysis and autophagy in stroma cells, which causes the release of nutrients needed for 
tumor cell survival (274).  Evidence for this has been shown in experiments that suggest 
tumor associated fibroblasts undergo autophagy due to oxidative stress induced by MCF7 
breast cancer cells (287).  Data suggest that these fibroblasts protect breast tumor cells 
from cell death through apoptosis (287).  HIF-1 alpha expression in stromal cells (which 
induced BNIP3L expression) promoted autophagy and promoted tumor growth, while 
HIF-1 alpha expression in tumor cells suppressed tumor growth (288).  Thus, BNIP3L 
expression and autophagy in the tumor stroma has been correlated with increased tumor 
growth, and may be relevant pro-tumorgenic role for BNIP3L.  Our microarray analysis 
of SELECT trial supplement exposed prostates (Chapter IV) did not show elevation of 
BNIP3L specifically in the normal stroma; however, data were not available for tumor 
stroma, so determining the relevance of this mechanism in human prostate tumorigenesis 
would require additional experiments.      
Autophagy induction by BNIP3 or BNIP3L may occur through three possible 
mechanisms (270).  The proteins could mediate mitochondrial membrane depolarization 
inducing intracellular ROS, which can lead to autophagy.   BNIP3 or BNIP3L can 
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displace autophagy promoter Beclin-1 from Bcl-2, promoting autophagy. Lastly, the 
proteins may influence autophagy by regulation of mTORC1 activity, which inhibits 
autophagy. BNIP3L has been clearly shown to play a role in mitochondrial clearance in 
reticulocytes, a process which requires functioning autophagy (289). Thus, alterations in 
expression of BNIP3L could logically either inhibit or promote prostate tumorigenesis.  
In our study, the TT (homozygous major allele) genotype at rs11781866 was 
associated with a significant increase in prostate cancer risk with vitamin E 
supplementation, which was diminished with each addition of a C allele (Table 12 and 
Table 13). This effect was not seen, however, in the selenium and selenium and vitamin E 
combination arms, suggesting a vitamin E-specific effect rather than an overall 
antioxidant effect may be responsible for the findings.  In order to determine which if any 
genes in the vicinity of rs11781866 might be regulated in a way to affect prostate 
tumorigenesis, we queried published data using the SELECT trial supplements in humans 
prior to prostatectomy (237).  The only gene in the vicinity of rs11781866 that was 
modulated by SELECT supplementation was BNIP3L, whose expression was increased 
in tumor tissue from the vitamin E group.  If one assumes the major allele of rs11781866 
is associated with normal expression of BNIP3L, and the minor allele with less 
expression of rs11781866, then vitamin E could be promoting BNIP3L expression to 
promote prostate tumorigenesis.    
Because BNIP3L levels are elevated with vitamin E supplementation, I 
hypothesize that BNIP3L is acting as an oncogene in the setting of elevated α-T levels. 
Using the JAPSAR transcription factor binding profile database, we found that the 
rs11781866 locus contains two putative binding sites for the transcription factor FOXC1, 
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which are eliminated by substitution with the minor allele.  FOXC1 levels are also 
significantly increased in vitamin E- supplemented prostate (237), which suggests that 
FOXC1 is positively regulating BNIP3L.  
I propose the following model summarizing our current results (depicted in Figure 
16).  Vitamin E increases FOXC1 levels, then, through positive regulation of BNIP3L by 
FOXC1 binding at the rs11781866 locus, BNIP3L levels increase. I propose that 
increased FOXC1 expression with vitamin E supplementation more strongly upregulates 
BNIP3L expression in the presence of the TT allele since there are two binding sites for 
FOXC1. The BNIP3L induction decreases with each addition of a C allele due to 
decreased binding of FOXC1. In the placebo group, the FOXC1 levels are not as high, 
and therefore BNIP3L is not induced to a high level. Therefore, differences in FOXC1 
binding to the rs11781866 locus in the placebo group do not alter BNIP3L levels and 
prostate cancer risk to a significant degree.  Further studies are required to confirm the 
changes proposed at each step of this model. 
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Figure 16.  Model of rs11781866 influenced and BNIP3L-mediated promotion of prostate cancer with 
vitamin E supplementation in SELECT. At the start of SELECT, all participants are screened and 
designated as ‘cancer naïve,’ thus the model starts at left with a normal prostate gland. When the 
participants were supplemented with vitamin E, this caused upregulation of the transcription factor FOXC1 
(as shown in Figure 14, indicated here by the presence of more FOXC1 molecules with vitamin E 
supplementation). I propose that FOXC1 positively regulates BNIP3L expression by binding to a putative 
regulatory region at rs11781866 with the major allele (T), with one binding site on each DNA strand for a 
total of 2 binding sites per chromosome at rs117818866. This putative FOXC1 binding site is lost in 
presence of the minor allele (C). Therefore, in the presence of larger quantities of FOXC1, FOXC1 
occupies its binding sites maximally and upregulates BNIP3L and promoting cancer development to the 
greatest degree via BNIP3L upregulation. There is less upregulation of BNIP3L in the presence of one or 
two minor alleles at rs11781866 and correspondingly less promotion of cancer. Without vitamin E 
supplementation, there is no induction of FOXC1, and thus, no promotion of cancer even with the major 
allele at rs11781866.  Therefore, genotype at rs11781866 does not alter prostate cancer risk in the placebo 
group.   
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CHAPTER V 
 
ROLE OF NKX3.1 AND MYC TARGET GENE PRDX6  
IN PROSTATE TUMORIGENESIS  
 
Introduction 
 
While many correlative gene expression changes have been described in the 
development of prostate cancer, mechanistic information about the role these changes 
play in cancer development is lacking. Gain of expression of the oncoprotein MYC is a 
common early event in prostate cancer development (290), (291) with 76% of PIN, 
81.6% of adenocarcinoma, and 68% of metastatic lesions overexpressing MYC (292).  
MYC expression drives cell cycle progression, helps cells maintain stem cell 
characteristics, increases cellular metabolic pathways, and increases protein synthesis 
(293). Another common gene expression change in prostate cancer is loss of expression 
of the tumor suppressor NKX3.1.  NKX3.1 expression is completely lost in 5% of benign 
prostatic hyperplasias, 20% of high-grade prostatic intraepithelial neoplasias, 34% of 
hormone-refractory prostate cancers, and 78% of metastases (153).  In addition, NKX3.1 
has been shown to be haploinsufficient (258); thus, a complete loss of NKX3.1 protein 
expression may not be necessary for important biological effects.  Concurrent gain of 
MYC expression with loss of NKX3.1 expression is a common event in prostate 
tumorigenesis.   
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Our laboratory has shown that the transcription factors Myc and Nkx3.1 cooperate 
in a mouse model of MYC-driven prostate tumorigenesis, sharing 65 common direct 
target genes (158).  One of the genes bound by NKX3.1 and MYC is peroxiredoxin 6 
(Prdx6).  Prdx6 mRNA expression is decreased in Nkx3.1-/- mice (155, 159) and in 
MYC+, Nkx3.1-/- lesions, Prdx6 protein expression is greatly depleted (158), suggesting 
that Nkx3.1 positively regulates Prdx6, while MYC negatively regulates Prdx6.  
PRDX6 is a member of the peroxiredoxin superfamily of selenium-independent 
peroxidases.  As a peroxidase, PRDX6 can reduce short-chain, fatty acid, and 
phospholipid peroxides (294).  It is singular among the peroxiredoxins in its ability to 
reduce phospholipid peroxides, as none of the other family members have this ability.  
Uniquely, PRDX6 is also a dual function enzyme, containing phospholipase A2 activity 
in addition to its peroxidase activity. Phosholipase A2 activity cleaves phospholipids at 
the second carbon of glycerol, releasing lysophospholipids and free fatty acids (such as 
arachidonic acid).  Prdx6 is expressed in all major organs of the body and has the highest 
expression in lung (295). Prdx6 has been extensively studied in the lung, but its role in 
prostate physiology has not been investigated.   
Here I show that high MYC expression is specifically associated with depleted 
Prdx6 expression in mouse prostate.  Our findings suggest that MYC may directly repress 
Prdx6 by binding to the Prdx6 promoter. Interestingly, although MYC is correlated with 
decreased Prdx6 expression in early prostate lesions, Prdx6 appears to have a pro-
tumorigenic function in aggressive prostate cancer cells, promoting proliferation in vitro 
and in vivo and by promoting anchorage-independent growth.  Our studies describe a 
novel functional role for PRDX6 in prostate tumorigenesis.   
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Methods 
 
Cell lines and mice  
The Myc-CaP mouse prostate cancer cell line (296) was derived from a prostate 
cancer from the Hi-Myc mouse (297) and was a gift from Charles Sawyers, Memorial 
Sloan Kettering Cancer Center. Myc-Cap cells were cultured in a 5% CO2 incubator at 
37°C in DMEM with 10% fetal bovine serum (FBS).  LNCaP, PC3, and DU145 cells 
were purchased from ATCC.  LNCaP and PC3 cells were maintained in RPMI with 10% 
FBS and DU145 cells were maintained in DMEM/F12 with 10% FBS.  Nkx3.1f/f, and 
PBcre4;Z-MYC,  PBcre4;Z-MYC;Nkx3.1f/f, and PBcre4;Z-MYC;Ptenf/+;p53f/+ mice have 
been described (152, 158, 207, 208).   
Lentiviral constructs  
FM-1 control lentiviral transfer vector was a kind gift from Dr. Jeffrey Milbrandt, 
Washington University.  Wild type Prdx6, peroxidase mutant C47S, and phopholipase 
mutant H26A constructs (kind gift from Aron Fisher, University of Pennsylvania) were 
cloned into the FM-1 lentiviral constructs. Lentiviruses generated specifically for this 
study were packaged in the African green monkey kidney fibroblast-like cell line COS-1 
(298) to avoid ethical concerns over use of other lentiviral packaging cell lines. 
Lentivirus was made by cotransfecting the transfer vector containing the gene of interest 
with the VSVG envelope glycoprotein plasmid and the HIV-1 packaging vector Δ8.9 
(gift from Dr. David Baltimore) into COS-1 cells (ATCC) using polyethylenimine 
(Polysciences Inc.).  Virus was concentrated by filtration in Centricon Plus-70 filter units 
(Millipore). Viral titer was determined by infecting HT1080 cells with serial dilutions of 
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virus and followed by quantification of GFP-positive cells by flow cytometry after two 
days of infection.  
In vitro proliferation assay  
Myc-CaP FM-1-control, FM-1-Prdx6, FM-1-C47S, and FM-1-H26A cell lines 
were plated in 96-well plates at a density of 200 or 100 cells per well. Cells were 
incubated for 3 or 4 days at which time 20 μl CellTiter 96® AQueous One Solution 
(Promega) was added to each well.  Cells were incubated for one to three hours in a 5% 
CO2 incubator at 37°C.  Absorbance at 490 nm was read on a Bio Tek Elx800 Plate 
Reader (Fisher Scientific).   
Soft agar colony formation assay  
Each well of a 6 well plate was coated with 1 mL DMEM containing 0.5% agar 
(Fisher).  Cells were then resuspended in DMEM containing 0.35% agarose (DNA grade) 
at a concentration of 10,000 cells per mL and 1 mL was plated in each well.  Cells were 
incubated in a 5% CO2 incubator overnight. 2 mL DMEM was added to each well the 
next day.  Media was changed every 2-4 days, adding replacing 2 or 3 mL per well.  Cells 
were incubated in a 5% CO2 incubator for 14 days.  Number of colonies >30 μm per 10x 
field was quantified by selecting three random fields per well and counting four wells.  
Myc-CaP allograft experiments  
Myc-CaP cells were infected with FM-1-control, FM-1-Prdx6, FM-1-C47S, or 
FM-1-H26A plates with 8 μl/mL polybrene in DMEM for ~24 hrs.  Cells were sorted for 
YFP positivity via fluorescence activated cell sorting (FACS) to establish stable cell lines 
with lentiviral-mediated gene expression. 250,000 non-infected parental Myc-CaP cells 
were combined with 250,000 stable FM-1-control, FM-1-Prdx6, FM-1-C47S, or FM-1-
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H26A lines for each graft. 0.2 mL matrigel (BD Matrigel™ Matrix Phenol Red-Free) was 
combined with the cells for each graft.  Cells with matrigel were injected subcutaneously 
in male athymic Nude (Foxn1 nu/nu) mice.  Grafts were allowed to grow for 15 days 
before harvest.   
Histology and immunostaining 
Tissue was fixed overnight in 10% formalin solution and washed in 70% ethanol. 
Tissue processing and hematoxalin and eosin (H&E) staining were performed by the 
Vanderbilt Translational Pathology Shared Resource. For immunohistochemistry, 
paraffin embedded sections were deparaffinized, rehydrated, and steam/pressure antigen 
retrieval was performed. The following antibodies were used: anti-phospho histone H3 
(rabbit, 1:500, Millipore), anti-cleaved caspase-3 (rabbit, 1:200, Cell Signaling), anti-
Prdx6 (1:200, gift from Aron Fisher laboratory), c-Myc (rabbit, 1:300, with ABC 
amplification, or 1:30,000 with TSA amplification, Abcam), and anti-green fluorescent 
protein (chicken, 1:200, Abcam).  For immunofluorescence, fluorescent-tagged 
secondary antibodies, including Alexa 488 (anti-rabbit, Invitrogen), and Alexa 546 (anti-
chicken, Invitrogen) were used.  Slides were mounted with Vectashield Mounting media 
with DAPI (Vector Laboratories). For non-fluorescent stains, DAB substrate (Sigma) was 
used and slides were counterstained with hematoxalin. 
Immunofluoresent image quantification for percent YFP stained area 
For percent YFP+ area analysis in Myc-CaP allograft tissue, random images of 
the YFP immunofluoresent stain were taken with a 20x objective of all samples in a 
blinded fashion. Percent stained area and total area was obtained using the Fovea Pro 
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plugin for Adobe Photoshop.  Percent YFP+ area was determined by dividing the 
%YFP+ value by the % of field filled by cells (total area).   
Quantification of pHH3 and caspase 3 staining index 
In the Myc-CaP allograft experiment, random fields including YFP+ tissue were 
chosen at 20x. At 40x, the total number of YFP+ cells and the number of pHH3 or 
caspase 3 positive cells were counted. The Fisher’s Exact Test was used to test the 
differences in percent of cells staining positive between all four groups.   
 
Results 
 
Prdx6 expression in mouse prostate  
Prdx6 is significantly expressed in wild type mouse prostate, with high expression 
in the distal region and almost a complete loss of expression in the extreme proximal 
region (Figure 17 A,B).   
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Figure 17. Spatial distribution of Prdx6 expression in mouse prostate. Immunofluorescent stain for 
Prdx6 (indicated in green) in anterior (A) and dosolateral (B) prostate. Nuclei are stained with DAPI (blue). 
Scale bar = 0.1 mm.   
 
Prdx6 expression is depleted in MYC-driven mouse prostate cancer  
 
Our previous study (158) identified Prdx6 as a co-direct target gene of Myc and 
the prostate tumor suppressor Nkx3.1. Myc and Nkx3.1 were shown to bind to the Prdx6 
locus via ChIP-seq, and in MYC+; Nkx3.1-null lesions, Prdx6 was greatly depleted, 
suggesting that Myc represses Prdx6 expression. To determine if Myc represses Prdx6 in 
other models of mouse of cancer, I analyzed Prdx6 expression in other published 
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microarray studies. Importantly, Prdx6 expression was decreased over 9-fold in Myc-
driven tumors of the hi-MYC mouse prostate (297) and was decreased over 2-fold in 
MYC tumor allografts (158, 299).  Via qRT-PCR analysis, Prdx6 expression was also 
decreased by about 48% in the Nkx3.1-/- mouse prostate (159). Interestingly, Prdx6 
expression was also decreased more than 5-fold in PBCre4; Ptenloxp/loxp tumors (95), a 
model which is driven by loss of the tumor suppressor Pten instead of high MYC 
expression, suggesting loss of Prdx6 may play a role in additional mechanisms of prostate 
tumor initiation. At the protein level, Prdx6 expression was not notably decreased in 
Nkx3.1-/- mice compared to wild type (Nkx3.1+/+) mice (Figure 18). Prdx6 expression was 
lower in PBCre;Ptenf/f mouse tumors than in normal wild type mouse prostate (Figure 
16).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Prdx6 expression is decreased in mouse models of prostate cancer. Immunofluoresent stain 
for Prdx6 (indicated in green) wild type anterior prostate, Nkx3.1-/- anterior prostate, PBCre;Ptenf/f, and 
PBCre;Z-MYC;Ptenf/f;p53f/+. Immnohistochemical staining for MYC (indicated in green) is also presented 
for PBCre;Z-MYC;Ptenf/f;p53f/+. Nuclei are stained with DAPI (blue). Scale bar = 0.1 mm.   
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I analyzed Prdx6 expression at the protein level in mouse prostates with focal 
MYC expression (the PBCre;Z-MYC mouse (207) and PBCre; Z-MYC; Nkx3.1f/f mouse 
(158) and saw that MYC expression tightly correlated with areas of Prdx6 depletion 
(Figure 19 A,B).  Prdx6 expression was also strongly decreased in MYC-expressing areas 
of the PBcre4;Z-MYC;Ptenf/+; p53f/+ tumor model (Figure 18).  These data suggest that 
Myc represses Prdx6 expression in the prostate.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.  Prdx6 is specifically depleted in MYC+ regions of mouse prostate. (A) H&E (left),  
immunofluorescent stain for MYC (center, in green), and immunofluorescent stain for Prdx6 (right, in 
green) in PBCre; Z-MYC prostate.  (B) H&E (left), immunohistochemical stain for MYC (center, in 
brown), and immunofluorescent stain for Prdx6 (right, in green) in PBCre; Z-MYC; Nkx3.1f/f prostate tissue 
recombination graft. Arrowheads indicate areas of low MYC expression on MYC stained sections and the 
corresponding areas in the Prdx6 stain on the adjacent section where Prdx6 expression is retained due to 
lack of MYC expression. Asterisk in the MYC immunofluorescence image for the PBCre;Z-MYC mouse 
indicates an entire gland which is MYC negative; the entire gland on the adjacent Prdx6 
immunofluorescence image is positive for Prdx6 expression.  
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Prdx6 promotes prostate cancer cell proliferation and tumorigenicity  
To determine functional effect of Prdx6 on prostate cancer cells, Prdx6 expression 
was driven in the Myc-CaP mouse prostate cancer cell line, a cell line derived from the 
hi-Myc mouse (296, 297).  The Myc-CaP line has high Myc expression and no Nkx3.1 
expression.  Lentivirus-mediated expression of wild type Prdx6, peroxidase mutant Prdx6 
(C47S), and phosholipase A2 mutant Prdx6 (H26A) was achieved in Myc-CaP cells 
(Figure 20 A, B).   
 
 
 
 
Figure 20. Prdx6 drives in vitro proliferation and anchorage-independent growth in Myc-CaP mouse 
prostate cancer cells. (A) Immunoblot for Prdx6 in lysates from Myc-CaP cell lines with lentiviral-
mediated expression of Prdx6. Actin immunoblot is presented as a loading control. (B) 
Immunocytochemical stain in Myc-CaP FM-1 cells (FM-1) and Myc-CaP Prdx6 cells (Prdx6) shows 
cytoplasmic expression of Prdx6.  (C) Optical density measurements at 490 nm (OD 490nm) measurement 
for the in vitro proliferation assay with Myc-CaP-Prdx6 expressing cell lines. N = 5 wells, experiment 
performed once with these conditions. (D). Soft agar colony formation assay results presented as colonies 
per field for Prdx6-expressing Myc-CaP cell lines.  Number of colonies >30 μm per 10x field was 
quantified by selecting three random fields per well and counting four wells. * p <0.05 for Student’s T-test.  
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Prdx6 promoted in vitro proliferation of the Myc-CaP cells in a manner that 
appeared to be dependent on both the peroxidase and phospholipase A2 activities of the 
Prdx6 enzyme (Figure 20C). Prdx6 increased anchorage-independent growth of Myc-CaP 
in the soft agar colony formation assay, in a manner that was dependent on both the 
peroxidase and phospholipase A2 functions of Prdx6 (Figure 20D). These functional 
assays suggest that Prdx6 promotes tumorigenicity of aggressive prostate cancer cells.     
To determine the ability of Prdx6 to modulate tumorigenicity in vivo, I performed 
allografts of the Prdx6-Myc-CaP cell lines mixed with equal numbers of uninfected, 
parental Myc-CaP cells (Figure 21A). Myc-CaP Prdx6 lines and the empty vector line 
(Myc-CaP-FM-1, Myc-CaP-Prdx6, Myc-CaP-C47S, and Myc-CaP-H26A) express YFP 
while the parental Myc-CaP line does not, resulting in a mosaic YFP expression in the 
grafts, designating the lentiviral-construct-expressing cells (Figure 21B).  
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Figure 21. Prdx6 drives proliferation in Myc-CaP subcutaneous allografts. (A)  Model of allograft 
scheme: 500,000 total cells, including 250,000 non-YFP expressing parental Myc-CaP cells and 250,000 
YFP-expressing Prdx6-expressing or control Myc-CaP cells, were injected subcutaneously in nude mice. 
Allografts were allowed to grow 15 days before harvest. (B) Represensative immunohistofluorescent 
images from double staining for YFP (in red) and phosphorylated histone H3 (pHH3, in green) (left) and 
YFP (in red) and activated caspase 3 (casp3, in green) (right).  Scale bar = 0.1mm. (C) Quantification of 
pHH3+ and casp3+ cells in YFP positive areas immunofluorescent stains of Prdx6-expressing and control 
Myc-CaP allografts.  The total cells indicates the total YFP positive cells counted in each group and the 
pHH3+ or casp3+ cell totals are the total number of cells which stained positive for these markers in the 
YFP positive area. Fisher’s Exact test was used to test if the distribution of positive cells differed in each 
group.  * p <0.05 by Fisher’s Exact test. (D) Immunofluoresent image quantification for percent YFP 
stained area in Prdx6-expressing and control Myc-CaP allograft tissue as obtained using the Fovea Pro 
plugin for Adobe Photoshop.   
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As Prdx6 promoted proliferation of Myc-CaP cells in vitro, I hypothesized that 
Prdx6 expression would increase proliferation in the allograft and, therefore, increase the 
percent of YFP-positive cells in the grafts. While none of cell lines significantly 
modulated the percent of YFP positive cells (Figure 21D), the number of pHH3-positive 
cells in the wild-type Prdx6 expressing cells was significantly higher than the control or 
Prdx6 mutant cell lines (Figure 21C). Apoptosis, as indicated by activated capspase 3 
staining, was not significantly altered (Figure 21C).  
 
Discussion 
 
Extensive research has been performed to analyze the role of the oncoprotein 
MYC in prostate tumorigenesis (158, 207, 293, 300). MYC is overexpressed at early 
stages of human prostate cancer and is elevated in a high percentage of advanced disease 
(292). MYC’s important role in normal cell physiology and in carcinogenesis cannot be 
overstated.  Classically, MYC has been thought of as transcription factor with distinct 
target genes, which when regulated, have crucial effects on the cell.  MYC target gene 
regulation stimulates proliferation, cell growth, cell metabolism, and apoptosis.  To carry 
out these changes, MYC promotes expression of some genes and represses expression of 
others.  However, the recent publications that have suggested MYC functions as a general 
amplifier, rather than a specifier, of gene expression (301, 302), have led to some 
controversy over the function of Myc. Supporting the role of MYC as a specifier of gene 
expression, our studies have characterized a unique MYC target gene which is distinctly 
repressed by MYC expression in the prostate, Prdx6. I have shown a sharp correlation of 
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high MYC expression with depleted Prdx6 expression in mouse prostate, suggesting that 
MYC directly represses Prdx6 expression; however, additional studies will be required to 
confirm direct transcriptional repression or to identify other mechanisms by which MYC 
inhibits Prdx6 protein levels.  
Our study has also described a functional role for the dual-function enzyme Prdx6 
in prostate tumorigenesis.  Prdx6 has been only recently studied in the setting of 
carcinogenesis.  Li et al. found that Prdx6 was upregulated in a highly metastatic variant 
of the MBA-MD-435 breast cancer cell line (303).  They went on to show that 
exogenously driven Prdx6 expression in MBA-MD-435 and MBA-MD-231 cells 
increased in vitro proliferation and invasion, and increased tumor growth and metastasis 
in a allograft model (189).  Knockdown of endogenous Prdx6 inhibited in vitro breast 
cancer cell invasion and tumor growth and metastasis in the allograft model (189).  Prdx6 
knockdown in A549 lung cancer cells decreases invasiveness (188).  Further studies 
suggested that the peroxidase activity of Prdx6 is responsible for its growth-promoting 
function and the PLA2 activity is responsible for its invasion-promoting function (187).  
Prdx6 is upregulated in pancreatic cancer (184), squamous cell carcinoma of the tongue 
(183), ovarian cancer (serum) (186), and endometrial cancer (185).  Investigators have 
shown that Prdx6 is upregulated in cells that gain resistance to chemotherapy (304).  
Therefore, the majority of studies in cancer cell lines and human cancer tissues indicate 
that Prdx6 is associated with aggressive cancer.   
The role of Prdx6 specifically in prostate tumorigenesis is completely unknown.  
Expression of Prdx1-6 were analyzed in normal and cancerous human prostate tissue by 
Basu et al. (305).  While Prdx3 and Prdx4 appear to be consistently upregulated in cancer 
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compared to normal tissue, Prdx6 was not shown to be differentially expressed in this 
study.  To our knowledge, our studies are the first investigation into the role of Prdx6 
prostate tumorigenesis.  
Our studies suggest that Prdx6 promotes a tumorigenic cell phenotype when 
expressed in cancer cells.  Prdx6 expression in Myc-CaP, an aggressive, Myc-driven 
mouse prostate cancer cell line, promoted proliferation in vitro and in vivo and promoted 
anchorage-independent growth.  The growth-promoting activity of Prdx6 appeared to be 
dependent on both the peroxidase and phospholipase A2 activities of Prdx6.  Peroxidase 
activity may help to maintain lower oxidative stress levels in cells, allowing for increased 
cell viability and proliferation.  Phospholipase A2 activity can generate arachidonic acid, 
a precursor of prostaglandins, many of which have been implicated in promotion of 
prostate tumorigenesis (176, 177).   
MYC expression is often associated with elevated aggressiveness and poor 
outcome in cancer (306).  Then, how does MYC inhibition of Prdx6, a pro-tumorgenic 
protein, make sense?  Our models of focal MYC expression in mouse prostate (PB-
Cre;Z-MYC and PB-Cre;Z-MYC;Nkx3.1 f/f)  display early lesions, PIN and early 
microinvasion, rather than extremely aggressive lesions with complete loss of glandular 
structure and massive invasion.  The cell line model used, Myc-CaP, was derived from a 
very aggressive tumor from the hi-Myc mouse and therefore may not be representative of 
the early lesions in our focal MYC models. Indeed, a recent publication by Rolfs et al. 
(307) has described a dual role of Prdx6 in mouse model of skin carcinogenesis: at early 
stages, Prdx6 inhibits tumor formation, but at late stages, Prdx6 promotes tumor 
progression of existing tumors.  In addition, human tissue studies which have suggested 
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an upregulation of PRDX6 in cancer may also be representative of more advanced 
lesions. Therefore, I propose that MYC normally represses PRDX6 in untransformed 
prostate epithelial cells, resulting in a decrease in the possible tumor-preventative activity 
of Prdx6.   However, advanced lesions may attain genetic mutations or other cellular 
changes that allow for escape from MYC repression of PRDX6, thereby allowing 
PRDX6 expression to promote tumor progression in aggressive prostate cancer cells.   
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CHAPTER VI 
 
DISCUSSION AND FUTURE DIRECTIONS  
 
In the preceding studies, I set out to investigate the relationship between oxidative 
stress and genetic alterations in prostate tumor initiation. I investigated the role of ROS in 
a mouse model of early prostate tumorigenesis with the lack of expression of a crucial 
tumor suppressor gene (Chapter III), explored the influence of genetic risk factors for 
prostate cancer development upon antioxidant supplementation (Chapter IV), and studied 
the function of an antioxidant protein in prostate tumorigenesis (Chapter V).  These 
analyses have provided new insight into the interplay of oxidative stress with prostate 
tumor initiation, antioxidant chemoprevention for prostate cancer, and helped to elucidate 
the roles of established prostate tumor suppressor NKX3.1 and novel prostate cancer 
associated genes BNIP3L and PRDX6 in prostate tumorigenesis.   
 
NKX3.1 and antioxidant chemoprevention in prostate tumorigenesis 
Due to the failure of SELECT and other antioxidant cancer chemoprevention 
trials, the need is apparent for a deeper understanding of the role ROS plays in tumor 
initiation depending on cellular context. Clinical trials are almost always performed in 
populations of diverse genetic background and diverse environmental contexts to 
determine measures which can be applicable to a widespread population.  However, as 
has been proposed for many essential nutrients a (250), I propose that a personalized 
approach to antioxidant chemoprevention, with genetics and environmental factors taken 
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into account, will be required for true success at improving prostate cancer and other 
health outcomes. 
In order to begin to address the complexities of antioxidant chemoprevention for 
prostate cancer in the pre-clinical setting, I supplemented Nkx3.1-deficient mice, a mouse 
model which accurately represents the very earliest stages of prostate tumorigenesis, with 
the antioxidant NAC.  After finding that this antioxidant promoted prostate epithelial cell 
proliferation in the mouse, I then assessed the rate of prostate cancer development in 
NKX3.1-deficient men upon antioxidant supplementation in SELECT. While rs2228013 
did not significantly modify prostate cancer risk overall or in any intervention arm, 
presence of the minor allele at rs11781886 genotype was associated with an increased 
risk of prostate cancer in the vitamin E and selenium arms.  This suggests that antioxidant 
supplementation in the presence of low NKX3.1 expression promotes development of 
prostate cancer, a finding consistent with our mouse study.  
In individuals with normal prostatic NKX3.1 expression, who have the major 
allele (T) at rs11781886, the tumor suppressor NXK3.1 can prevent proliferation and 
maintain low oxidative stress via regulation of oxidative control genes.  However, men 
with the minor allele (C) at rs11781886, associated with decreased NKX3.1 expression 
(227), have heightened prostate cancer risk with vitamin E and selenium 
supplementation. Figure 22 summarizes the proposed mechanism behind this 
observation. In subjects who have the minor allele (C) at rs1781886, a binding site for the 
transcription factor Sp1 is created (227) causing repression of NKX3.1 expression. In 
these individuals, we propose there is an increase in proliferation in the prostate 
epithelium, as seen in the Nkx3.1-/- mouse, but this proliferation is held in check by 
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elevated ROS in the cell.  Thus, individuals with the minor allele at rs11781886 who are 
not supplemented with antioxidants do not have a very large increase in prostate cancer 
risk. However, those with the rs11781886 minor allele individuals who are supplemented 
with antioxidants will have further elevated prostate epithelial proliferation and increased 
prostate cancer risk due to quenching of the NKX3.1-loss associated ROS that normally 
inhibit proliferation to some degree (Figure 22). Thus, these data suggest that individuals 
with an elevated prostate cancer risk due to low NKX3.1 levels likely contributed to the 
overall 17% increased risk of prostate cancer with vitamin E supplementation in 
SELECT.    
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Figure 22.  Effects of antioxidant supplementation in prostate epithelial cells with the rs11781886 
minor allele (C). The C genotype at rs11781886 allows for the transcription factor Sp1 to bind and inhibit 
NKX3.1 expression. This results in increased oxidative stress due to direct dysregulation of oxidative stress 
enzymes, which would usually partially inhibit the increased proliferation associated with loss of NKX3.1 
expression.  Antioxidant supplementation helps to quench the elevated oxidative stress, releasing the cells 
from ROS-mediated inhibition of proliferation, increasing the risk for transformation of the cell and cancer 
development.  
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Future directions  
Specificity of antioxidant promotion of prostate epithelial proliferation  
Several investigations could expand our understanding of the effects of ROS 
modulation in early prostate tumorigenesis. In my mouse study, I observed increased 
proliferation upon NAC supplementation in Nkx3.1-deficient prostates, and in my human 
genotyping study, I observed an increased prostate cancer risk with a genotype reported 
to be associated with decreased NKX3.1 expression. Although I propose that a similar 
mechanism is at play in the mouse and human prostate, and among the different 
antioxidants as they could all result in an overall decrease in oxidative stress in the 
prostate epithelium, the possibility exists for species-specific and supplement specific 
effects.   
In order to determine if the pro-proliferative effect seen with NAC 
supplementation in Nkx3.1-/- mice is due to an overall antioxidant effect or due to an 
effect specific to NAC, Nkx3.1-/- mice could be supplemented with other antioxidants 
such as vitamin E, vitamin C, selenium, soy, lycopene, and beta-carotene. Also, as some 
investigators have claimed that the decrease in serum γ-T was responsible for the 
increased risk of vitamin E supplementation in SELECT (142), it would be especially 
interesting to supplement with vitamin E as either α-T as was done in SELECT or γ-T to 
see if there is a different effect.  Duration and dosage of supplementation could also be 
altered to determine specific effects on tumor initiation.  
Similarly, in human studies, influence of rs11781866 genotype on prostate cancer 
risk with plasma levels or supplementation with of various antioxidants could be 
investigated.  Large studies such as the Health Professionals Follow-Up Study (HPFS) 
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(308) and the Physicians Health Study (PHS) (309), with data on plasma vitamin E 
levels, selenium levels, lycopene levels, beta carotene levels, or other antioxidants, could 
be analyzed to confirm the effect and determine whether a similar effect is seen with 
other antioxidants.   
Effect of antioxidant supplementation at different stages of prostate tumor progression 
In addition to supplementing early in life to study chemoprevention, mice which 
develop tumors slowly (such as Nkx3.1+/-; Pten+/- mice) could be supplemented with 
antioxidants after tumor formation in order to determine the effect of quenching ROS on 
prostate tumor progression. Mice which develop advanced tumors, such as PB-Cre; Z-
MYC; Ptenf/+; p53f/+ (208), will also be supplemented after advanced tumor formation to 
determine the effect of antioxidants in late-stage tumors. These studies would help inform 
the discordant results from pre-clinical and clinical trials of prostate cancer 
chemoprevention and treatment.   
Molecular mechanism responsible for antioxidant-mediated promotion of proliferation  
Using accurate prostate cancer mouse models, global gene expression could be 
performed to determine changes in expression due to each antioxidant chemoprevention 
or cancer treatment.  Differences in expression with supplementation of each antioxidant 
compound and at each stage of tumor formation will help elucidate the complexity of 
findings observed in human clinical trials and possibly inform molecular mechanisms of 
early prostate tumorigenesis. Findings may help determine if any antioxidant compounds 
may be efficacious for chemoprevention or in later stages of tumor development. As 
these models use similar genetic changes to those observed during human prostate 
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tumorigenesis, they may better represent effects of antioxidant compounds in 
chemoprevention than in historically used models.   
If particular antioxidants show a protective or detrimental effect in a specific 
genetic context, this could then be investigated in human studies.  For example, if one 
agent promotes cancer development in mice with PTEN-deficiency, samples from clinical 
trials using that agent could be stratified based on PTEN genetic or expression status to 
confirm that the agent affects human prostate tumorigenesis in a similar manner to the 
mouse model.  
Importantly, the gene expression changes seen in mice after short term 
supplementation with α-tocopherol acetate and selenomethionine as used in SELECT 
should be compared to gene expression changes seen in the Phase II clinical study which 
performed microarray in men after supplementation with the SELECT antioxidants (237). 
This important comparison will help to determine the accuracy of our preclinical models 
and their ability to predict the efficacy of chemoprevention compounds in prostate 
cancer.  
To determine the mechanism of increased risk with NKX3.1 downregulation due 
to rs11781886 in the human prostate, global gene expression analysis could be performed 
on tissue from individuals with different genotypes at rs11781886 who were 
supplemented with SELECT trial or other antioxidants.  These data could be compared to 
the antioxidant- supplemented prostate from accurate models of mouse prostate cancer to 
determine if similar pro-proliferative gene signatures are enriched with antioxidant 
supplementation.  This analysis may help to uncover genes which could be implicated in 
  134
the pro-tumorigenic phenotype, providing possible targets for cancer treatment or 
prevention.     
Alternative mechanisms  
While the effects of antioxidant compounds are often described as working 
through alterations in prostatic oxidative stress, there remains the possibility that these 
compounds act through mechanisms distinct from ROS regulation. To help determine if 
modulation of oxidative stress is actually occurring, detailed studies of ROS levels or 
oxidative damage in the prostate in observational and intervention studies are needed in 
mouse models and human studies.  Even if ROS are altered, it may be the case that the 
preventative effects or promotion seen by compounds are actually due to other effects.    
Personalized chemoprevention 
“Personalized medicine” is a recent phenomenon in cancer treatment which has 
come about due to our increased knowledge of the disease pathology. It allows for 
determination of the type of treatment has the greatest probability of helping at patient 
due to patient-specific information. A similar process may be extended in the future to 
determine the correct supplementation to prevent cancer development depending on 
patient-specific risk factors, serving as “personalized chemoprevention.” This can be used 
is to approximate the risk or benefit associated with a single individual taking a specific 
chemopreventative agent.  For example, although the average of vitamin E 
supplementation across participants of all genotypes in SELECT was to increase prostate 
cancer risk by 17%, the information gained from genetic modifications of this risk (such 
as genotype at rs11781886 and rs11781866) could be used to accurately estimate an 
individual’s probable risk or benefit.  This information could be clinically useful, for 
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example, as some may derive benefit from vitamin E supplementation for another 
disease.  If these individuals knew how their specific genetic profile affected the prostate 
cancer risk associated with taking vitamin E, they could make an informed decision about 
whether taking vitamin E for benefit for another disease was worth the risk.   
Therefore, through integrating new information gained on genetic context, point 
in tumor progression, relationship between animal models and human disease processes, 
and specific antioxidant compounds employed proposed by these studies, a deeper 
understanding of the complex molecular events involved in prostate cancer 
chemoprevention will be obtained.   
 
BNIP3L SNP rs11781866 and prostate cancer risk in SELECT 
 
In another such investigation, I described another genetic polymorphism 
(rs11781866) that modifies the risk of prostate cancer associated with SELECT 
randomization arm. While the SNP did not influence prostate cancer risk in the entire 
study population, I made the surprising finding that presence of the minor allele at 
rs11781866 in the region of BNIP3L decreases the risk of prostate cancer associated with 
vitamin E supplementation.   
At present, the effect of rs11781866 genotype on BNIP3L expression or 
expression of other genes is unknown.  Because BNIP3L levels are elevated with vitamin 
E supplementation, I hypothesize that BNIP3L is acting as an oncogene in the setting of 
elevated α-T levels. Thus, if having the minor allele negates this effect, I hypothesize that 
rs11781866 decreases BNIP3L expression or function to cause this change.  
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Figure 23 summarizes the proposed mechanism behind increased prostate cancer 
risk with major allele (T) at rs11781866.  Vitamin E supplementation elevates FOXC1 
expression as was observed in our analysis of microarray data from individuals 
supplemented with SELECT antioxidants (Chapter IV, (237)).  Interestingly, whereas 
FOXC1 upregulation has been shown to be important for the response to oxidative stress 
(310, 311), we are the first to propose upregulation of FOXC1 in response the antioxidant 
α-T. Therefore, the mechanism of elevated FOXC1 upon α-T supplementation is 
unknown and its discovery will require significant investigation.  I propose that FOXC1 
binding to the rs11781866 locus positively regulates BNIP3L expression. Thus, with high 
FOXC1 levels in the setting of α-T supplementation, BNIP3L levels are also high.  As we 
observed an increased risk of prostate cancer development with the major allele at 
rs11781866, I hypothesize that elevated BNIP3L promotes prostate cancer development, 
possilbe through induction of autophagy and survival of the prostate epithelial cells.  
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Figure 23.  Model displaying vitamin E promotion of tumorigenesis via regulation of BNIP3L by 
FOXC1. Vitamin E supplementation increases FOXC1 levels in the prostate epithelial cells. The major 
allele at rs11781866 creates two FOXC1 binding sites.  As I propose FOXC1 binding to rs11781866 
positively regulates BNIP3L, vitamin E supplementation upregulates BNIP3L.  BNIP3L then promotes 
transformation of the prostate epithelial cells, possibly through induction of autophagy and cell survival, 
increasing the risk of prostate tumorigenesis.   
 
 
 
 
 
 
  138
Future directions  
Direct modulation of BNIP3L by FOXC1 at rs11781866 
As my results in the rs11781866 study suggest a possible novel link of BNIP3L to 
prostate tumorigenesis, many studies could be performed to investigate the role of this 
gene in the disease.  The direct modulation of BNIP3L expression by the rs11781866 
SNP could be studied using molecular genetics approaches.  The Cancer Genome Atlas 
(TCGA) is a database which includes genetic and gene expression data from many tissue 
and tumor types which can be queried to determine the relationship between rs11781866 
and expression of BNIP3L. I hypothesize that the minor allele (C) at rs11781866 will be 
associated with decreased BNIP3L expression.   
As I hypothesize that differential binding of FOXC1 to rs11781866 largely 
determines the degree of upregulation of BNIP3L, experiments could be performed to 
confirm differential binding of FOXC1 to the rs11781866 in vitro and in vivo. To begin 
to investigate functional changes in gene regulation due to the rs118781866 allele, a 
luciferase assay with the rs11781866 putative enhancer region controlling transcription at 
a minimal promoter region could be carried out. I hypothesize that the presence of the 
minor allele at rs11781866 will decrease activity of the enhancer region.  
It is possible that rs11781866 is not the functional SNP, but merely a SNP in 
linkage with the actual polymorphism causing the alteration in phenotype. Thus, it may 
not be through differential regulation and binding of FOXC1 that BNIP3L levels are 
altered.  If this is the case, additional SNPs in the vicinity of rs11781866 must be 
genotyped in SELECT to determine the quantitative trait locus (QTL) associated with the 
enhanced risk of prostate cancer with antioxidant supplementation.  Additional functional 
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analysis of SNPs in the rs11781866 QTL will be required to then determine the 
functional SNP responsible for the phenotype.   
Functional role of BNIP3L in prostate tumorigenesis 
As the role of BNIP3L in prostate tumorigenesis has not been established, basic 
analyses of its effect on tumor cell proliferation, apoptosis, migration, invasion, and 
tumorigenicity could be performed using established prostate cancer cell lines. However, 
the functional significance of BNIP3L in prostate tumor initiation would be best studied 
using a tissue recombination approach with modulation of BNIP3L expression in 
nonmalignant prostate stromal or epithelial cells.  This could be done using primary cells 
from mouse models of prostate cancer or human prostate epithelial and stromal cell lines. 
Tissue recombination would uniquely allow for a direct test of the “Autophagic Tumor 
Stroma Model of Cancer Metabolism” in the prostate, where tumor and stromal cell 
interactions are highly studied and extremely important to glandular pathology.   
To further assess the importance of BNIP3L regulation in human prostate cancer 
patients even in the absence of high dose antioxidant supplementation, clinical data could 
be queried for expression of BNIP3L upon differing levels of plasma α-T or γ-T to 
determine if these compounds in the normal physiological range can influence BNIP3L 
levels and therefore change prostate cancer risk.  Also, patient tissue samples from the 
SELECT biorepository, or other studies where antioxidant supplementation has been 
performed with subsequent biopsy, should be analyzed for expression via BNIP3L 
immunohistochemistry to determine if changes in BNIP3L RNA truly correlate with 
altered BNIP3L protein levels.     
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While extensive future experiments are needed to elucidate the role of increased 
BNIP3L in prostate tumorigenesis and the effect of rs11781866 on prostate cancer risk 
with antioxidant supplementation, this investigation has uncovered a possible new 
molecule related to prostate tumorigenesis. As with the NKX3.1 SNP rs11781886, 
BNIP3L SNP genotype may contribute to important “personalized chemoprevention” in 
the future, especially due to the greater than 40% increased risk of prostate cancer 
development with vitamin E supplementation in those with the TT genotype.  If BNIP3L 
is found to play a functional role in promotion of prostate tumor progression, it may also 
possible serve as a new molecular chemoprevention or therapeutic target.   
 
Role of NKX3.1 and MYC target gene Prdx6 in prostate tumorigenesis  
  
The preceding discussion has highlighted that the roles of oxidative stress and 
antioxidants in prostate cancer are complex and much remains to be understood.  I began 
studying the role of PRDX6 in prostate tumorigenesis not only because it was a co-direct 
target of NKX3.1 and MYC, but because it is an antioxidant protein which may play a 
significant role in the development of prostate cancer. Based on previous work in our 
laboratory which showed that Myc expression and loss of Nkx3.1 decreased Prdx6 in 
early lesions in the mouse prostate (158, 159), I hypothesized that Prdx6 expression 
inhibits prostate tumor initiation.  Significant future investigation will be required to test 
this hypothesis. In my analysis of the functional role of Prdx6 in the aggressive mouse 
prostate cancer cell line Myc-CaP, however, I found that Prdx6 promoted proliferation 
and tumorigenesis.  Therefore, I hypothesize that Prdx6 plays a dual role in prostate 
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tumorigenesis, preventing tumor formation at an early stage, but promoting 
aggressiveness in established tumors.   
I propose two ways in which Prdx6 may both inhibit and promote prostate 
tumorigenesis depending on the cellular context.  ROS can have diverse roles depending 
on their level, the exact species, and the cell with which it is interacting.  At very early 
stages in prostate tumorigenesis, Prdx6 may be important in quenching ROS which could 
cause damaging mutations to cells, thus preventing tumor initiation.  However, at 
advanced stages, Prdx6 quenching of ROS may inhibit oxidative-stress induced apoptosis 
or cell cycle arrest. On the other hand, the dual function of Prdx6 may explain its dual 
role during tumorigenesis.  Again, early in tumor initiation, Prdx6 peroxidase activity 
may prevent initiating mutations, but late in tumorigenesis, the phospholipase A2 activity 
of Prdx6 may promote elevated levels of prostaglandins which promote tumor growth.   
Future directions  
Regulation of PRDX6 by MYC 
The regulation of PRDX6 by Myc should be investigated in more detail.  First, 
siRNA-mediated depletion of MYC in normal and malignant human prostate cell lines 
could be performed to determine if decreased MYC expression correlates with increased 
PRDX6 expression, suggesting that MYC could repress PRDX6.  Because the genome-
wide MYC binding sites in PRDX6 have been described in non-prostate cell types, a 
reporter assay using the PRDX6 promoter containing the MYC binding sites could be 
carried out.  Thus, I expect that MYC transfection will repress the basal level of 
transcription of the PRDX6 promoter.  ChIP could be performed for MYC human 
prostate cell lines and human tissue lysates to confirm MYC binding to the in vivo 
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PRDX6 locus.  Presence of well-known MYC cofactors involved in transcriptional 
repression, such as DNMT3a (312), could be assessed to support the direct transcriptional 
repression of PRDX6 by MYC.   
Functional role of PRDX6 in early and late prostate tumorigenesis 
The proposed dual role of PRDX6 in prostate tumorigenesis could be tested by 
several investigations.  PRDX6 expression could be driven or depleted via shRNA in 
non-malignant and malignant human prostate epithelial cells and tested in a tissue 
recombination model for tumorigenicity.  Overexpression experiments could be 
performed with wild type and mutant PRDX6 constructs to determine the role of the 
distinct Prdx6 functions in the phenotype observed.  In addition, animal hosts of the 
tissue recombination grafts could be treated with specific inhibitors to Prdx6 peroxidase 
(mercaptosuccinate) or phospholipase A2 (MJ33) (313) activity to determine the Prdx6 
function responsible for the phenotype and possibly define a therapeutic target for Prdx6-
overexpressing tumors.   
To investigate the relevance of PRDX6 in clinical prostate tumorigenesis, human 
tissue microarrays containing tissue from normal prostate, hyperplastic prostate, PIN 
lesions, early, low grade carcinoma, and advanced, high grade carcinoma could be 
stained for MYC, PRDX6, and NKX3.1.  I hypothesize that in early, pre-malignant 
lesions, high MYC and low NKX3.1 expression will be correlated with low PRDX6 
expression, as seen in our mouse model.  However, in advanced lesions, I expect to see 
high PRDX6 in many cases, even in the presence of high MYC expression as PRDX6 
may be able to escape normal repression by MYC in advanced lesions to exert its tumor 
promoting effects.   
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Explanation of the role of PRDX6 in human prostate tumorigenesis may help in 
understanding the molecular mechanisms of the disease, allowing for efficacious 
prevention and treatment strategies to be developed.   
  
Conclusions 
 
Prostate cancer is a major worldwide public health concern and will most likely 
remain so for many years to come.  Due the widespread prevalence of the disease, 
success in prostate cancer prevention is highly desired, yet has been largely unsuccessful 
to date.   The lack of success is most likely because of the complex and diverse 
mechanisms of prostate cancer development, which are highlighted by the intricate roles 
of oxidative stress in prostate tumorigenesis.   
My dissertation work has provided valuable insight, showing that antioxidants do 
not always prevent cancer, and in prostate cancer, may even promote malignancy in 
certain populations. My observations would suggest that one cannot assume that taking 
high dose antioxidants can always be done without harm. Although many do not view 
antioxidants and other supplements as “drugs” because prescriptions are not required, 
they can and do alter normal physiological processes, sometimes resulting in various 
forms of pathology.  By defining subpopulations with differential response to antioxidant 
treatment, I have supported the future of possible “personalized chemoprevention” which 
could allow for individualized determination of risk or benefit from antioxidant 
supplementation.   
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My data confirm the crucial role of NKX3.1 in prostate tumorigenesis, as loss of 
NKX3.1 expression in both the mouse and human prostate increases cancer risk with 
antioxidant supplementation.  In addition, I have identified another possible gene, 
BNIP3L, which may promote prostate tumorigenesis with vitamin E supplementation.   
Lastly, I have proposed a complex role for the antioxidant enzyme PRDX6 in 
prostate tumorigenesis, a protein which may have a significant function in MYC-driven 
tumor initiation. Gaining an understanding of how PRDX6 relates to prostate cancer 
development with its antioxidant and phospholipase A2 functions at different stages of 
tumorigenesis may allow for future development of preventative and treatment 
interventions. Further investigation will help to delineate the complex interplay of 
oxidative stress and genetic alterations in prostate tumor initiation.   
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Appenidix A. TOP GENE SETS ENRICHED IN NAC-SUPPLEMENTED Nkx3.1-/- ANTERIOR PROSTATE  
 
* Gene sets with a FDR q-value < 0.25 are listed*      
      
Gene Set Name 
Gene Set 
Size 
Enrichment 
Score 
Normalized 
Enrichment Score 
NOM p-
value 
FDR q-
value 
LEE_LIVER_CANCER_MYC_E2F1_DN 54 0.6687 2.0786 0.0000 0.0296 
LIAN_LIPA_TARGETS_3M 63 0.6321 2.0697 0.0000 0.0165 
LEE_LIVER_CANCER_E2F1_DN 54 0.6587 2.0367 0.0000 0.0150 
LEE_LIVER_CANCER_MYC_DN 51 0.6449 2.0146 0.0000 0.0159 
LIAN_LIPA_TARGETS_6M 78 0.6114 2.0052 0.0000 0.0152 
HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN 80 0.5729 1.9349 0.0000 0.0459 
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN 63 0.6068 1.9301 0.0000 0.0424 
REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS 147 0.5361 1.9250 0.0000 0.0408 
GAL_LEUKEMIC_STEM_CELL_DN 185 0.5161 1.9233 0.0000 0.0379 
CADWELL_ATG16L1_TARGETS_UP 95 0.5614 1.9072 0.0000 0.0433 
KEGG_PPAR_SIGNALING_PATHWAY 57 0.6099 1.9063 0.0000 0.0398 
REACTOME_CLASS_A1_RHODOPSIN_LIKE_RECEPTORS 250 0.4960 1.9009 0.0000 0.0393 
PAL_PRMT5_TARGETS_DN 28 0.6665 1.8969 0.0000 0.0387 
REACTOME_STRIATED_MUSCLE_CONTRACTION 28 0.6805 1.8848 0.0000 0.0434 
LEE_LIVER_CANCER_DENA_DN 62 0.5935 1.8843 0.0000 0.0409 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_DN 25 0.7011 1.8740 0.0000 0.0457 
LEE_LIVER_CANCER_MYC_TGFA_DN 55 0.5976 1.8576 0.0000 0.0532 
KEGG_ADIPOCYTOKINE_SIGNALING_PATHWAY 65 0.5750 1.8510 0.0000 0.0548 
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_D
N 50 0.5925 1.8478 0.0000 0.0546 
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_DN 69 0.5638 1.8430 0.0000 0.0560 
GERY_CEBP_TARGETS 112 0.5311 1.8426 0.0000 0.0535 
KEGG_HEMATOPOIETIC_CELL_LINEAGE 65 0.5724 1.8285 0.0000 0.0619 
POOLA_INVASIVE_BREAST_CANCER_UP 225 0.4793 1.8273 0.0000 0.0601 
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VERRECCHIA_EARLY_RESPONSE_TO_TGFB1 48 0.5884 1.8126 0.0016 0.0696 
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP 75 0.5459 1.7943 0.0000 0.0852 
SHEPARD_BMYB_MORPHOLINO_DN 146 0.4956 1.7939 0.0000 0.0821 
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP 139 0.5060 1.7934 0.0000 0.0795 
CROONQUIST_NRAS_VS_STROMAL_STIMULATION_DN 72 0.5433 1.7903 0.0030 0.0793 
FURUKAWA_DUSP6_TARGETS_PCI35_DN 57 0.5595 1.7769 0.0000 0.0909 
NADERI_BREAST_CANCER_PROGNOSIS_UP 32 0.6239 1.7765 0.0032 0.0884 
RICKMAN_HEAD_AND_NECK_CANCER_F 50 0.5676 1.7704 0.0030 0.0920 
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 58 0.5550 1.7651 0.0015 0.0953 
REACTOME_PLATELET_DEGRANULATION 80 0.5312 1.7592 0.0000 0.0992 
URS_ADIPOCYTE_DIFFERENTIATION_DN 28 0.6437 1.7525 0.0078 0.1039 
REACTOME_G_ALPHA_I_SIGNALLING_EVENTS 151 0.4838 1.7517 0.0000 0.1020 
MCLACHLAN_DENTAL_CARIES_UP 161 0.4818 1.7502 0.0000 0.1010 
REACTOME_GPCR_LIGAND_BINDING 346 0.4463 1.7500 0.0000 0.0986 
LEE_LIVER_CANCER_TOP50 32 0.6084 1.7461 0.0015 0.1007 
SETLUR_PROSTATE_CANCER_TMPRSS2_ERG_FUSION_DN 17 0.7022 1.7350 0.0137 0.1108 
LE_EGR2_TARGETS_UP 97 0.5114 1.7336 0.0000 0.1097 
MCLACHLAN_DENTAL_CARIES_DN 184 0.4631 1.7209 0.0000 0.1236 
LEE_LIVER_CANCER 32 0.6084 1.7202 0.0049 0.1217 
BERTUCCI_INVASIVE_CARCINOMA_DUCTAL_VS_LOBULAR_DN 39 0.5845 1.7065 0.0077 0.1387 
SABATES_COLORECTAL_ADENOMA_DN 227 0.4517 1.7058 0.0000 0.1368 
STEARMAN_TUMOR_FIELD_EFFECT_UP 40 0.5818 1.7028 0.0047 0.1382 
YU_MYC_TARGETS_UP 37 0.5795 1.6982 0.0082 0.1420 
RICKMAN_HEAD_AND_NECK_CANCER_D 20 0.6706 1.6958 0.0016 0.1423 
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 215 0.4493 1.6925 0.0000 0.1436 
WIELAND_UP_BY_HBV_INFECTION 70 0.5189 1.6798 0.0014 0.1600 
CAIRO_HEPATOBLASTOMA_POOR_SURVIVAL 15 0.6968 1.6752 0.0190 0.1646 
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KEGG_LINOLEIC_ACID_METABOLISM 17 0.6617 1.6745 0.0193 0.1623 
MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_UP 18 0.6576 1.6639 0.0163 0.1779 
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP 148 0.4584 1.6540 0.0026 0.1926 
YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP 74 0.5057 1.6509 0.0057 0.1951 
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP 55 0.5309 1.6487 0.0030 0.1962 
SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN 31 0.5850 1.6456 0.0065 0.1985 
LIU_VAV3_PROSTATE_CARCINOGENESIS_UP 76 0.5012 1.6444 0.0030 0.1972 
VALK_AML_WITH_CEBPA 29 0.6001 1.6438 0.0092 0.1948 
VERRECCHIA_RESPONSE_TO_TGFB1_C1 18 0.6466 1.6433 0.0178 0.1922 
JEON_SMAD6_TARGETS_UP 20 0.6340 1.6364 0.0201 0.2011 
SHEPARD_BMYB_TARGETS 55 0.5091 1.6326 0.0079 0.2041 
SMID_BREAST_CANCER_LUMINAL_A_UP 74 0.4925 1.6280 0.0029 0.2095 
VARELA_ZMPSTE24_TARGETS_DN 43 0.5380 1.6241 0.0115 0.2138 
LE_EGR2_TARGETS_DN 107 0.4678 1.6240 0.0014 0.2108 
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN 69 0.5041 1.6193 0.0031 0.2161 
KEGG_ECM_RECEPTOR_INTERACTION 79 0.4958 1.6108 0.0029 0.2296 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_D
N 15 0.6550 1.6105 0.0256 0.2266 
NAKAJIMA_EOSINOPHIL 18 0.6406 1.6102 0.0272 0.2239 
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_
LYMPHOID_AND_A_NON_LYMPHOID_CELL 45 0.5225 1.6097 0.0122 0.2216 
REACTOME_MUSCLE_CONTRACTION 48 0.5235 1.6089 0.0164 0.2201 
REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PEROXISO
ME_PROLIFERATOR_ACTIVATED_RECEPTOR_ALPHA 51 0.5165 1.6074 0.0138 0.2199 
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER 119 0.4605 1.6061 0.0014 0.2196 
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_U
P 134 0.4508 1.6017 0.0053 0.2251 
KOBAYASHI_EGFR_SIGNALING_24HR_DN 215 0.4235 1.6010 0.0000 0.2234 
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP 118 0.4513 1.6008 0.0029 0.2208 
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CROMER_TUMORIGENESIS_DN 38 0.5523 1.5996 0.0106 0.2201 
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 248 0.4199 1.5982 0.0000 0.2199 
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP 76 0.4839 1.5968 0.0045 0.2201 
COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_DN 28 0.5756 1.5968 0.0201 0.2173 
CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_DN 32 0.5735 1.5945 0.0224 0.2193 
REACTOME_NA_CL_DEPENDENT_NEUROTRANSMITTER_TRANSPOR
TERS 16 0.6504 1.5935 0.0162 0.2184 
KEGG_CELL_ADHESION_MOLECULES_CAMS 102 0.4578 1.5864 0.0057 0.2301 
EBAUER_MYOGENIC_TARGETS_OF_PAX3_FOXO1_FUSION 45 0.5218 1.5834 0.0168 0.2331 
VERRECCHIA_RESPONSE_TO_TGFB1_C2 18 0.6282 1.5831 0.0232 0.2310 
SABATES_COLORECTAL_ADENOMA_UP 105 0.4568 1.5818 0.0041 0.2307 
MOROSETTI_FACIOSCAPULOHUMERAL_MUSCULAR_DISTROPHY_U
P 17 0.6469 1.5818 0.0362 0.2280 
LEE_LIVER_CANCER_CIPROFIBRATE_DN 55 0.5065 1.5812 0.0107 0.2265 
MARKEY_RB1_CHRONIC_LOF_DN 115 0.4538 1.5806 0.0069 0.2251 
SHEN_SMARCA2_TARGETS_DN 247 0.4185 1.5802 0.0000 0.2234 
COULOUARN_TEMPORAL_TGFB1_SIGNATURE_DN 97 0.4599 1.5797 0.0028 0.2216 
AMIT_SERUM_RESPONSE_240_MCF10A 53 0.5031 1.5745 0.0163 0.2294 
REACTOME_HEMOSTASIS 245 0.4095 1.5714 0.0013 0.2332 
KONDO_PROSTATE_CANCER_WITH_H3K27ME3 139 0.4389 1.5674 0.0027 0.2386 
TANG_SENESCENCE_TP53_TARGETS_DN 33 0.5529 1.5669 0.0175 0.2373 
DELYS_THYROID_CANCER_UP 364 0.3931 1.5637 0.0000 0.2411 
RUIZ_TNC_TARGETS_DN 112 0.4460 1.5626 0.0085 0.2407 
WANG_CISPLATIN_RESPONSE_AND_XPC_UP 118 0.4399 1.5614 0.0028 0.2411 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6 70 0.4786 1.5604 0.0075 0.2406 
KUNINGER_IGF1_VS_PDGFB_TARGETS_DN 19 0.6155 1.5566 0.0287 0.2458 
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Appendix B. TOP GENE SETS DEPLETED IN NAC-SUPPLEMENTED Nkx3.1-/- ANTERIOR PROSTATE 
 
* Gene sets with a FDR q-value < 0.25 are listed*      
      
Gene Set Name 
Gene Set 
Size 
Enrichment 
Score 
Normalized 
Enrichment score 
NOM p-
val 
FDR q-
val 
MOSERLE_IFNA_RESPONSE 20 -0.8749 -2.4193 0.0000 0.0000 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_3D_UP 132 -0.5704 -2.2829 0.0000 0.0033 
DAUER_STAT3_TARGETS_DN 28 -0.7439 -2.2618 0.0000 0.0026 
DER_IFN_BETA_RESPONSE_UP 68 -0.5917 -2.1501 0.0000 0.0181 
BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS 18 -0.7845 -2.1353 0.0026 0.0216 
EINAV_INTERFERON_SIGNATURE_IN_CANCER 22 -0.7500 -2.1197 0.0000 0.0226 
SHEN_SMARCA2_TARGETS_UP 353 -0.4734 -2.1077 0.0000 0.0220 
MILI_PSEUDOPODIA_HAPTOTAXIS_UP 464 -0.4643 -2.1023 0.0000 0.0203 
BROWNE_INTERFERON_RESPONSIVE_GENES 54 -0.6101 -2.0896 0.0000 0.0212 
ZHAN_MULTIPLE_MYELOMA_LB_DN 34 -0.6481 -2.0617 0.0000 0.0296 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP 125 -0.5218 -2.0523 0.0000 0.0301 
KIM_LRRC3B_TARGETS 18 -0.7318 -1.9726 0.0000 0.0778 
LIANG_SILENCED_BY_METHYLATION_2 28 -0.6323 -1.9469 0.0000 0.0943 
DER_IFN_ALPHA_RESPONSE_UP 47 -0.5755 -1.9350 0.0031 0.1000 
FARMER_BREAST_CANCER_CLUSTER_1 32 -0.6243 -1.8871 0.0000 0.1458 
DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP 197 -0.4416 -1.8764 0.0000 0.1525 
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP 61 -0.5236 -1.8509 0.0031 0.1826 
MAHADEVAN_RESPONSE_TO_MP470_UP 15 -0.6978 -1.8291 0.0074 0.2095 
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP 148 -0.4444 -1.8280 0.0000 0.1997 
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN 375 -0.4060 -1.8250 0.0000 0.1945 
KANG_CISPLATIN_RESISTANCE_UP 15 -0.6962 -1.8135 0.0000 0.2057 
DACOSTA_UV_RESPONSE_VIA_ERCC3_XPCS_DN 69 -0.5121 -1.8112 0.0000 0.2005 
YANG_BREAST_CANCER_ESR1_BULK_UP 16 -0.6918 -1.8026 0.0095 0.2072 
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POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN 31 -0.5722 -1.7809 0.0185 0.2369 
ZHANG_BREAST_CANCER_PROGENITORS_UP 384 -0.3911 -1.7775 0.0000 0.2334 
REACTOME_RNA_POLYMERASE_I_III_AND_MITOCHONDRIAL_TRA
NSCRIPTION 80 -0.4892 -1.7769 0.0069 0.2258 
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN 39 -0.5457 -1.7614 0.0053 0.2469 
REACTOME_TRANSCRIPTION 150 -0.4293 -1.7588 0.0000 0.2429 
ZHU_CMV_8_HR_UP 27 -0.5904 -1.7581 0.0051 0.2359 
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